

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/044095

International filing date: 20 December 2004 (20.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/531,482
Filing date: 18 December 2003 (18.12.2003)

Date of receipt at the International Bureau: 11 March 2005 (11.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1290343

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

March 01, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/531,482

FILING DATE: *December 18, 2003*

RELATED PCT APPLICATION NUMBER: *PCT/US04/44095*



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

16562 U.S. PTO
121803

PTO/SB/16 (08-03)
Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV 311 017 668 US

17858 U.S. PTO
60/531482
121803

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Laurie H.		Glimcher		West Newton, Massachusetts	
Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
MODULATION OF IMMUNE SYSTEM FUNCTION BY MODULATION OF POLYPEPTIDE ARGININE METHYLTRANSFERASES					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number: 00959					
OR					
<input type="checkbox"/> Firm or Individual Name		Giulio A. DeConti, Jr. LAHIVE & COCKFIELD, LLP			
Address		28 State Street			
City		Boston	State	MA	Zip 02109
Country		US	Telephone	(617) 227-7400	Fax (617) 742-4214
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages		112	<input type="checkbox"/> CD(s), Number		
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets		22	<input type="checkbox"/> Other Sequence Listing (14 pages) Return Receipt Postcard		
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		(specify):			
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.					FILING FEE AMOUNT (\$) 80.00
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees.					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 12-0080					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input type="checkbox"/> No		<input checked="" type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: National Institute of Health - AI37833			

[Page 1 of 1]

Respectfully submitted,

Date December 18, 2003

SIGNATURE

TYPED OR
PRINTED NAME

Megan E. Williams

REGISTRATION NO.
(if appropriate)

43,270

TELEPHONE

(617) 227-7400

Docket Number:

HUI-054-1

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 311 017 668 US, in an envelope addressed to: MS Provisional Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 18, 2003

Signature:

(Megan E. Williams)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003, Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 80.00

Complete if Known

Application Number Not Yet Assigned
Filing Date Concurrently herewith
First Named Inventor Laurie H. Glimcher
Examiner Name Not Yet Assigned
Art Unit N/A
Attorney Docket No. HUI-054-1

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number 12-0080
Deposit Account Name Lahive & Cockfield, LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	80.00

SUBTOTAL (1) (\$) 80.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	** =	x	=
Multiple Dependent	** =	x	=

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 0.00

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 0.00

SUBMITTED BY

Name (Print/Type) Megan E. Williams

Registration No. (Attorney/Agent)

43,270

(Complete (if applicable))

Telephone (617) 227-7400

Signature

Megan E. Williams

Date

December 18, 2003

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 311 017 668 US, in an envelope addressed to: MS Provisional Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 18, 2003

Signature:

Megan E. Williams

(Megan E. Williams)

**MODULATION OF IMMUNE SYSTEM FUNCTION BY MODULATION OF
POLYPEPTIDE ARGININE METHYLTRANSFERASES**

Related Applications

5 This application is related to USSN 10/448,748, titled "NFAT-
INTERACTING PROTEIN NIP45 AND METHODS OF USE THEREFOR," filed on May
30, 2003, now pending, which is a continuation of USSN 09/617,923, titled "NFAT-
INTERACTING PROTEIN NIP45 AND METHODS OF USE THEREFOR", filed on July
17, 2000, now U.S. Pat. No. 6,573,365 B1, which is a divisional of USSN 09/192,611 titled
10 "NFAT-INTERACTING PROTEIN NIP45 AND METHODS OF USE THEREFOR," filed
on November 16, 1998, now U.S. Pat. No. 6,090,561, which is a divisional of USSN
08/755,584 titled "NFAT-INTERACTING PROTEIN NIP45 AND METHODS OF USE
THEREFOR," filed on January 12, 1999, now U.S. Pat. No. 5,858,711. This application is
also related to USSN 08/636,602, entitled "METHODS AND COMPOSITIONS FOR
15 REGULATING T CELL SUBSETS BY MODULATING TRANSCRIPTION FACTOR
ACTIVITY", filed April 23, 1996, and to a continuation-in-part application thereof, entitled
"METHODS FOR REGULATING T CELL SUBSETS BY MODULATING
TRANSCRIPTION FACTOR ACTIVITY", USSN 08/755,592, filed on November 25,
1996. The entire contents of each of these applications is incorporated herein by reference.

20

Government Funding

Work described herein was supported, at least in part, under grant AI37833
awarded by the National Institutes of Health. The U.S. government therefore may have
certain rights in this invention.

25

Background of the Invention

CD4⁺ T helper cells are not a homogeneous population but can be divided on
the basis of cytokine secretion into at least two subsets termed T helper type 1 (Th1) and T
helper type 2 (Th2) (see *e.g.*, Mosmann, T.R. *et al.* (1986) *J. Immunol.* 136:2348-2357;
30 Paul, W.E. and Seder, R.A. (1994) *Cell* 76:241-251; Seder, R.A. and Paul, W.E. (1994)
Ann. Rev. Immunol. 12:635-673). Th1 cells secrete interleukin-2 (IL-2) and interferon- γ
(IFN- γ) while Th2 cells produce interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-10

(IL-10) and interleukin-13 (IL-13). Both subsets produce cytokines such as tumor necrosis factor (TNF) and granulocyte/macrophage-colony stimulating factor (GM-CSF). In addition to their different pattern of cytokine expression, Th1 and Th2 cells are thought to have differing functional activities. For example, Th1 cells are involved in inducing delayed type hypersensitivity responses, whereas Th2 cells are involved in providing efficient "help" to B lymphocytes and stimulating production of IgG1 and IgE antibodies.

There is now abundant evidence that the ratio of Th1 to Th2 cells is highly relevant to the outcome of a wide array of immunologically-mediated clinical diseases including autoimmune, allergic and infectious diseases. For example, in experimental leishmania infections in mice, animals that are resistant to infection mount predominantly a Th1 response, whereas animals that are susceptible to progressive infection mount predominantly a Th2 response (Heinzel, F.P., *et al.* (1989) *J. Exp. Med.* 169:59-72; Locksley, R. M. and Scott, P. (1992) *Immunoparasitology Today* 1:A58-A61). In murine schistosomiasis, a Th1 to Th2 switch is observed coincident with the release of eggs into the tissues by female parasites and is associated with a worsening of the disease condition (Pearce, E.J., *et al.* (1991) *J. Exp. Med.* 173:159-166; Grzych, J-M., *et al.* (1991) *J. Immunol.* 141:1322-1327; Kullberg, M.C., *et al.* (1992) *J. Immunol.* 148:3264-3270). Many human diseases, including chronic infections (such as with human immunodeficiency virus (HIV) and tuberculosis) and certain metastatic carcinomas, also are characterized by a Th1 to Th2 switch (see *e.g.*, Shearer, G.M. and Clerici, M. (1992) *Prog. Chem. Immunol.* 54:21-43; Clerici, M and Shearer, G.M. (1993) *Immunology Today* 14:107-111; Yamamura, M., *et al.* (1993) *J. Clin. Invest.* 91:1005-1010; Pisa, P., *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:7708-7712; Fauci, A.S. (1988) *Science* 239:617-623). Furthermore, certain autoimmune diseases have been shown to be associated with a predominant Th1 response. For example, patients with rheumatoid arthritis have predominantly Th1 cells in synovial tissue (Simon, A.K., *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:8562-8566) and experimental autoimmune encephalomyelitis (EAE) can be induced by autoreactive Th1 cells (Kuchroo, V.K., *et al.* (1993) *J. Immunol.* 151:4371-4381).

The ability to alter or manipulate ratios of Th1 and Th2 subsets requires an understanding of the mechanisms by which the differentiation of CD4⁺ T helper precursor cells (Thp), which secrete only IL-2, choose to become Th1 or Th2 effector cells. It is clear that the cytokines themselves are potent Th cell inducers and form an autoregulatory loop (see *e.g.*, Paul, W.E. and Seder, R.A. (1994) *Cell* 76:241-251; Seder, R.A. and Paul, W.E.

(1994) *Ann. Rev. Immunol.* 12:635-673). Thus, IL-4 promotes the differentiation of Th2 cells while preventing the differentiation of precursors into Th1 cells, while IL-12 and IFN- γ have the opposite effect. One possible means therefore to alter Th1:Th2 ratios is to increase or decrease the level of selected cytokines. Direct administration of cytokines or antibodies to cytokines has been shown to have an effect on certain diseases mediated by either Th1 or Th2 cells. For example, administration of recombinant IL-4 or antibodies to IL-12 ameliorate EAE, a Th1-driven autoimmune disease (see Racke; M.K. *et al.* (1994) *J. Exp. Med.* 180:1961-1966; and Leonard, J.P. *et al.* (1995) *J. Exp. Med.* 181:381-386), while anti-IL-4 antibodies cure the Th2-mediated parasitic disease, *Leishmania major* (Sadick, M.D. *et al.* (1990) *J. Exp. Med.* 171:115-127). However, as therapeutic options, systemic administration of cytokines or antibodies may have unwanted side effects and, accordingly, alternative approaches to manipulating Th1/Th2 subsets are still needed.

While the molecular basis for the tissue-specific expression of T cell cytokines has remained elusive, study of the transcriptional elements of cytokine genes has provided insight into their regulation. Analysis of the IL-4 cytokine promoter, for example, has revealed functionally critical sites for several transcription factors including members of the NFAT and AP-1 families (Rooney, J.W. *et al.* (1995) *Immunity* 2:473-483; Szabo, S.J. *et al.* (1993) *Mol. Cell. Biol.* 13:4793-4805). NFAT is a multisubunit transcription complex that contains a cyclosporin A sensitive cytoplasmic phosphoprotein and an inducible nuclear component composed of AP-1 family member proteins (Flanagan, W.M. *et al.* (1991) *Nature* 352:803-807; Jain, J. *et al.* (1992) *Nature* 356:801-804). Purification and cloning of NFATp revealed a region of limited sequence identity to the Rel Homology Domain (RHD) of the NF κ B family of transcription factors (McCaffrey, P.G. *et al.* (1993) *Science* 262:750-754). Subsequent cloning and sequencing of three related genes, NFATc, NFAT4/x/c3, and NFAT3/c4 revealed similar domains. NFAT family members share approximately 70% sequence similarity within this domain and approximately 18% sequence similarity to the RHD of the Rel/NF κ B family of transcription factors. Consistent with their very limited sequence similarity in the RHD, there are marked differences in the behavior of NF κ B and NFAT proteins, and much less is known about the pathways that mediate transcriptional regulation of NFAT target genes. However, considering that NFAT family members can bind to and transactivate the promoters of multiple cytokine genes including IL-2 and IL-4 (Rooney, J. *et al.* (1995) *Immunity* 2:545-553; Szabo, S.J. *et al.*

(1993) *Mol. Cell. Biol.* **13**:4793-4805; Flanagan, W.M. *et al.* (1991) *Nature* **352**:803-807; Northrop, J.P. *et al.* (1994) *Nature* **369**:497), NFAT proteins are not likely to be directly responsible for mediating Th1- or Th2-specific cytokine transcription.

Most, if not all, NFAT binding sites in cytokine promoter regulatory regions are accompanied by nearby sites that bind auxiliary transcription factors, usually members of the AP-1 family. It has been shown that NFAT and AP-1 proteins bind coordinately and cooperatively and are required for full activity of the IL-2 and IL-4 promoters. Different AP-1 proteins, specifically c-Jun, c-Fos, Fra-1, Fra-2, Jun B and Jun D, have been shown to bind to these sites (Rao, A. *et al.* (1994) *Immunol. Today* **15**:274-281; Jain, J. *et al.* (1993) *Nature* **365**:352-355; Boise, L.H. *et al.* (1993) *Mol. Cell. Biol.* **13**:1911-1919; Rooney, J. *et al.* (1995) *Immunity* **2**:545-553; Rooney, J. *et al.* (1995) *Mol. Cell. Biol.* **15**:6299-6310). However, none of these AP-1 proteins is expressed in a Th1- or Th2-specific manner and there is no evidence for the differential recruitment of AP-1 family members to the IL-2 or IL-4 composite sites (Rooney, J. *et al.* (1995) *Mol. Cell. Biol.* **15**:6299-6310). Thus, neither NFAT proteins nor the AP-1 family members c-Jun, c-Fos, Fra-1, Fra-2, Jun B and Jun D can account for the tissue-specific transcription of IL-4 in Th2 cells. NFAT has also been shown to be a regulator of IFN- γ production (Kiani *et al.* *Blood*. 2001 **98**:1480-8).

The proto-oncogene c-maf is expressed selectively in Th2 cells and is responsible for tissue-specific IL-4 expression. Interestingly, c-Maf acts in synergy with NFAT proteins to transactivate the IL-4 promoter. This is consistent with previous data showing that the inducible expression of multiple cytokine genes and cell surface proteins following T cell receptor stimulation requires members of the NFAT transcription factor family (Rooney, J.W. *et al.* (1995) *Immunity* **2**:473-483; Cockerill, P.N. *et al.* (1995) *Mol. Cell. Biol.* **15**:2071-2079; Goldfeld, A.E. *et al.* (1993) *J. Exp. Med.* **178**:1365-1379; Shaw, J.P. *et al.* (1988) *Science* **241**:202-205).

The identification of novel molecules involved in control of gene expression, particularly cytokine gene expression, in immune cells would be of great benefit.

Summary of the Invention

Post-translational modification adds a layer of complexity to the control of cytokine gene expression. Posttranslational modifications are often utilized to translate changes in the extracellular milieu into environment-sensitive gene expression in a timely and efficient fashion. Phosphorylation of serine, threonine, and tyrosine residues and

protein ubiquitination have been widely studied (Roose, J. and Weiss, A. (2000) *Nat Immunol* 1:317-321). Although methylation of arginine residues was discovered over 30 years ago, it has only recently aroused substantial interest (McBride, A. E., and Silver, P. A. (2001) *Cell* 106: 5-8). The present invention is based, at least in part, on the finding that

5 NIP45 is a target of arginine methyl transferases (PRMTs) and that NIP45 and PRMTs are involved in cytokine production in both T and non-T cells. As described in more detail below, activation of arginine methyltransferase (PRMT) in cells (*e.g.*, T and non-T cells), results in the methylation of NIP45 which in turn leads to augmented cytokine production (*e.g.*, IL-4 or IFN- γ production). Two types of arginine methyltransferases have been

10 subclassified based on the symmetry of their reaction products. Both Type I (PRMT1, PRMT3, CARM1, PRMT6) and Type II (PRMT5) methyltransferases induce mono-methylation of arginine residues as a reaction intermediate, but type I protein arginine methyltransferases (PRMT) also generate asymmetric di-methylation of arginine residues and type II PRMTs catalyze the formation of symmetric dimethyl arginine residues

15 (McBride, A. E., and Silver, P. A. (2001) *Cell* 106: 5-8; Frankel, A., *et al.* (2002) *J Biol Chem* 277: 3537-3543). Although isolated by sequence similarity with PRMT1, PRMT2 has not been demonstrated to have enzymatic activity (Scott, H. S., *et al.* (1998) *Genomics* 48: 330-340; Qi, C., *et al.* (2002). *J Biol Chem* 277: 28624-28630). Arginine methylation has been shown to regulate subcellular localization (Shen, E. C., *et al.* (1998) *Genes Dev*

20 12: 679-691; Yun, C. Y., and Fu, X. D. (2000) *J Cell Biol* 150: 707-718) as well as to modulate protein-protein interactions. For example, arginine methylation of the proline-rich region of Sam68 prevents its interaction with its SH3 domain binding partners, Fyn, Lck, and Itk, without altering its affinity to WW domains (Bedford, M. T., *et al.* (2000) *J Biol Chem* 275: 16030-16036), while arginine methylation of a conserved arginine residue

25 of Stat1 in response to IFN α/β signaling prevents interaction with its inhibitor PIAS1, thereby regulating Stat1 transcriptional ability (Mowen, K. A., *et al.* (2001) *Cell* 104: 731-741). PRMT1 deficient mice are embryonic lethal and CARM1 deficient mice die during late embryonic development or perinatally, suggesting a critical role for these PRMTs in cellular processes (Pawlak, M. R., *et al.* (2002) *J Cell Biochem* 87: 394-407; Yadav, N., *et al.* (2003) *Proc Natl Acad Sci U S A* 100: 6464-6468). Until the present invention,

30 however, it was unknown how post-translational modification such as arginine methylation could affect the regulation of signal transduction and cytokine gene expression.

In one aspect, the invention pertains to a method of identifying a compound that modulates cytokine production, comprising: a) providing an indicator composition comprising a type I polypeptide arginine methyltransferase (PRMT1) polypeptide; b) contacting the indicator composition with a plurality of test compounds; c) selecting from the library of test compounds a compound of interest that modulates an activity of PRMT1; to thereby identify a compound that modulates cytokine production.

In another aspect, the invention pertains to a method of identifying a compound that modulates T cell receptor-mediated signaling, comprising: a) providing an indicator composition comprising a type I polypeptide arginine methyltransferase (PRMT1) polypeptide; b) contacting the indicator composition with a plurality of test compounds; c) selecting from the library of test compounds a compound of interest that modulates an activity of PRMT1; to thereby identify a compound that modulates T cell receptor-mediated signaling.

In one embodiment, the activity of PRMT1 is a NIP45-related activity. In another embodiment, the step of determining the effect of the compound of interest on a NIP45-related activity of PRMT1 comprises measuring cytokine production or cytokine gene transcription

In another aspect, the invention pertains to a method of identifying a compound that modulates cytokine production, comprising: a) providing an indicator composition comprising the upstream regulatory regions controlling expression of a type I polypeptide arginine methyltransferase (PRMT1) polypeptide operably linked to a reporter gene; b) contacting the indicator composition with a plurality of test compounds; c) selecting from the library of test compounds a compound of interest that modulates the expression of the reporter gene; to thereby identify a compound that modulates cytokine production.

In one embodiment the method further comprises determining the effect of the compound of interest on a NIP45-related activity of PRMT1. In another embodiment, the indicator composition is a cell that expresses the PRMT1 polypeptide. In one embodiment, the cell has been engineered to express the PRMT1 polypeptide by introducing into the cell an expression vector encoding the PRMT1 polypeptide. In yet another embodiment, the cell further comprises a NIP45 polypeptide. In still another embodiment, the cell further comprises an NFAT polypeptide.

In one embodiment, the cytokine is IFN- γ or IL-4.

In yet another embodiment the indicator composition is a cell free composition.

In one embodiment, the step of determining the effect of the compound of interest on an activity of PRMT1 comprises measuring the ability of the PRMT1 to methylate one or more arginine residues of a target polypeptide. In one embodiment, the target polypeptide is NIP45.

In one aspect, the invention pertains to a method of identifying a compound that modulates cytokine production in a non-T cell, comprising: a) providing non-T cell comprising a NIP45 molecule; b) contacting the non-T cell with a plurality of test compounds;

and c) selecting from the library of test compounds a compound of interest that modulates the activity of NIP45; to thereby identify a compound that modulates cytokine production in a non-T cell.

5 In one embodiment, the cell further comprises PRMT1. In another embodiment, the cell further comprises NFAT.

In one embodiment, the activity of NIP45 is selected from the group consisting of: binding to NFAT, binding to PRMT1, and activation of gene transcription. In one embodiment, the gene is selected from the group consisting of: IL-4, IFN- γ , Egr2, Egr3, c-Rel, and p65.

10 In another aspect, the invention pertains to a method of identifying a compound that modulates gene expression comprising: a) contacting an indicator composition comprising a first polypeptide comprising amino acids 1-32 of NIP45 and a second polypeptide which is a PRMT1 polypeptide with a plurality of test compounds; b) detecting an activity of the first polypeptide or a NIP45-related activity of the second
15 polypeptide in the presence and absence of a test compound, and c) selecting a compound of interest that modulates an activity of the first or second polypeptide; to thereby identify a compound that modulates gene expression.

In one embodiment, the indicator composition is a cell. In one embodiment, the cell further comprises an NFAT polypeptide and the activity of the first polypeptide is
20 detected by measuring the binding of the first polypeptide to the NFAT polypeptide. In one embodiment, the NFAT polypeptide is selected from the group consisting of: NFATc1, NFATc2, and NFATc3. In another embodiment, the activity of the first polypeptide is detected by measuring transcription from a promoter. In one embodiment, the promoter is an IL-4 or the IFN- γ promoter. In another embodiment, the promoter is selected
25 from the group consisting of: the Egr2, Egr3, c-Rel, and p65 promoter.

In another embodiment, the indicator composition is present in a cell free system.

In yet another embodiment, the NIP45-related activity of the second polypeptide is detected by measuring the methylation of one or more arginine residues of
30 NIP45.

In still another embodiment, the NIP45-related activity of the second polypeptide is detected by measuring the interaction between the second polypeptide and the first polypeptide.

35 In a further embodiment, the test compounds are present in a library of small molecules. In one embodiment, the test compound decreases the degree of arginine methylation of NIP45 as compared to the degree of arginine methylation of NIP45 in the absence of the test compound, and the test compound is identified as an agent that reduces cytokine production. In one embodiment, the test compound increases the degree of arginine

methylation of NIP45 as compared to the degree of arginine methylation of NIP45 in the absence of the test compound, and the test compound is identified as an agent that increases cytokine production.

5 In another aspect, the invention pertains to a method of identifying a compound that modulates an interaction between NIP45 and a PRMT polypeptide, comprising: a) contacting an indicator composition comprising a polypeptide comprising amino acids 1-32 of NIP45 and a PRMT polypeptide with a plurality of test compounds; b) detecting a readout of the interaction between the NIP45 and PRMT polypeptides in the presence and absence of a test compound, and c) selecting a compound of interest that
10 modulates the interaction between the NIP45 and PRMT polypeptides; to thereby identify a compound that modulates an interaction between NIP45 and PRMT polypeptide.

In one embodiment, the indicator composition is a cell based composition. In another embodiment, the indicator composition is a cell free composition.

15 In one embodiment, the readout of the interaction between the NIP45 and PRMT1 polypeptides is the binding of NIP45 to PRMT1 or the methylation of one or more arginine residues of NIP45. In another embodiment, the readout of the interaction between the first and second polypeptides is modulation of gene transcription. In one embodiment, the gene is selected from the group consisting of IL-4 and IFN- γ .

20 In one embodiment, the test compounds are present in a library of small molecules. In one embodiment, the test compound decreases the interaction between NIP45 and PRMT1 as compared to the interaction between NIP45 and PRMT1 in the absence of the test compound, and the test compound is identified as an agent that reduces interaction between NIP45 and PRMT1. In another embodiment, the test compound increases the
25 interaction between NIP45 and PRMT1 as compared to the interaction between NIP45 and PRMT1 in the absence of the test compound, and the test compound is identified as an agent that increases interaction between NIP45 and PRMT1.

30 In yet another aspect, the invention pertains to a method of identifying a compound that modulates cytokine production in a cell, comprising; a) providing a cell containing one or more constructs which comprise: a cytokine promoter operably linked to a reporter gene, a nucleotide sequence encoding PRMT1, and a nucleotide sequence encoding at least one activator of cytokine gene transcription; b) stimulating the cell with an activating signal; c) contacting the cell with a plurality of test compounds; d) measuring the expression or activity of the reporter gene; and e) selecting a compound of interest that
35 modulates the expression or activity of the reporter gene, to thereby identify a compound that modulates cytokine production in a cell.

In one embodiment, the cytokine promoter is an IFN γ promoter. In another embodiment, the cytokine promoter is an IL-4 promoter. In one embodiment, the activator of

cytokine gene transcription is T-bet. In another embodiment, the activator of cytokine gene transcription is selected from the group consisting of NFATc2 and NIP45.

In one embodiment, the cell further comprises a construct comprising a nucleotide sequence encoding c-maf.

5 In yet another aspect, the invention pertains to a method of modulating cytokine production in a non-T cell comprising contacting a non-T cell with an agent that modulates the expression and/or activity of at least one molecule selected from the group consisting of: NIP45, PRMT1, and NFAT, such that cytokine production in the non-T cell is modulated.

10 In one embodiment, the cell is selected from the group consisting of: a dendritic cell, an NK cell, and a mast cell.

In yet another aspect, the invention pertains to a method of modulating cytokine production comprising contacting a T cell with an agent that modulates PRMT1 expression and/or activity such that cytokine production is modulated.

15 In one embodiment, the T cell is a CD4⁺ T cell. In another embodiment, the T cell is a CD8⁺ T cell.

In one embodiment, IFN γ production is modulated. In another embodiment, IL-4 production is modulated.

20 In one embodiment, PRMT1 activity is increased, thereby increasing cytokine production. In another embodiment, PRMT1 activity is decreased, thereby decreasing cytokine production.

In another aspect, the invention pertains to a method of modulating IFN γ production, comprising contacting a cell with an agent that modulates PRMT1 expression and/or activity such that IFN γ production is modulated.

25 In one embodiment, the cell is an NK cell or a dendritic cell.

In one aspect, the invention pertains to a method of modulating IL-4, comprising contacting a cell with an agent that modulates PRMT1 expression and/or activity such that IL-4 production is modulated.

In one embodiment, the cell is an NK cell or a mast cell.

30 In another aspect, the invention pertains to a method of modulating the relative number of Th1 or Th2 cell, comprising contacting a population of T cells with an agent that modulates PRMT1 activity such that the relative number of Th1 or Th2 cells is modulated.

35 In still another aspect, the invention pertains to a method of treating a subject that would benefit from the modulation of cytokine production comprising contacting an immune cell from the subject with an agent that modulates PRMT1 expression and/or activity in the immune cell such that cytokine production is modulated and the subject that would benefit from the modulation of cytokine production is treated.

In one embodiment, PRMT1 activity is increased, thereby increasing cytokine production. In a further embodiment, the patient is suffering from an immunodeficiency.

5 In another embodiment, PRMT1 activity is decreased, thereby decreasing cytokine production. In a further embodiment, the subject is suffering from an autoimmune or allergic condition.

Brief Description of the Drawings

10 *Figure 1* is photograph of yeast colonies, in triplicate, transformed with the NIP45 plasmid and either NFATp-RHD as "bait" or control baits, Max, CDK2 or pEG202, together with the LacZ reporter plasmid pSH18, indicating that only those colonies containing the NIP45 plasmid and the NFATp-RHD bait expressed the LacZ reporter gene.

Figure 2 is a photograph of an immunoprecipitation/Western blot experiment demonstrating that NIP45 and NFATp interact in HepG2 cells.

15 *Figure 3* is a schematic diagram comparing the structures of the original NIP45 cDNA clone isolated from the yeast two-hybrid screen (top) and the longest NIP45 cDNA clone isolated from a D10.G4 lambda zap II library (bottom).

Figure 4 depicts the nucleotide and predicted amino acid sequences of the original NIP45 cDNA isolate.

20 *Figure 5* depicts the hydrophobicity plot of the NIP45 cDNA.

Figure 6 is a photograph of an RNA blot analysis of NIP45 transcript levels in various tissues.

25 *Figure 7A* is a photograph of immunofluorescence analysis of BHK cells transfected with an expression construct encoding an HA-epitope tagged NIP45 protein and probed with a monoclonal antibody specific for the HA peptide as the primary antibody and an indocarbocyanine labeled goat anti-mouse secondary reagent.

Figure 7B is a photograph of the same cells depicted in Figure 7A counterstained with the DNA staining dye Hoechst 33258.

30 *Figure 7C* is a photograph of immunofluorescence analysis of unstimulated BHK cells transfected with an expression construct encoding NFAT4 and probed with an anti-NFAT4 specific antibody as the primary antibody and an indocarbocyanine labeled goat anti-mouse secondary reagent.

Figure 7D is a photograph of the same cells depicted in Figure 7C counterstained with the DNA staining dye Hoechst 33258.

Figure 7E is a photograph of immunofluorescence analysis of ionomycin-treated BHK cells transfected with an expression construct encoding NFAT4 and probed with an anti-NFAT4 specific antibody as the primary antibody and an indocarbocyanine labeled goat anti-mouse secondary reagent.

Figure 7F is a photograph of the same cells depicted in Figure 7D counterstained with the DNA staining dye Hoechst 33258.

Figure 8 depicts CAT assay results (left) and a bar graph quantitating the relative fold induction of CAT activity (right) in HepG2 cells transfected with a 3X NFAT-CAT reporter gene construct (containing three NFAT binding sites) and either a control expression plasmid or an NFAT family expression plasmid (NFATp, NFATc, NFAT3 or NFAT4), alone (-) or in combination with a NIP45 expression plasmid (+).

Figure 9 depicts CAT assay results (left) and a bar graph quantitating the relative fold induction of CAT activity (right) in HepG2 cells transfected with an IL-4-CAT reporter gene construct (extending to -732 bp of the IL-4 promoter) and combinations of NFATp, NIP45 and/or c-Maf expression constructs, as indicated.

Figure 10 is a bar graph depicting the level of IL-4 (in pg/ml) in the supernatants of M12 B lymphoma cells transiently cotransfected with expression plasmids for NFATp, c-Maf and a pCI vector control (top bar) or expression plasmids for NFATp, c-Maf and NIP45 (bottom bar).

Figures 11A-11C depict the effects of MTA on T helper cytokine production. (A) T helper cells were isolated from the lymph nodes of DO11.10 TCR transgenic mice and grown under Th1 or Th2 conditions for 7 days. Th1 and Th2 cells were treated with PMA/ionomycin for 3 hrs or pretreated with 1mM MTA for 60 min prior to PMA/ionomycin stimulation. RNA was isolated with analyzed by RNase protection analysis for transcript level of indicated cytokines. L32 and GAPDH included in the multitemplate probe set served as an internal control. (B) Cells were grown as in (A) either pretreated with 1mM MTA or left untreated and intracellular cytokine analysis was performed after stimulation with PMA/ionomycin for 2 hrs and an additional 2 hrs with 3mM monensin. (C) MTA inhibits IL-4 promoter activity. Jurkat cells were transfected with IL-4 reporter vector (2.5µg) and expression vectors for c-Maf (2.5µg), NFATc2 (2.5µg), and PRMT1 (10µg) along with a TK-renilla luciferase vector (5ng) as an internal control. Transfectants were left unstimulated or pretreated with 1mM MTA before a 6hr PMA/ionomycin stimulation. Luciferase values were calculated relative to TK renilla

luciferase internal controls and are expressed relative to unstimulated reporter activity.

Similar results were obtained in at least three independent experiments.

Figures 12A-12C show that T helper cells highly express PRMT1. (A) PRMT expression in T helper cells. Thp, Th1, Th2, and 293 cell protein lysates (30 µg) were analyzed by western blot with antibodies to PRMT1, PRMT2, PRMT3, CARM1, PRMT5, and PRMT6. The location of PRMT6 is indicated by an arrow. Equal loading was confirmed using an antibody to HSP90. (B) PRMT1 transcripts are upregulated by TCR stimulation. T helper cells from DO11.10 TCR transgenic mice were unstimulated or stimulated with plate-bound anti-CD3 and anti-CD28 for 1 day or 3 days. On day 3, cells were split into fresh media with IL-2 until day 5 or day 6. For D6R samples, cells from day 5 were restimulated with plate-bound anti-CD3 for 24 hrs. RNA was prepared and analyzed by northern blot with a probe to PRMT1. Northern blots were reprobed with a β -actin probe to assess loading. (C) TCR induced PRMT1 expression is rapid and cyclosporin A (CsA) sensitive. T helper cells isolated from the lymph nodes of DO11.10 TCR transgenic mice were untreated or pretreated with CsA for 1 hr prior to stimulation with anti-CD3 and anti-CD28 for 0, 3, and 6 hours. RNA was harvested and Northern blot analysis for PRMT1 expression was performed. Equal loading was determined by reprobing with a β -actin probe.

Figures 13A-13D depict the regulation of the IFN γ and IL-4 promoters by PRMT1. (A) Jurkat cells were transfected with the 9.2kb IFN γ luciferase reporter (5 µg) and expression vectors for T-bet (5 µg) and PRMT1 (10 µg). Cells were unstimulated or stimulated with PMA/ionomycin for 6 hrs prior to luciferase assays. (B) Jurkat cells were transfected with the IL-4 luciferase reporter (2.5 µg) and expression vectors for NFATc2 (2.5 µg), c-Maf (2.5 µg), and PRMT1 (10 µg). Cells were treated as in (A). (C) Jurkat cells were transfected with the IL-4 luciferase reporter (2.5 µg) and expression vectors for JunB (2.5 µg), c-Maf (2.5 µg), and PRMT1 (10 µg). Cells were treated as in (A). (D) Jurkat cells were transfected with an luciferase reporter driven by NFAT consensus sites and expression vectors for NFATc2 (2.5 µg) and PRMT1 (10 µg). Cells were treated as in (A). (Luciferase units were normalized to TK-renilla luciferase activity. Results are representative to at least three independent experiments.)

Figures 14A-14C show that NIP45 also augments transcription from IFN γ and IL-4 promoters. (A) Jurkat cells were transfected with the 9.2kb IFN γ luciferase

reporter (5 µg) and expression vectors for T-bet (5µg) and NIP45 (5µg) or with the IL-4 luciferase reporter (2.5µg) and expression vectors for NFATc2 (2.5µg), c-Maf (2.5µg), and NIP45 (5µg). Cells were unstimulated or stimulated with PMA/ionomycin for 6hrs prior to luciferase assays. (Luciferase units were normalized to TK-renilla luciferase activity.

- 5 Results are representative to at least three independent experiments.) (B) The amino terminus (a.a. 6-32) of NIP45 contains 11 arginine residues within consensus motifs for arginine methylation. Putative methylated arginines are indicated in bold. (C) NIP45 is methylated but ΔN-NIP45, NFATc2, T-bet, and c-Maf are not. 293 cells were transfected with expression vectors for NIP45, ΔN-NIP45, NFATc2, T-bet, and c-Maf and were
- 10 immunoprecipitated from cell extracts. Immunoprecipitates were subjected to *in vitro* methylation by recombinant PRMT1. Westerns were performed on immunoprecipitate samples to confirm expression. c-Maf expression is indicated by an arrow.

- Figures 15A-15D** show that NIP45 is methylated by PRMT1. (A) PRMT1, PRMT3, CARM1, and PRMT 5 proteins were immunoprecipitated from 293 cell extracts
- 15 using anti-Flag agarose. These proteins were used for *in vitro* methylation assays with recombinant GST-NIP45. Western blot analysis of the Flag epitope tagged expression constructs was performed with a monoclonal antibody against the Flag epitope. (B)
- PRMT1-His and GST-CARM1 were used in *in vitro* methylation assays with GST, GST-NIP45, and GST-ΔN-NIP45 (GST-ΔN) and transferred to PVDF membrane. Histone H3
- 20 was used as a positive control for CARM1 activity and the input was verified by probing the PVDF with a polyclonal GST antibody. (C) Wild-type ES cells and PRMT1^{-/-} ES cells were transfected with control vector or Flag-tagged NIP45. Lysates were immunoprecipitated with anti-Flag agarose. Resolved proteins were immunoblotted with a polyclonal anti-dimethyl-arginine (asymmetric) antibody. Immunoblots were restripped and
- 25 probed with a monoclonal antibody against the Flag epitope to determine equal loading. (D) Th1 and Th2 lysates from day 7 differentiation cultures were immunoprecipitated with a mixture of two monoclonal antibodies against NIP45 or the appropriate isotype control. Immunoblots were probed a polyclonal anti-dimethyl-arginine (asymmetric) antibody and were reprobed with a polyclonal NIP45 antibody to determine equal loading.

- 30 **Figures 16A-16C** depict the interaction of NIP45 and PRMT. (A) Jurkat cell lysates were used in pulldown assays with 25µg of recombinant GST, GST-NIP45, and GST-ΔN-NIP45. The presence of PRMT1 or CARM1 in pulldown samples was

determined by immunoblotting with a monoclonal PRMT1 antibody and a polyclonal CARM1 antibody. PVDF membranes were reprobed with anti-GST antibodies to determine equal amount of recombinant proteins in pulldown samples. (B) Flag-NIP45 or Flag-ΔN-NIP45 or vector control and HA- PRMT1 expression constructs were transfected in 293 cells. Lysates were immunoprecipitated with anti-Flag agarose and interaction with PRMT1 was determined by probing immunoblots with a monoclonal anti-HA antibody. Equal loading was assessed by probing with an anti-Flag antibody. (C) Lysates from unstimulated or 60 min PMA/ionomycin stimulated day 7 Th1 or Th2 differentiation cultures were immunoprecipitated with a monoclonal PRMT1 antibody or appropriate isotype control. Interaction with endogenous NIP45 was determined by immunoblotting PRMT1 antibody to determine equal loading.

Figures 17A-17B show that MTA inhibits NIP45 and NFATc2 interaction.

(A) Jurkat cells were transfected with the IL-4 promoter (2.5μg) and expression vectors encoding NFATc2 (2.5μg), c-Maf (2.5μg), NIP45 (5μg), ΔN-NIP45 (5μg), and PRMT1 (10μg). Cells were unstimulated or stimulated with PMA/ionomycin for 6hrs prior to luciferase assays. (Luciferase units were normalized to TK-renilla luciferase activity. Results are representative to at least three independent experiments.) (B) 293 cells were transfected with HA-NFATc2 and NIP45-MycHis expression vectors and left untreated or treated with 1mM MTA. Lysates were immunoprecipitated with anti-Myc agarose or isotype control. Immunoblots were probed with a monoclonal anti-HA antibody and reprobed with a monoclonal anti-Myc (9E10) antibody to determine equal loading.

Figures 18A-18D show that NIP45 deficient mice have defects in Th cell cytokine production as well as non-T cell cytokine production.

25 **Detailed Description of the Invention**

This invention is based, at least in part, on the finding that NIP45 is a target of arginine methyl transferases (PRMTs) and that NIP45 and PRMTs are involved in cytokine production in both T and non-T cells. NIP45 (NFAT Interacting Protein 45) is a 45 kDa protein that interacts with NFAT proteins. A cDNA encoding NIP45 was isolated based upon the interaction of NIP45 with the Rel homology domain (RHD) of NFATp using a two-hybrid interaction trap assay in yeast (see Example 1). Coimmunoprecipitation experiments demonstrated that NIP45 and NFAT interact *in vivo* in mammalian cells (see

Example 2). The cDNA encoding NIP45 has been sequenced and characterized (see Example 3). Examination of the tissue expression pattern of NIP45 mRNA revealed that the NIP45 transcript is preferentially expressed in spleen, thymus and testis (see Example 4). Subcellular localization studies demonstrated that NIP45 protein is evenly distributed throughout the cell nucleus (see Example 5). Functional studies showed that NIP45 synergizes with NFAT to stimulate transcription from promoters containing NFAT binding sites and, moreover, synergizes with NFAT and c-Maf to stimulate transcription from the IL-4 promoter (see Example 6). Moreover, NIP45, NFAT and c-Maf can act in concert to induce expression of the endogenous IL-4 gene in cells that do not normally express IL-4 (*e.g.*, B cells.) (see Example 7).

In addition, the present invention demonstrates that arginine methylation plays an important role in cytokine production (Example 8). PRMT1 is the predominantly expressed arginine methyltransferase in T helper cells, and expression of PRMT1 is induced by TCR stimulation (Example 9). PRMT1 activates the IFN- γ and IL-4 promoters (Example 10), and one target of PRMT1 activity is the amino-terminus of the NFAT interacting protein, NIP45. Arginine methylation of NIP45 acts to modulate the interaction between NIP45 and NFAT, resulting in alterations of cytokine gene expression (Examples 11-14).

So that the invention may be more readily understood, certain terms are first defined.

I. Definitions

As used herein, the term "NFAT family protein" (also referred to as simply "NFAT") refers to the family of Nuclear Factors of Activated T cell transcription factors, including NFATp, NFATc, NFAT4/x/c3 and NFAT3/c4.

As used herein the term "Rel Homology Domain of an NFAT family protein" (abbreviated as RHD domain) refers to a domain within NFAT family proteins having approximately 70% sequence similarity within the RHD of the Rel/NF κ B family of transcription factors.

As used herein a "NIP45-interacting molecule" or "NIP45-binding molecule", used interchangeably herein, includes molecules, *e.g.*, a polypeptide, that interacts with NIP45. Non-limiting examples of NIP45-interacting molecules are PRMTs, *e.g.* PRMT1, and NFAT family members.

The term "interact" as used herein is meant to include detectable interactions between molecules, such as can be detected using, for example, a yeast two hybrid assay or coimmunoprecipitation. The term interact is also meant to include "binding" interactions between molecules. Interactions may be protein-protein or protein-nucleic acid in nature.

5 As used herein, "PRMT", includes *e.g.*, PRMT1, PRMT2, PRMT3, PRMT5, PRMT6, and CARM1. In a preferred embodiment, the term "PRMT" refers to PRMT1. PRMTs are polypeptide arginine methyltransferases that induce methylation, *e.g.*, monomethylation, of arginine residues as a reaction intermediate. PRMTs catalyze the sequential transfer of a methyl group from S-adenosylmethionene to the side chain
10 nitrogens of arginine residues within proteins to form methylated arginine derivatives and S-adenosyl-L-homocysteine. PRMTs are categorized as Type I (*e.g.*, PRMT1, PRMT3, PRMT6, and CARM1) and Type 2 (*e.g.*, PRMT). Type I protein arginine methyltransferases generate asymmetric dimethylation of arginine residues; type II protein arginine methyltransferases generate symmetric dimethyl arginine residues ((McBride, A.
15 E., and Silver, P. A. (2001) *Cell* 106: 5-8, Frankel, A., *et al.* (2002) *J Biol Chem* 277: 3537-3543). PRMTs are also described, *e.g.*, in USSN 20030017489.

As used herein the term "PRMT activity" or "PRMT biological activity" includes modulation of methylation of at least one arginine residue on a polypeptide.

As used herein, the term "NIP45-related activity of PRMT" includes one or
20 more of the following: the ability of a PRMT to bind to NIP45, the ability of a PRMT to modulate binding of NIP45 to NFAT family proteins, the ability of a PRMT to methylate at least one arginine residue of NIP45, the ability to modulate (*e.g.*, inhibit or enhance) cytokine production (for example, T cell receptor (TCR) initiated cytokine production or cytokine production by non-T cells such as mast cells), or the ability to modulate various
25 immune responses downstream of cytokine production (*e.g.*, the ability to modulate immune cell effector function, the ability to modulate the relative number of Th1 or Th2 cells).

As used herein, the various forms of the term "modulate" include stimulation (*e.g.*, increasing or upregulating a particular response or activity) and inhibition (*e.g.*,
30 decreasing or downregulating a particular response or activity).

As used herein, the term "contacting" (*i.e.*, contacting a cell *e.g.* an immune cell, with an compound) is intended to include incubating the compound and the cell together *in vitro* (*e.g.*, adding the compound to cells in culture) or administering the

compound to a subject such that the compound and cells of the subject are contacted *in vivo*. The term "contacting" is not intended to include exposure of cells to a modulator or compound that may occur naturally in a subject (*i.e.*, exposure that may occur as a result of a natural physiological process).

5 As used herein the term "upstream regulatory regions" or "upstream regulatory sequences" includes those sequences 5' of a gene, *e.g.*, promoters and/or enhancers, that control transcription of the gene. Upstream regulatory regions of many genes are known in the art and one of ordinary skill in the art can identify such regions. For example, given the sequence of genomic DNA upstream of, for example PRMT1 available
10 at GI:38083885, one of ordinary skill in the art can identify promoters and/or enhancers of PRMT.

 As used herein, the term "test compound" includes a compound that has not previously been identified as, or recognized to be one or more of the following: a modulator of the activity of a NIP45-interacting molecule, *e.g.*, PRMT, in immune cells; a modulator
15 of a NIP45-related activity of PRMT; or a modulator of the interaction between NIP45 and a NIP45 interacting polypeptide, *e.g.*, PRMT.

 The term "library of test compounds" is intended to refer to a panel comprising a multiplicity of test compounds.

 As used herein, the term "cell free composition" refers to an isolated
20 composition which does not contain intact cells. Examples of cell free compositions include cell extracts and compositions containing isolated proteins.

 As used herein, an "antisense" nucleic acid molecule comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, *e.g.*, complementary to the coding strand of a double-stranded cDNA molecule, complementary
25 to an mRNA sequence or complementary to the coding strand of a gene. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid.

 In one embodiment, a nucleic acid molecule of the invention is a compound that mediates RNA interference, RNAi. RNA interfering agents include, but are not limited to, nucleic acid molecules including RNA molecules which are homologous to the target
30 gene or genomic sequence, *e.g.*, NIP45 or a NIP45-interacting molecule, or a fragment thereof, "short interfering RNA" (siRNA), "short hairpin" or "small hairpin RNA" (shRNA), and small molecules which interfere with or inhibit expression of a target gene by RNA interference (RNAi). RNA interference is a post-transcriptional, targeted gene-

silencing technique that uses double-stranded RNA (dsRNA) to degrade messenger RNA (mRNA) containing the same sequence as the dsRNA (Sharp, P.A. and Zamore, P.D. 287, 2431-2432 (2000); Zamore, P.D., *et al. Cell* 101, 25-33 (2000). Tuschl, T. *et al. Genes Dev.* 13, 3191-3197 (1999)). The process occurs when an endogenous ribonuclease cleaves the longer dsRNA into shorter, 21- or 22-nucleotide-long RNAs, termed small interfering RNAs or siRNAs. The smaller RNA segments then mediate the degradation of the target mRNA. Kits for synthesis of RNAi are commercially available from, *e.g.* New England Biolabs and Ambion. In one embodiment one or more of the chemistries known in the art for use in antisense RNA can be employed.

As used herein, the term “immune response” includes immune cell-mediated (*e.g.*, T cell and/or B cell-mediated) immune responses that are influenced by modulation of immune cell activation. Exemplary immune responses include B cell responses (*e.g.*, antibody production), T cell responses (*e.g.*, proliferation, cytokine production and cellular cytotoxicity), and activation of cytokine responsive cells, *e.g.*, macrophages. In a preferred embodiment of the invention, an immune response is T cell mediated. As used herein, the term “downregulation” with reference to the immune response includes a diminution in one or more immune responses (*e.g.*, modulation of T cell-mediated immune responses) while the term “upregulation” with reference to the immune response includes an increase in any one or more immune responses, *e.g.*, T cell responses. It will be understood that upregulation of one type of immune response may lead to a corresponding downregulation in another type of immune response. For example, upregulation of the production of certain cytokines (*e.g.*, IL-10) can lead to downregulation of cellular immune responses.

As used herein, the term “immune cell” includes cells that are of hematopoietic origin and that play a role in the immune response. Immune cells include lymphocytes, such as B cells and T cells; natural killer cells; and myeloid cells, such as monocytes, macrophages, eosinophils, mast cells, basophils, and granulocytes.

As used herein, the term “T cell” includes CD4⁺ T cells and CD8⁺ T cells. The term T cell also includes both T helper 1 (Th1) type T cells and T helper 2 (Th2) type T cells, also referred to herein as “effector T cells”. The terms “antigen presenting cell” and “APC”, as used interchangeably herein, include professional antigen presenting cells (*e.g.*, B lymphocytes, monocytes, dendritic cells, and Langerhans cells) as well as other antigen presenting cells (*e.g.*, keratinocytes, endothelial cells, astrocytes, fibroblasts, and oligodendrocytes).

As used herein, the term “receptor” includes immune cell receptors that bind antigen, complexed antigen (*e.g.*, in the context of MHC molecules), or antibodies. Activating receptors include, *e.g.*, T cell receptors (TCRs), B cell receptors (BCRs), cytokine receptors, LPS receptors, complement receptors, and Fc receptors. For example, T cell receptors are present on T cells and are associated with CD3 molecules. T cell receptors are stimulated by antigen in the context of MHC molecules (as well as by polyclonal T cell activating reagents). T cell activation via the TCR results in numerous changes, *e.g.*, protein phosphorylation, membrane lipid changes, ion fluxes, cyclic nucleotide alterations, RNA transcription changes, protein synthesis changes, and cell volume changes.

As used herein, the term “dominant negative” includes polypeptide molecules (*e.g.*, portions or variants thereof) that compete with native (*i.e.*, wild-type) polypeptide molecules, but which compete with the native polypeptide and lack at least one activity of the native polypeptide, thereby downmodulating the activity of the native polypeptide.

As used herein, the term “nucleic acid molecule” includes DNA molecules (*e.g.*, cDNA or genomic DNA) and RNA molecules (*e.g.*, mRNA). The nucleic acid molecule may be single-stranded or double-stranded, but preferably is double-stranded DNA.

As used herein, the term “nucleic acid” includes wild-type nucleic acid molecules or fragments or equivalents thereof (*e.g.*, fragments or equivalents of NIP45 or NIP45-interacting molecules, *e.g.*, PRMT or NFAT). The nucleotide sequences of the wild-type NIP45, NFATc1, NFATc2, NFATc3 and PRMT1 are known in the art and described in, for example, Mak, C.H., *et al.* (1998) *Immunogenetics* 48:32-39, Pan, S., *et al.* (1997) *Biochem Biophys Res Comm* 240:314-323, McCaffrey, P.G., *et al.* (1993) *Science* 262:750-754, Ho, S.N., *et al.* (1995) *J Biol Chem* 270:19898-19907, and Pawlak, M.R., *et al.* (2000) *Mol Cell Biol* 20:4859-4869, respectively, the contents of which are incorporated herein by reference. The amino acid sequence of NIP45 protein has been determined (shown in SEQ ID NO: 2) and a cDNA encoding NIP45 protein has been isolated (the nucleotide sequence of which is shown in SEQ ID NO: 1). The nucleotide sequence of NFATc1 is shown in SEQ ID NO:3, the amino acid sequence in SEQ ID NO:4. The nucleotide sequence of NFATc2 is shown in SEQ ID NO:5, the amino acid sequence in SEQ ID NO:6. The nucleotide sequence of NFATc3 is shown in SEQ ID NO:7, the amino acid sequence in

SEQ ID NO:8. The nucleotide sequence of PRMT1 is shown in SEQ ID NO:9, the amino acid sequence in SEQ ID NO:10.

As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (*e.g.*, encodes a natural protein).

The term "equivalent" is intended to include nucleotide sequences encoding polypeptides that are functionally equivalent (*e.g.*, to NIP45 or NIP45-interacting molecule proteins) *i.e.*, proteins which maintain at least one biological activity of the native nucleic acid molecule. In one embodiment, a functionally equivalent NIP45 amino acid molecule has ability to interact with NFAT, in particular the NFAT Rel homology domain. In another embodiment, NIP45 has the ability to interact with PRMT. In another preferred embodiment, a functionally equivalent NIP45-interacting molecule has the ability to bind NIP45 in an immune cell, *e.g.*, a T cell. In another preferred embodiment, a functionally equivalent PRMT protein has at least one PRMT biological activity, preferably at least one NIP45-related biological activity, *e.g.*, the ability to modulate the binding of NIP45 and NFAT in an immune cell, *e.g.*, a T cell.

As used herein, an "isolated nucleic acid molecule" refers to a nucleic acid molecule that is free of gene sequences which naturally flank the nucleic acid in the genomic DNA of the organism from which the nucleic acid is derived (*i.e.*, gene sequences that are located adjacent to the isolated nucleic molecule in the genomic DNA of the organism from which the nucleic acid is derived). For example, in various embodiments, an isolated NIP45 or NIP45-interacting molecule nucleic acid molecule may contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, may be free of other cellular material.

As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60 % homologous to each other typically remain hybridized to each other. Preferably, the conditions are such that at least sequences at least 65 %, more preferably at least 70 %, and even more preferably at least 75 % homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989),

6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C.

As used herein, the term "coding region" refers to regions of a nucleotide sequence comprising codons which are translated into amino acid residues, whereas the term "noncoding region" refers to regions of a nucleotide sequence that are not translated into amino acids (*e.g.*, 5' and 3' untranslated regions).

As used herein, an "isolated protein" or "isolated polypeptide" refers to a protein or polypeptide that is substantially free of other proteins, polypeptides, cellular material and culture medium when isolated from cells or produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of, for example, NIP45 or NIP45-interacting molecules, protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced.

The nucleic acids of the invention can be prepared by standard recombinant DNA techniques. A nucleic acid of the invention can also be chemically synthesized using standard techniques. Various methods of chemically synthesizing polydeoxynucleotides are known, including solid-phase synthesis which has been automated in commercially available DNA synthesizers (See *e.g.*, Itakura *et al.* U.S. Patent No. 4,598,049; Caruthers *et al.* U.S. Patent No. 4,458,066; and Itakura U.S. Patent Nos. 4,401,796 and 4,373,071, incorporated by reference herein).

As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon

introduction into the host cell, and thereby are replicated along with the host genome.

Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" or simply "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" may be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

As used herein, the term "host cell" is intended to refer to a cell into which a nucleic acid of the invention, such as a recombinant expression vector of the invention, has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It should be understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

As used herein, the term "transgenic cell" refers to a cell containing a transgene.

As used herein, a "transgenic animal" refers to a non-human animal, *e.g.*, a swine, a monkey, a goat, or a rodent, *e.g.*, a mouse, in which one or more, and preferably essentially all, of the cells of the animal include a transgene, preferably a mammal, more preferably a mouse, in which one or more of the cells of the animal includes a "transgene". The term "transgene" refers to exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, for example directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal.

As used herein, the term "rodent" refers to all members of the phylogenetic order *Rodentia*.

As used herein, a "homologous recombinant animal" refers to a type of transgenic non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous gene, *e.g.*, NIP45 or a NIP45-interacting molecule, has been altered by homologous recombination between the endogenous gene and an exogenous DNA

molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

As used herein, the term "misexpression" includes a non-wild-type pattern of gene expression. Expression as used herein includes transcriptional, post transcriptional, *e.g.*, mRNA stability, translational, and post translational stages. Misexpression includes: expression at non-wild-type levels, *i.e.*, over or under expression; a pattern of expression that differs from wild-type in terms of the time or stage at which the gene is expressed, *e.g.*, increased or decreased expression (as compared with wild-type) at a predetermined developmental period or stage; a pattern of expression that differs from wild-type in terms of decreased expression (as compared with wild-type) in a predetermined cell type or tissue type; a pattern of expression that differs from wild-type in terms of the splicing size, amino acid sequence, post-translational modification, or biological activity of the expressed polypeptide; a pattern of expression that differs from wild-type in terms of the effect of an environmental stimulus or extracellular stimulus on expression of the gene, *e.g.*, a pattern of increased or decreased expression (as compared with wild-type) in the presence of an increase or decrease in the strength of the stimulus. Misexpression includes any expression from a transgenic nucleic acid. Misexpression includes the lack or non-expression of a gene or transgene, *e.g.*, that can be induced by a deletion of all or part of the gene or its control sequences.

As used herein, the term "knockout" refers to an animal or cell therefrom, in which the insertion of a transgene disrupts an endogenous gene in the animal or cell therefrom. For example, the disruption can essentially eliminate NIP45 or a NIP45-interacting molecule in the animal or cell. In preferred embodiments, misexpression of the gene encoding the NIP45 or a NIP45-interacting protein is caused by disruption of the gene encoding NIP45 or a NIP45-interacting molecule. For example, the gene can be disrupted through removal of DNA encoding all or part of the protein.

In preferred embodiments, the animal can be heterozygous or homozygous for a misexpressed gene, *e.g.*, it can be a transgenic animal heterozygous or homozygous for a transgene encoding NIP45 or a NIP45-interacting molecule.

In preferred embodiments, the animal is a transgenic mouse with a transgenic disruption of the gene encoding NIP45 or a NIP45-interacting molecule, preferably an insertion or deletion, which inactivates the gene product.

In another aspect, the invention features, a nucleic acid molecule which, when introduced into an animal or cell, results in the misexpression of the NIP45 or a NIP45-interacting molecule gene in the animal or cell. In preferred embodiments, the nucleic acid molecule, includes an NIP45 or a NIP45-interacting molecule nucleotide
5 sequence which includes a disruption, *e.g.*, an insertion or deletion and preferably the insertion of a marker sequence.

As used herein, the term "marker sequence" includes a nucleic acid molecule that (a) is used as part of a nucleic acid construct (*e.g.*, the targeting construct) to disrupt the expression of the gene of interest (*e.g.*, the NIP45 or a NIP45-interacting molecule) and (b)
10 is used to identify those cells that have incorporated the targeting construct into their genome. For example, the marker sequence can be a sequence encoding a protein which confers a detectable trait on the cell, such as an antibiotic resistance gene, *e.g.*, neomycin resistance gene, or an assayable enzyme not typically found in the cell, *e.g.*, alkaline phosphatase, horseradish peroxidase, luciferase, beta-galactosidase and the like.

As used herein, "disruption of a gene" refers to a change in the gene
15 sequence, *e.g.*, a change in the coding region. Disruption includes: insertions, deletions, point mutations, and rearrangements, *e.g.*, inversions. The disruption can occur in a region of the native NIP45 or a NIP45-interacting molecule DNA sequence (*e.g.*, one or more exons) and/or the promoter region of the gene so as to decrease or prevent expression of the
20 gene in a cell as compared to the wild-type or naturally occurring sequence of the gene. The "disruption" can be induced by classical random mutation or by site directed methods. Disruptions can be transgenically introduced. The deletion of an entire gene is a disruption. Preferred disruptions reduce NIP45 or a NIP45-interacting molecule levels to about 50% of wild-type, in heterozygotes or essentially eliminate NIP45 or a NIP45-interacting molecule
25 in homozygotes.

As used herein, the term "antibody" is intended to include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as Fab and F(ab')₂ fragments. Preferably, antibodies of the invention bind
30 specifically or substantially specifically to NIP45 or a NIP45-interacting molecule, *e.g.*, PRMT or NFAT molecules, (*i.e.*, have little to no cross reactivity with non-PRMT, non-NIP45, or non-NFAT molecules). The terms "monoclonal antibody" and "monoclonal antibody composition", as used herein, refer to a population of antibody molecules that

contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of an antigen. A monoclonal antibody composition thus typically displays a single binding affinity for a particular antigen with which it immunoreacts.

In one embodiment, small molecules may be used as test compounds. The term “small molecule” is a term of the art and includes molecules that are less than about 7500, less than about 5000, less than about 1000 molecular weight or less than about 500 molecular weight. In one embodiment, small molecules do not exclusively comprise peptide bonds. In another embodiment, small molecules are not oligomeric. Exemplary small molecule compounds which can be screened for activity include, but are not limited to, peptides, peptidomimetics, nucleic acids, carbohydrates, small organic molecules (*e.g.*, Cane *et al.* 1998. *Science* 282:63), and natural product extract libraries. In another embodiment, the compounds are small, organic non-peptidic compounds. In a further embodiment, a small molecule is not biosynthetic. For example, a small molecule is preferably not itself the product of transcription or translation.

Various aspects of the invention are described in further detail in the following subsections:

II. Screening Assays

The invention provides methods (also referred to herein as “screening assays”) for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptidomimetics, small molecules or other drugs) which modulate, for example one or more of: NIP45 activity (*e.g.*, the ability to bind to NFAT; the ability to modulate cytokine production in an immune cell (*e.g.*, a T cell or a non-T cell, such as an NK cell or a mast cell); or the ability to bind to PRMT); PRMT activity in an immune cell (*e.g.*, methylation of at least one arginine residue on a polypeptide; modulation of gene transcription); NIP45-related PRMT activity (*e.g.*, methylation of at least one residue on NIP45; modulation of the ability of NIP45 to bind to NFAT; modulation of cytokine production) or for testing or optimizing the activity of such agents.

The assays can be used to identify agents that modulate the function of NIP45 and/or a NIP45-binding molecule. For example, such agents may interact with NIP45 or the NIP45-binding molecule (*e.g.*, to inhibit or enhance their activity). The function of NIP45 or the NIP45-binding molecule can be affected at any level, including

transcription, protein expression, protein localization, and/or cellular activity. The subject assays can also be used to identify, *e.g.*, agents that alter the interaction of NIP45 or the NIP45-binding molecule with a binding partner, substrate, or cofactors.

The subject screening assays can measure the activity of NIP45 or a NIP45-binding protein directly (*e.g.*, arginine methylation of NIP45, binding of NIP45 to a NIP45-binding protein such as PRMT or NFAT, activation of gene transcription by NIP45), or can measure a downstream event controlled by modulation of NIP45 or a NIP45-binding protein (*e.g.*, by measuring the amount of cytokine produced by a cell or by measuring an effect of such cytokine production on a cell or organism).

The subject screening assays employ indicator compositions. These indicator compositions comprise the components required for performing an assay that detects and/or measures a particular event. The indicator compositions of the invention provide a reference readout and changes in the readout can be monitored in the presence of one or more test compounds. A difference in the readout in the presence and the absence of the compound indicates that the test compound is a modulator of the molecule(s) present in the indicator composition.

The indicator composition used in the screening assay can be a cell that expresses a NIP45 polypeptide or a NIP45-binding molecule, *e.g.*, the PRMT1, protein. For example, a cell that naturally expresses or, more preferably, a cell that has been engineered to express the protein by introducing into the cell an expression vector encoding the protein may be used. Preferably, the cell is a mammalian cell, *e.g.*, a human cell. In one embodiment, the cell is a T cell. In another embodiment, the cell is a non-T cell. Alternatively, the indicator composition can be a cell-free composition that includes the protein (*e.g.*, a cell extract or a composition that includes *e.g.*, either purified natural or recombinant protein).

In another embodiment, the indicator composition comprises more than one polypeptide. For example, in one embodiment the subject assays are performed in the presence of NIP45 and at least one NIP45-binding molecule, *e.g.*, PRMT. The indicator composition may further comprise a gene encoding at least one activator of cytokine gene transcription, *e.g.*, T-bet or an NFAT polypeptide, *e.g.*, NFATc1, NFATc2. In another embodiment, the indicator composition may further comprise a *maf* gene. In an exemplary embodiment, an indicator composition comprises expression vector(s) encoding PRMT, NIP45, NFATc2 and *c-maf*.

Compounds that modulate the expression and/or activity of PRMT, identified using the assays described herein can be useful for treating a subject that would benefit from the modulation of cytokine production. Exemplary conditions that can benefit from modulation of cytokine production include autoimmune disorders as well as
5 immunodeficiency disorders.

The subject screening assays can be performed in the presence or absence of other agents. In one embodiment, the subject assays are performed in the presence of an agent that provides a stimulatory signal to a cell. For example, in one embodiment, assays are performed in the presence of an agent that delivers (*e.g.*, an antibody that recognizes the
10 T cell receptor or an associated molecule) or mimics a T cell receptor-mediated signal (*e.g.*, PMA and Ionomycin).

In one embodiment, secondary assays can be used to confirm that the modulating agent effects a PRMT molecule or an NFAT molecule in a NIP45 related manner. For example, compounds identified in a primary screening assay can be used in a
15 secondary screening assay to determine whether the compound affects a NIP45-related activity. Accordingly, in another aspect, the invention pertains to a combination of two or more of the assays described herein. For example, a modulating agent can be identified using a cell-based or a cell-free assay, and the ability of the agent to modulate the activity of PRMT can be confirmed *in vivo*, *e.g.*, in an animal such as, for example, in an animal
20 model of a disorder or a NIP45 transgenic animal.

Moreover, a modulator of cytokine production, expression and/or activity identified as described herein (*e.g.*, an antisense nucleic acid molecule, or a specific antibody, or a small molecule) may be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such a modulator. Alternatively, a modulator
25 identified as described herein may be used in an animal model to determine the mechanism of action of such a modulator.

In one embodiment, the screening assays of the invention are high throughput or ultra high throughput (*e.g.*, Fernandes PB, Curr Opin Chem Biol. 1998 2:597; Sundberg SA, Curr Opin Biotechnol. 2000, 11:47).

30 In one embodiment, secondary assays can be used to confirm that the modulating agent effects a PRMT molecule or an NFAT molecule in a NIP45 related manner. For example, compounds identified in a primary screening assay can be used in a

secondary screening assay to determine whether the compound affects a NIP45-related activity.

Exemplary cell based and cell free assays of the invention are described in more detail below.

5

A. Cell Based Assays

The indicator compositions of the invention may be cells that express a NIP45 or a NIP45-interacting molecule (*e.g.*, a PRMT or an NFAT protein). For example, a cell that naturally expresses endogenous polypeptide, or, more preferably, a cell that has
10 been engineered to express one or more exogenous polypeptides, *e.g.*, by introducing into the cell an expression vector encoding the protein may be used in a cell based assay.

The cells used in the instant assays can be eukaryotic or prokaryotic in origin. For example, in one embodiment, the cell is a bacterial cell. In another embodiment, the cell is a fungal cell, *e.g.*, a yeast cell. In another embodiment, the cell is a
15 vertebrate cell, *e.g.*, an avian or a mammalian cell (*e.g.*, a murine cell, or a human cell). In a preferred embodiment, the cell is a human cell.

Preferably a cell line is used which expresses low levels of endogenous NIP45 and/or a NIP45-interacting polypeptide and is then engineered to express recombinant protein.

20 Preferably, a cell is capable of producing IFN- γ or IL-4 (either naturally or upon expression of transgenic sequences). For example, IFN- γ is naturally secreted by CD4⁺ T cells, CD8⁺ T cells, natural killer cells and dendritic cells, while IL-4 is naturally produced by CD4⁺ T cells, NK T cells, and mast cells.

Recombinant expression vectors that may be used for expression of
25 polypeptides are known in the art. For example, the cDNA is first introduced into a recombinant expression vector using standard molecular biology techniques. A cDNA can be obtained, for example, by amplification using the polymerase chain reaction (PCR) or by screening an appropriate cDNA library.

Following isolation or amplification of a cDNA molecule encoding the gene
30 of interest, *e.g.*, NIP45 or a NIP45-interacting polypeptide, the DNA fragment is introduced into an expression vector. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which

additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other
5 vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" or simply "expression vectors". In general, expression vectors of utility
10 in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" may be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

15 The recombinant expression vectors of the invention comprise a nucleic acid molecule in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression and the level of expression desired, which is operatively linked to the nucleic acid sequence to be expressed. Within a
20 recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" includes promoters, enhancers and other expression control elements (*e.g.*,
25 polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell, those which direct expression of the nucleotide sequence only in certain host cells (*e.g.*, tissue-specific
30 regulatory sequences) or those which direct expression of the nucleotide sequence only under certain conditions (*e.g.*, inducible regulatory sequences).

When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are

derived from polyoma virus, adenovirus, cytomegalovirus and Simian Virus 40. Non-limiting examples of mammalian expression vectors include pCDM8 (Seed, B., (1987) *Nature* 329:840) and pMT2PC (Kaufman *et al.* (1987), *EMBO J.* 6:187-195). A variety of mammalian expression vectors carrying different regulatory sequences are commercially available. For constitutive expression of the nucleic acid in a mammalian host cell, a preferred regulatory element is the cytomegalovirus promoter/enhancer. Moreover, inducible regulatory systems for use in mammalian cells are known in the art, for example systems in which gene expression is regulated by heavy metal ions (see *e.g.*, Mayo *et al.* (1982) *Cell* 29:99-108; Brinster *et al.* (1982) *Nature* 296:39-42; Searle *et al.* (1985) *Mol. Cell. Biol.* 5:1480-1489), heat shock (see *e.g.*, Nouer *et al.* (1991) in *Heat Shock Response*, e.d. Nouer, L., CRC, Boca Raton, FL, pp167-220), hormones (see *e.g.*, Lee *et al.* (1981) *Nature* 294:228-232; Hynes *et al.* (1981) *Proc. Natl. Acad. Sci. USA* 78:2038-2042; Klock *et al.* (1987) *Nature* 329:734-736; Israel & Kaufman (1989) *Nucl. Acids Res.* 17:2589-2604; and PCT Publication No. WO 93/23431), FK506-related molecules (see *e.g.*, PCT Publication No. WO 94/18317) or tetracyclines (Gossen, M. and Bujard, H. (1992) *Proc. Natl. Acad. Sci. USA* 89:5547-5551; Gossen, M. *et al.* (1995) *Science* 268:1766-1769; PCT Publication No. WO 94/29442; and PCT Publication No. WO 96/01313). Still further, many tissue-specific regulatory sequences are known in the art, including the albumin promoter (liver-specific; Pinkert *et al.* (1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji *et al.* (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne and Ruddle (1989) *Proc. Natl. Acad. Sci. USA* 86:5473-5477), pancreas-specific promoters (Edlund *et al.* (1985) *Science* 230:912-916) and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the α -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546).

Vector DNA may be introduced into mammalian cells via conventional transfection techniques. As used herein, the various forms of the term "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.*, DNA) into mammalian host cells, including calcium phosphate co-precipitation,

DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transfecting host cells can be found in Sambrook *et al.* (*Molecular Cloning: A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory manuals.

5 For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.*, resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable
10 markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on a separate vector from that encoding NIP45 or a NIP45-interacting polypeptide, *e.g.* PRMT or, more preferably, on the same vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the
15 selectable marker gene will survive, while the other cells die).

 In one embodiment, within the expression vector coding sequences are operatively linked to regulatory sequences that allow for constitutive expression of the molecule in the indicator cell (*e.g.*, viral regulatory sequences, such as a cytomegalovirus promoter/enhancer, may be used). Use of a recombinant expression vector that allows for
20 constitutive expression of the genes in the indicator cell is preferred for identification of compounds that enhance or inhibit the activity of the molecule. In an alternative embodiment, within the expression vector the coding sequences are operatively linked to regulatory sequences of the endogenous gene (*i.e.*, the promoter regulatory region derived from the endogenous gene). Use of a recombinant expression vector in which expression is
25 controlled by the endogenous regulatory sequences is preferred for identification of compounds that enhance or inhibit the transcriptional expression of the molecule.

 For example, an indicator cell can be transfected with an expression vector comprising a polypeptide arginine methyltransferase (PRMT), incubated in the presence and in the absence of a test compound, and the effect of the compound on the expression of
30 the molecule or on a biological response regulated by PRMT, *e.g.*, a NIP45-related activity of PRMT1, can be determined. The biological activities of PRMT include activities determined *in vivo*, or *in vitro*, according to standard techniques. Activity can be a direct activity, such as an association with or enzymatic activity on a target molecule (*e.g.*, a

protein such as the NIP45 protein). Alternatively, activity may be an indirect activity, such as, for example, a cellular signaling activity occurring downstream of the interaction of the protein with a target molecule or a biological effect occurring as a result of the signaling cascade triggered by that interaction. For example, indirect biological activities of PRMT described herein include: the ability to modulate cytokine production, for example, T cell receptor (TCR) initiated cytokine production or non-T cell cytokine production.

Compounds that modulate cytokine production, expression and/or activity of may be identified using various "read-outs." For example, a variety of reporter genes are known in the art and are suitable for use in the screening assays of the invention. Examples of suitable reporter genes include those which encode chloramphenicol acetyltransferase, beta-galactosidase, alkaline phosphatase or luciferase. Standard methods for measuring the activity of these gene products are known in the art.

For example, in one embodiment, gene expression of NIP45, or a NIP45-binding molecule can be measured. In another embodiment, expression of a gene controlled by NIP45 (*e.g.*, IFN- γ , IL-4, Egr2, Egr3, c-Rel, or p65) can be measured.

To determine whether a test compound modulates expression, *in vitro*, transcriptional assays can be performed. For example, mRNA or protein expression can be measured using methods well known in the art. For instance, one or more of Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR, or microarray analysis (*e.g.*, Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, eds., John Wiley & Sons, Inc.; Freeman WM *et al.*, Biotechniques 1999 26:112; Kallioniemi *et al.* 2001 Ann. Med. 33:142; Blohm and Guiseppi-Eli 2001 Curr Opin Biotechnol. 12:41) may be used to confirm that expression is modulated in cells treated with a modulating agent.

In another example, agents that modulate the expression of a PRMT can be identified by operably linking the upstream regulatory sequences (*e.g.*, the full length promoter and enhancer) of a PRMT to a reporter gene such as chloramphenicol acetyltransferase (CAT) or luciferase and introducing in into host cells. The ability of an agent to modulate the expression of the reporter gene product as compared to control cells (*e.g.*, not exposed to the compound) can be measured.

In another exemplary embodiment, the ability of a compound to modulate the ability of PRMT and NIP45 to control cytokine gene expression can be measured. For example, a cell comprising NIP45, or a biologically active fragment thereof (*e.g.*, amino acids 1-32 of NIP45), PRMT, and upstream regulatory sequences (*e.g.*, the full length

promoter and enhancer) of a cytokine gene, such as IFN γ or IL-4, operably linked to a reporter gene can be used to assay for the ability of a compound to modulate cytokine gene production. A change in reporter gene expression (*e.g.*, as compared to a control not exposed to the compound) identifies the compound as a modulator of cytokine gene expression. Other techniques are well known to those of skill in the art. Additional exemplary techniques are illustrated in the instant examples.

As used interchangeably herein, the terms “operably linked” and “operatively linked” are intended to mean that the nucleotide sequence is linked to a regulatory sequence in a manner which allows expression of the nucleotide sequence in a host cell (or by a cell extract). Regulatory sequences are art-recognized and can be selected to direct expression of the desired protein in an appropriate host cell. The term regulatory sequence is intended to include promoters, enhancers, polyadenylation signals and other expression control elements. Such regulatory sequences are known to those skilled in the art and are described in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). It should be understood that the design of the expression vector may depend on such factors as the choice of the host cell to be transfected and/or the type and/or amount of protein desired to be expressed.

In one embodiment, the level of expression of the reporter gene in the indicator cell in the presence of the test compound is higher than the level of expression of the reporter gene in the indicator cell in the absence of the test compound and the test compound is identified as a compound that stimulates the expression of a cytokine gene. In another embodiment, the level of expression of the reporter gene in the indicator cell in the presence of the test compound is lower than the level of expression of the reporter gene in the indicator cell in the absence of the test compound and the test compound is identified as a compound that inhibits the expression of a cytokine gene.

In another embodiment, protein expression may be measured. For example, standard techniques such as Western blotting or in situ detection can be used.

In one embodiment, the ability of a compound to modulate cytokine production can be determined by measuring the intracellular concentration of a cytokine (using intracellular cytokine FACS). In one embodiment, the ability of a compound to modulate cytokine production can be determined by measuring the concentration of the cytokine secreted by a cell. For example, IFN γ or IL-4 can be measured by measuring the

effect of the supernatant on an indicator cell line (*e.g.*, on proliferation of the indicator cell line), or, *e.g.*, in an ELISA assay.

In one embodiment a downstream effect of modulation of cytokine production, *e.g.*, the effect of a compound on differentiation of cells, *e.g.*, T cells, may be used as an indicator of modulation of NIP45 or a NIP45-interacting protein. Cell differentiation can be monitored directly (*e.g.* by microscopic examination of the cells for monitoring cell differentiation), or indirectly, *e.g.*, by monitoring one or more markers of cell differentiation (*e.g.*, an increase in mRNA for a gene product associated with cell differentiation, or the secretion of a gene product associated with cell differentiation, such as the secretion of a protein (*e.g.*, the secretion of cytokines) or the expression of a cell surface marker. Standard methods for detecting mRNA of interest, such as reverse transcription-polymerase chain reaction (RT-PCR) and Northern blotting, are known in the art. Standard methods for detecting protein secretion in culture supernatants, such as enzyme linked immunosorbent assays (ELISA), are also known in the art. Proteins can also be detected using antibodies, *e.g.*, in an immunoprecipitation reaction or for staining and FACS analysis.

In another embodiment, the ability of a compound to modulate immune cell function (*e.g.*, effector T cell function) can be determined. For example, in one embodiment, the ability of a compound to modulate cellular function(s) dependent on exposure to cytokines. For example, cell proliferation, cell differentiation, cytokine production, cytotoxicity, or phagocytosis can be measured using techniques well known in the art. A number of art-recognized readouts can be used.

The ability of the test compound to modulate NIP45 or a NIP45-interacting polypeptide binding to a substrate or target molecule can also be determined. Determining the ability of the test compound to modulate, for example, PRMT, binding to a target molecule (*e.g.*, a binding partner such as a substrate) can be accomplished, for example, by determining the ability of the molecules to be coimmunoprecipitated or by coupling the target molecule with a radioisotope or enzymatic label such that binding of the target molecule to NIP45 or a NIP45-interacting polypeptide can be determined, *e.g.*, by detecting the labeled NIP45 target molecule in a complex. Alternatively, for example, PRMT, can be coupled with a radioisotope or enzymatic label to monitor the ability of a test compound to modulate, PRMT, binding to a target molecule in a complex.

Whereas the ability of NIP45 to bind to PRMT or NFAT is associated with increased cytokine production, the ability of NIP45 to bind to TRAF2 is associated with decreased binding of NIP45 to NFAT and decreased IL-4 production (Liebersson *et al.* 2001 J. Exp. Med 194:89). Accordingly, in another embodiment, the ability of a compound to modulate the binding of NIP45 to TRAF2 can also be measured. Increased binding to TRAF2 is associated with decreased NIP45 activity and decreased cytokine production.

Determining the ability of the test compound to bind to NIP45 can be accomplished, for example, by coupling the compound with a radioisotope or enzymatic label such that binding of the compound can be determined by detecting the labeled compound in a complex. For example, targets can be labeled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation counting. Alternatively, compounds can be labeled, *e.g.*, with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

In another embodiment, fluorescence technologies can be used, *e.g.*, fluorescence polarization, time-resolved fluorescence, and fluorescence resonance energy transfer (Selvin PR, Nat. Struct. Biol. 2000 7:730; Hertzberg RP and Pope AJ, Curr Opin Chem Biol. 2000 4:445).

It is also within the scope of this invention to determine the ability of a compound to interact with NIP45, a NIP45-interacting molecule without the labeling of any of the interactants. For example, a microphysiometer may be used to detect the interaction of a compound with a NIP45, a NIP45-interacting molecule without the labeling of either the compound or the molecule (McConnell, H. M. *et al.* (1992) *Science* 257:1906-1912). As used herein, a "microphysiometer" (*e.g.*, Cytosensor) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate may be used as an indicator of the interaction between compounds.

In yet another aspect of the invention, the NIP45 or a NIP45-interacting polypeptide protein or fragments thereof may be used as "bait protein" *e.g.*, in a two-hybrid assay or three-hybrid assay (see, *e.g.*, U.S. Patent No. 5,283,317; Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054; Bartel *et al.* (1993) *Biotechniques* 14:920-924; Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and Brent

WO94/10300), to identify other proteins, which bind to or interact with NIP45 or a NIP45-interacting polypeptide ("binding proteins" or "bp") and are involved in NIP45 or a NIP45-interacting molecule activity. Such NIP45- or NIP45-interacting molecule-binding proteins are also likely to be involved in the propagation of signals by the NIP45 or a NIP45-

5 interacting molecule proteins. The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a NIP45 or a NIP45-interacting molecule protein is fused to a gene encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct, 10 a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming an NIP45- or a NIP45-interacting molecule-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This 15 proximity allows transcription of a reporter gene (*e.g.*, LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the NIP45 or a NIP45-interacting molecule protein.

20

B. Cell-free assays

Alternatively, the indicator composition can be a cell-free composition that includes a NIP45 and/or a NIP45-interacting molecule (*e.g.*, PRMT1 or an NFAT protein) 25 *e.g.*, a cell extract from a cell expressing the protein or a composition that includes purified either natural or recombinant protein.

In one embodiment, the indicator composition is a cell free composition. Polypeptides expressed by recombinant methods in a host cells or culture medium can be isolated from the host cells, or cell culture medium using standard methods for protein 30 purification. For example, ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies may be used to produce a purified or semi-purified protein that may be used in a cell free composition. Alternatively, a lysate or an extract of cells expressing the protein of interest can be

prepared for use as cell-free composition. Cell extracts with the appropriate post-translation modifications of proteins can be prepared using commercially available resources found at, for example Promega, Inc., and include but are not limited to reticulocyte lysate, wheat germ extract and *E. coli* S30 extract.

5 In one embodiment, compounds that specifically modulate an activity of NIP45 or a NIP45-binding molecule may be identified. For example. Compounds that modulate an activity of PRMT (*e.g.*, a NIP45 related activity) are identified based on their ability to modulate the interaction of PRMT with a target molecule to which PRMT binds, *e.g.*, NIP45. In another embodiment, compounds that modulate an activity of NIP45 are
10 identified based on their ability to modulate interaction of NIP45 with a NIP45-binding molecule, *e.g.*, NFAT. Suitable assays are known in the art that allow for the detection of protein-protein interactions (*e.g.*, immunoprecipitations and the like) or that allow for the detection of interactions between a DNA binding protein with a target DNA sequence (*e.g.*, electrophoretic mobility shift assays, DNase I footprinting assays and the like). By
15 performing such assays in the presence and absence of test compounds, these assays may be used to identify compounds that modulate (*e.g.*, inhibit or enhance) the interaction of NIP45 or a NIP45-binding molecule with a target molecule.

 In the methods of the invention for identifying test compounds that modulate an interaction between a NIP45-interacting protein and NIP45, the complete NIP45 protein
20 may be used in the method, or, alternatively, only portions of the protein may be used. For example, an isolated NIP45 domain (*e.g.*, consisting of amino acids 1-32 or a larger subregion comprising amino acids 1-32 or a fusion protein comprising amino acids 1-32 of NIP45) may be used. An assay may be used to identify test compounds that either stimulate or inhibit the interaction between the NIP45 protein and a target molecule. A test
25 compound that stimulates the interaction between the protein and a target molecule is identified based upon its ability to increase the degree of interaction between (*e.g.*, NIP45 and a target molecule or PRMT and a target molecule) as compared to the degree of interaction in the absence of the test compound and such a compound would be expected to increase the activity of NIP45 in the cell. A test compound that inhibits the interaction
30 between the protein and a target molecule is identified based upon its ability to decrease the degree of interaction between the protein and a target molecule as compared to the degree of interaction in the absence of the compound and such a compound would be expected to decrease NIP45 activity.

In one embodiment, the amount of binding of NIP45 to a NIP45-interacting molecule in the presence of the test compound is greater than the amount of binding in the absence of the test compound, in which case the test compound is identified as a compound that enhances binding of NIP45 to a NIP45 interacting molecule. In another embodiment, the amount of binding of the NIP45 to the binding molecule in the presence of the test compound is less than the amount of binding of NIP45 to the binding molecule in the absence of the test compound, in which case the test compound is identified as a compound that inhibits binding of NIP45 to the binding molecule.

For example, binding of the test compound to NIP45 or a NIP45-interacting polypeptide can be determined either directly or indirectly as described above. Determining the ability of NIP45 protein to bind to a test compound can also be accomplished using a technology such as real-time Biomolecular Interaction Analysis (BIA) (Sjolander, S. and Urbaniczky, C. (1991) *Anal. Chem.* 63:2338-2345; Szabo *et al.* (1995) *Curr. Opin. Struct. Biol.* 5:699-705). As used herein, "BIA" is a technology for studying biospecific interactions in real time, without labeling any of the interactants (*e.g.*, BIAcore). Changes in the optical phenomenon of surface plasmon resonance (SPR) may be used as an indication of real-time reactions between biological molecules.

In another embodiment, the ability of a compound to modulate the ability of NIP45 or a NIP45-interacting molecule to be acted on by an enzyme or to act on a substrate can be measured. In one embodiment, transferase assays can be used to detect the ability of PRMTs to methylate at least one arginine residue on a substrate. Such assays are well known in the art and may be performed as described (*e.g.*, Tang *et al.* 2000 *J. Biol. Chem.* 275:7723). In another embodiment, cell lysates may be harvested and immunoprecipitated with antibodies to isolate individual polypeptides for analysis of arginine methylation. Immunoprecipitates (*e.g.*, of NIP45) may then be subjected to an *in vitro* methylation assay, *e.g.*, using recombinant PRMT1.

For example, in one embodiment, hypomethylated cell lysates can produced and the ability of PRMTs to methylate various substrates after addition of 3H-S-adenosylmethionene is evaluated. In another embodiment, an anti-methylated arginine antibody (*e.g.*, specific for asymmetrically methylated arginines within RG repeats similar to those found in the amino-terminus of NIP45) can be used to identify polypeptides containing methylated arginine residues.

In one embodiment of the above assay methods, it may be desirable to immobilize either NIP45 or a NIP45-interacting polypeptide for example, to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, or to accommodate automation of the assay. Binding to a surface can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided in which a domain that allows one or both of the proteins to be bound to a matrix is added to one or more of the molecules. For example, glutathione-S-transferase fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or NIP45 protein, and the mixture incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components, the matrix is immobilized in the case of beads, and complex formation is determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, proteins may be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies which are reactive with protein or target molecules but which do not interfere with binding of the protein to its target molecule can be derivatized to the wells of the plate, and unbound target or NIP45 protein is trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with NIP45 or a NIP45-interacting polypeptide or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the NIP45 protein or binding molecule.

C. Assays Using Knock-Out Cells

In another embodiment, the invention provides methods for identifying compounds that modulate a cytokine production in cells deficient in NIP45. As described in the Examples, inhibition of NIP45 activity (*e.g.*, by disruption of the NIP45 gene) in immune cells results, *e.g.*, in a deficiency of IL-4 and IFN- γ production. Thus, cells deficient in NIP45 and/or a NIP45-binding molecule (*e.g.*, PRMT or NFAT) may be used to identify agents that modulate a biological response regulated by NIP45 by means other than modulating NIP45 itself (*i.e.*, compounds that “rescue” the NIP45 deficient phenotype). Alternatively, a “conditional knock-out” system, in which the gene is rendered non-functional in a conditional manner, may be used to create deficient cells for use in screening assays. For example, a tetracycline-regulated system for conditional disruption of a gene as described in WO 94/29442 and U.S. Patent No. 5,650,298 may be used to create cells, or animals from which cells can be isolated, deficient in specific polypeptides in a controlled manner through modulation of the tetracycline concentration in contact with the cells. Specific cell types, *e.g.*, lymphoid cells (*e.g.*, thymic, splenic and/or lymph node cells) or purified cells such as T cells from such animals may be used in screening assays. In one embodiment, the entire 5.4 kB exon 2 of NIP45 can be replaced, *e.g.*, with a neomycin cassette, resulting in an allele that produces no NIP45 protein. This embodiment is described in the appended examples.

In the screening method, cells deficient in NIP45 or a NIP45-binding molecule can be contacted with a test compound and a biological response regulated by NIP45 measured. Modulation of the response in the cells deficient in NIP45 (as compared to an appropriate control such as, for example, untreated cells or cells treated with a control agent) identifies a test compound as a modulator of the response.

In one embodiment, the test compound is administered directly to a non-human knock out animal, preferably a mouse (*e.g.*, a mouse in which the NIP45 gene or NIP45 interacting molecule gene, such as a PRMT gene) is conditionally disrupted by means described above, or a chimeric mouse in which the lymphoid organs are deficient in the gene, to identify a test compound that modulates the *in vivo* responses of cells deficient in the gene. In another embodiment, cells deficient in the gene are isolated from the non-human animal and contacted with the test compound *ex vivo* to identify a test compound that modulates a response regulated by the gene in the cells

Preferred non-human animals include monkeys, dogs, cats, mice, rats, cows, horses, goats and sheep. In preferred embodiments, the deficient animal is a mouse. Mice deficient in the gene can be made using methods known in the art. One example of such a method and the resulting NIP45 heterozygous and homozygous animals is described in the appended examples. Non-human animals deficient in a particular gene product typically are created by homologous recombination. In an exemplary embodiment, a vector is prepared which contains at least a portion of the gene into which a deletion, addition or substitution has been introduced to thereby alter, *e.g.*, functionally disrupt, the endogenous gene. The gene preferably is a mouse gene. For example, a mouse gene can be isolated from a mouse genomic DNA library using the mouse cDNA as a probe. The mouse gene then may be used to construct a homologous recombination vector suitable for modulating an endogenous gene in the mouse genome. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a "knock out" vector).

Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous gene is mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous protein). In the homologous recombination vector, the altered portion of the gene is flanked at its 5' and 3' ends by additional nucleic acid of the gene to allow for homologous recombination to occur between the exogenous gene carried by the vector and an endogenous gene in an embryonic stem cell. The additional flanking nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (see *e.g.*, Thomas, K.R. and Capecchi, M. R. (1987) *Cell* 51:503 for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (*e.g.*, by electroporation) and cells in which the introduced gene has homologously recombined with the endogenous gene are selected (see *e.g.*, Li, E. *et al.* (1992) *Cell* 69:915). The selected cells are then injected into a blastocyst of an animal (*e.g.*, a mouse) to form aggregation chimeras (see *e.g.*, Bradley, A. in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E.J. Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells may be used to breed animals in which all cells of the

animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, A. (1991) *Current Opinion in Biotechnology* 2:823-829 and in PCT International Publication Nos.: WO 90/11354 by Le
5 Mouellec *et al.*; WO 91/01140 by Smithies *et al.*; WO 92/0968 by Zijlstra *et al.*; and WO 93/04169 by Berns *et al.*

In one embodiment, compounds that modulate cytokine production are identified by contacting cells deficient in one or more test compounds *ex vivo* with the compound and determining the effect of the test compound on a read-out. In one
10 embodiment, deficient cells contacted with a test compound *ex vivo* can be readministered to a subject.

In one embodiment of the screening assay, compounds tested for their ability to modulate a cytokine production are contacted with deficient cells by administering the test compound to a non-human deficient animal *in vivo* and evaluating the effect of the test
15 compound on the response in the animal.

The test compound can be administered to a non-knock out animal as a pharmaceutical composition. Such compositions typically comprise the test compound and a pharmaceutically acceptable carrier. As used herein the term "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial
20 and antifungal compounds, isotonic and absorption delaying compounds, and the like, compatible with pharmaceutical administration. The use of such media and compounds for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or compound is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be
25 incorporated into the compositions. Pharmaceutical compositions are described in more detail below.

For practicing the screening method *ex vivo*, cells deficient, *e.g.*, in NIP45, can be isolated from a non-human deficient animal or embryo by standard methods and incubated (*i.e.*, cultured) *in vitro* with a test compound. Cells (*e.g.*, T cells) can be isolated
30 from *e.g.*, NIP45, deficient animals by standard techniques.

Following contact of the deficient cells with a test compound (either *ex vivo* or *in vivo*), the effect of the test compound on cytokine can be determined by any one of a variety of suitable methods, such as those set forth herein, *e.g.*, including light microscopic

analysis of the cells, histochemical analysis of the cells, production of proteins, induction of certain genes, *e.g.*, cytokine genes, such as IL-4 and IFN- γ .

III. Test Compounds

5 A variety of test compounds can be evaluated using the screening assays described herein. The term "test compound" includes any reagent or test agent which is employed in the assays of the invention and assayed for its ability to influence the production, expression and/or activity of cytokines. More than one compound, *e.g.*, a plurality of compounds, can be tested at the same time for their ability to modulate cytokine
10 production, expression and/or activity in a screening assay. The term "screening assay" preferably refers to assays which test the ability of a plurality of compounds to influence the readout of choice rather than to tests which test the ability of one compound to influence a readout. Preferably, the subject assays identify compounds not previously known to have the effect that is being screened for. In one embodiment, high throughput screening may be
15 used to assay for the activity of a compound.

 In certain embodiments, the compounds to be tested can be derived from libraries (*i.e.*, are members of a library of compounds). While the use of libraries of peptides is well established in the art, new techniques have been developed which have allowed the production of mixtures of other compounds, such as benzodiazepines (Bunin *et al.* (1992). *J. Am. Chem. Soc.* 114:10987; DeWitt *et al.* (1993). *Proc. Natl. Acad. Sci. USA* 90:6909) peptoids (Zuckermann. (1994). *J. Med. Chem.* 37:2678) oligocarbamates (Cho *et al.* (1993). *Science*. 261:1303-), and hydantoins (DeWitt *et al. supra*). An approach for the synthesis of molecular libraries of small organic molecules with a diversity of 104-105 as been described (Carell *et al.* (1994). *Angew. Chem. Int. Ed. Engl.* 33:2059- ; Carell *et al.*
20 (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061-).

 The compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries, synthetic library methods requiring deconvolution, the 'one-bead one-compound' library
30 method, and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S. (1997) *Anticancer Drug Des.* 12:145). Other exemplary methods for the

synthesis of molecular libraries can be found in the art, for example in: Erb *et al.* (1994). *Proc. Natl. Acad. Sci. USA* 91:11422- ; Horwell *et al.* (1996) *Immunopharmacology* 33:68- ; and in Gallop *et al.* (1994); *J. Med. Chem.* 37:1233.

Exemplary compounds which can be screened for activity include, but are
5 not limited to, peptides, nucleic acids, carbohydrates, small organic molecules, and natural product extract libraries.

Candidate/test compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, *e.g.*, Lam, K.S. *et al.* (1991) *Nature* 354:82-84; Houghten, R. *et al.* (1991) *Nature* 354:84-
10 86) and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids; 2) phosphopeptides (*e.g.*, members of random and partially degenerate, directed phosphopeptide libraries, see, *e.g.*, Songyang, Z. *et al.* (1993) *Cell* 72:767-778); 3) antibodies (*e.g.*, antibodies (*e.g.*, intracellular, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab')₂, Fab
15 expression library fragments, and epitope-binding fragments of antibodies); 4) small organic and inorganic molecules (*e.g.*, molecules obtained from combinatorial and natural product libraries); 5) enzymes (*e.g.*, endoribonucleases, hydrolases, nucleases, proteases, synthetases, isomerases, polymerases, kinases, phosphatases, oxido-reductases and ATPases), and 6) mutant forms of molecules (*e.g.*, dominant negative mutant forms of
20 NIP45 or a NIP45-binding protein).

The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library
25 method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S. (1997) *Anticancer Drug Des.* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in
30 the art, for example in: DeWitt *et al.* (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:6909; Erb *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann *et al.* (1994) *J. Med. Chem.* 37:2678; Cho *et al.* (1993) *Science* 261:1303; Carrell *et al.* (1994) *Angew. Chem. Int. Ed.*

Engl. 33:2059; Carell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and Gallop *et al.* (1994) *J. Med. Chem.* 37:1233.

Libraries of compounds can be presented in solution (*e.g.*, Houghten (1992) *Biotechniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), chips (Fodor (1993) *Nature* 364:555-556), bacteria (Ladner USP 5,223,409), spores (Ladner USP '409), plasmids (Cull *et al.* (1992) *Proc Natl Acad Sci USA* 89:1865-1869) or phage (Scott and Smith (1990) *Science* 249:386-390; Devlin (1990) *Science* 249:404-406; Cwirla *et al.* (1990) *Proc. Natl. Acad. Sci.* 87:6378-6382; Felici (1991) *J. Mol. Biol.* 222:301-310; Ladner *supra.*).

10 Compounds identified in the subject screening assays may be used, *e.g.*, in methods of modulating receptor mediated signaling, cytokine production or in methods of modulating one or more of the biological responses regulated by cytokine expression, and/or activity, *e.g.*, the modulation of immune cell effector function, or the relative number of Th1/Th2 cells. It will be understood that it may be desirable to formulate such
15 compound(s) as pharmaceutical compositions (described *supra*) prior to contacting them with cells.

 Once a test compound is identified that directly or indirectly modulates, *e.g.*, production, expression and/or activity of a gene regulated by NIP45 and/or a NIP45-binding molecule, by one of the variety of methods described herein, the selected test compound (or
20 "compound of interest") can then be further evaluated for its effect on cells, for example by contacting the compound of interest with cells either *in vivo* (*e.g.*, by administering the compound of interest to a subject) or *ex vivo* (*e.g.*, by isolating cells from the subject and contacting the isolated cells with the compound of interest or, alternatively, by contacting the compound of interest with a cell line) and determining the effect of the compound of
25 interest on the cells, as compared to an appropriate control (such as untreated cells or cells treated with a control compound, or carrier, that does not modulate the biological response).

 The instant invention also pertains to compounds identified in the subject screening assays.

30 **IV. Pharmaceutical Compositions**

 A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. For example, solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following

components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial compounds such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating compounds such as ethylenediaminetetraacetic acid; buffers
5 such as acetates, citrates or phosphates and compounds for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile
10 aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition will preferably be sterile and should be fluid to the extent that easy
15 syringability exists. It will preferably be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can
20 be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal compounds, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic compounds, for example,
25 sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an compound which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active
30 compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those

enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

5 Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding compounds, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating compound 10 such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening compound such as sucrose or saccharin; or a flavoring compound such as peppermint, methyl salicylate, or orange flavoring.

 In one embodiment, the test compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release 20 formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers may be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from, *e.g.*, Alza Corporation and Nova Pharmaceuticals, Inc. 25 Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

30

V. *Methods of Use*

The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder

that would benefit from modulation of NIP45 or a NIP45-binding molecule. Such disorders include those associated with an aberrant cytokine production, *e.g.*, inappropriate Th1 or Th2 responses. For example, an immune system disorder or condition associated with an undesirable immune response (such as an unwanted or excessive inflammatory response, an autoimmune disorder, graft-versus-host disease (GVHD), an allogeneic transplant) or an immune system disorder or condition that would benefit from an enhanced immune response, *e.g.* immunosuppression.

In one aspect, the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant or unwanted immune response or, alternatively, an abnormally low immune response, by administering to the subject an agent which modulates the activity of NIP45 or a NIP45-interacting polypeptide, *e.g.*, PRMT. Subjects at risk for such disorders can be identified, for example, using methods described herein or any one or a combination of diagnostic or prognostic assays known in the art. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the aberrant immune response, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of immune response aberrancy, for example, a compound that stimulates the expression and/or activity of NIP45 or a NIP45 binding molecule or a compound that inhibits the expression and/or activity of NIP45 or a NIP45-binding molecule may be used for treating a subject. Agents for use can be known (*e.g.*, sense or antisense nucleic acid molecules encoding NIP45 or NIP45 interacting molecules or the polypeptides they encode) or can be identified, *e.g.*, using the screening assays described herein (*e.g.*, a PRMT1 agonist or antagonist, a peptidomimetic of a PRMT1 agonist or antagonist, a PRMT1 peptidomimetic, or other small molecule).

Modulatory methods of the invention involve contacting a cell (*e.g.*, an immune cell, *e.g.*, a T cell or a non-T cell) with a agent that modulates the activity and/or expression of NIP45 and/or a NIP45 interacting molecule.

These modulatory methods can be performed *in vitro* (*e.g.*, by contacting the cell with the agent) or, alternatively, *in vivo* (*e.g.*, by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a condition or disorder that would benefit from up- or down-modulation of cytokine production, *e.g.*, a disorder characterized by an unwanted, insufficient, or aberrant immune response. In one embodiment, the method involves administering an agent (*e.g.*, an agent

identified by a screening assay described herein), or combination of agents that modulates (e.g., upregulates or downregulates) cytokine expression and/or activity.

Inhibition of cytokine production is desirable in situations in which cytokine production is abnormally upregulated and/or in which decreased cytokine production is likely to have a beneficial effect, for example in a situation of an excessive or unwanted immune response. Such situations include conditions, disorders, or diseases such as an autoimmune disorder, a transplant (e.g., a bone marrow transplant, a stem cell transplant, a heart transplant, a lung transplant, a liver transplant, a kidney transplant, a cornea transplant, or a skin transplant), graft versus host disease (GVHD), an allergy, or in inflammatory disorder. Likewise, upregulation of cytokine production is desirable in situations in which cytokine production is abnormally downregulated and/or in which increased cytokine production is likely to have a beneficial effect (e.g., in a neoplasia). In addition, INF- γ production is not detected in AIDS patients and has been shown to be important for controlling infection by intracellular parasites, e.g., *Cryptosporidium*, and preventing chronic disease (White, *et al.* (2000) *J. Infect. Dis.* 181: 701-709). In addition, Takayanagi, H., *et al.* ((2000) *Nature* 408: 600-605) demonstrated that T-cell production of INF- γ strongly suppresses osteoclastogenesis. Further, enhance immune responses may be of benefit in treating neoplastic conditions.

As used herein, the term "autoimmunity" refers to the condition in which a subject's immune system starts reacting against his or her own tissues. Non-limiting examples of autoimmune diseases and disorders having an autoimmune component that would benefit from modulation of a cytokine production include type 1 diabetes, arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis), multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, autoimmune thyroiditis, dermatitis (including atopic dermatitis and eczematous dermatitis), psoriasis, Sjögren's Syndrome, including keratoconjunctivitis sicca secondary to Sjögren's Syndrome, alopecia areata, allergic responses due to arthropod bite reactions, Crohn's disease, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma, cutaneous lupus erythematosus, scleroderma, drug eruptions, leprosy reversal reactions, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic

sprue, lichen planus, Crohn's disease, Graves ophthalmopathy, sarcoidosis, primary biliary cirrhosis, uveitis posterior, and interstitial lung fibrosis.

The terms "neoplasia," "hyperplasia," and "tumor" are often commonly referred to as "cancer," which is a general name for more than 100 disease that are characterized by uncontrolled, abnormal growth of cells. Examples of malignancies include but are not limited to acute lymphoblastic leukemia; acute myeloid leukemia; adrenocortical carcinoma; AIDS-related lymphoma; cancer of the bile duct; bladder cancer; bone cancer, osteosarcoma; malignant fibrous histiocytoma; brain stem glioma; brain tumor; breast cancer; bronchial adenomas; carcinoid tumors; adrenocortical carcinoma; central nervous system lymphoma; cancer of the sinus, cancer of the gall bladder; gastric cancer; cancer of the salivary glands; cancer of the esophagus; neural cell cancer; intestinal cancer (*e.g.*, of the large or small intestine); cervical cancer; colon cancer; colorectal cancer; cutaneous T-cell lymphoma; B-cell lymphoma; T-cell lymphoma; endometrial cancer; epithelial cancer; endometrial cancer; intraocular melanoma; retinoblastoma; hairy cell leukemia; liver cancer; Hodgkin's disease; Kaposi's sarcoma; acute lymphoblastic leukemia; lung cancer; non-Hodgkin's lymphoma; melanoma; multiple myeloma; neuroblastoma; prostate cancer; retinoblastoma; Ewing's sarcoma; vaginal cancer; Waldenstrom's macroglobulinemia; adenocarcinomas; ovarian cancer, chronic lymphocytic leukemia, pancreatic cancer; and Wilm's tumor.

Exemplary agents for use in upmodulating cytokine production include, *e.g.*, nucleic acid molecules encoding NIP45 or NIP45-interacting molecule polypeptides (*e.g.*, PRMT or NFAT), NIP45 or NIP45-interacting molecule polypeptides, and compounds that stimulate the expression and/or activity of NIP45 or a NIP45-binding molecule (*e.g.*, interaction of NIP45 with PRMT1 or NFAT family members).

Exemplary agents for use in downmodulating cytokine production (*i.e.*, cytokine antagonists) include agents that inhibit the activity of NIP45 or NIP45-interacting molecule in an immune cell (*e.g.*, antisense molecules, siRNA molecules, dominant negative mutants, or compounds identified in the subject screening assays).

A. Downregulation of Immune Responses

There are numerous embodiments of the invention for downregulating the function of a cytokines to thereby downregulate immune responses. Downregulation can be in the form of inhibiting or blocking an immune response already in progress, or may

involve preventing the induction of an immune response. The functions of activated immune cells can be inhibited by downregulating immune cell responses or by inducing specific anergy in immune cells, or both.

For example, cytokine activity can be inhibited by contacting a cell which
5 expresses NIP45 or NIP45-interacting molecule with an agent that inhibits the expression and/or activity NIP45 or NIP45-interacting molecule.

In another embodiment, immune responses can be downregulated in a subject by removing immune cells from the patient, contacting the immune cells *in vitro* with an agent (*e.g.*, a small molecule) that downregulates NIP45 or NIP45-interacting
10 molecule activity, and reintroducing the *in vitro*-stimulated immune cells into the patient.

Downregulating immune responses by inhibiting NIP45 activity or a NIP45-interacting polypeptide activity is useful in downmodulating the immune response, *e.g.*, in situations of tissue, skin and organ transplantation, in graft-versus-host disease (GVHD), or allergies, or in autoimmune diseases such as systemic lupus erythematosus and multiple
15 sclerosis. For example, blockage of Th1 cytokine production may result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by immune cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits the activity of NIP45, *e.g.*, by blocking the interaction of NIP45 with, for example,
20 NFAT family members or PRMT, in immune cells alone or in conjunction with another downmodulatory agent can inhibit the generation of an immune response.

An immune response can be further inhibited by the use of an additional agent that can thereby downmodulate the immune response, as described further herein. Downmodulatory agents that may be used in connection with the downmodulatory
25 methods of the invention include, for example, blocking antibodies against other immune cell markers, or soluble forms of other receptor ligand pairs (*e.g.*, agents that disrupt the interaction between CD40 and CD40 ligand (*e.g.*, anti CD40 ligand antibodies)), antibodies against cytokines, general immunosuppressive drugs (*e.g.*, FK506, cyclosporin, rapamycin, steroids) or inhibitors of IL-4, *e.g.*, AG-490, a Janus tyrosine kinase (JAK) 2-JAK3
30 inhibitor.

Inhibition of cytokine production, in particular TH2 cytokine production, may also be useful in treating autoimmune disease. Many autoimmune disorders are the result of inappropriate activation of immune cells that are reactive against self tissue and

which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive immune cells may reduce or eliminate disease symptoms. For example, administration of agents that inhibit an activity of NIP45 or NIP45-interacting molecule may lead to long-term relief from the disease.

5 Additionally, co-administration of agents which block costimulation of immune cells by disrupting receptor-ligand interactions may be useful in inhibiting immune cell activation to prevent production of autoantibodies or cytokines which may be involved in the disease process. The efficacy of reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune
10 diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosus in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., *Fundamental Immunology*, Raven Press, New York, 1989, pp. 840-856).

15 Inhibition of Th2 cytokine production is also useful therapeutically in the treatment of allergies and allergic reactions, e.g., by inhibiting IgE production. An agent that inhibits, for example, NIP45 or NIP45-interacting molecule activity can be administered to an allergic subject to inhibit immune cell-mediated allergic responses in the subject. Inhibition of NIP45 or NIP45-interacting molecule activity can be accompanied by
20 exposure to allergen in conjunction with appropriate MHC molecules. Allergic reactions can be systemic or local in nature, depending on the route of entry of the allergen and the pattern of deposition of IgE on mast cells or basophils. Thus, immune cell-mediated allergic responses can be inhibited locally or systemically by administration of an agent that inhibits NIP45 or NIP45-interacting molecule activity.

25 Downregulation of immune cell activation through inhibition of cytokine production may also be important therapeutically in pathogenic infections of immune cells (e.g., by viruses or bacteria). For example, in the acquired immune deficiency syndrome (AIDS), viral replication is stimulated by immune cell activation. Inhibition of NIP45 or NIP45-interacting molecule activity may result in inhibition of viral replication and thereby
30 ameliorate the course of AIDS.

Downregulation of immune cell activation via inhibition of cytokine production may also be useful in treating inflammatory disorders and in promoting the

maintenance of pregnancy when there exists a risk of immune-mediated spontaneous abortion.

i. Exemplary Inhibitory Compounds

5 Since inhibition of cytokine production is associated with an decreased immune response, to downmodulate or inhibit the immune response, cells (*e.g.*, T cells) are contacted with an agent that inhibits NIP45 or a NIP45-interacting molecule activity. The immune cells may be contacted with the agent *in vitro* and then the cells can be administered to a subject or, alternatively, the agent may be administered to the subject
10 (*e.g.*, directly to an articular site at which T growth and/or differentiation is desired). The methods of the invention using cytokine inhibitory compounds may be used in the treatment of disorders in which the immune response is diminished, blocked, inhibited, downregulated or the like.

 Inhibitory compounds of the invention can be, for example, intracellular
15 binding molecules that act to specifically inhibit the expression or activity of NIP45 or a NIP45-interacting molecule. As used herein, the term "intracellular binding molecule" is intended to include molecules that act intracellularly to inhibit the expression or activity of a protein by binding to the protein or to a nucleic acid (*e.g.*, an mRNA molecule) that encodes the protein. Examples of intracellular binding molecules, described in further
20 detail below, include antisense nucleic acids, intracellular antibodies, peptidic compounds that inhibit the interaction of NIP45 or a NIP45-interacting molecule with a target molecule (*e.g.*, calcineurin) and chemical agents that specifically inhibit NIP45 or a NIP45-interacting molecule activity.

25 *a. Antisense Nucleic Acid Molecules*

 In one embodiment, an inhibitory compound of the invention is an antisense nucleic acid molecule that is complementary to a gene encoding NIP45 or a NIP45-interacting molecule, or to a portion of said gene, or a recombinant expression vector encoding said antisense nucleic acid molecule. The use of antisense nucleic acids to
30 downregulate the expression of a particular protein in a cell is well known in the art (see *e.g.*, Weintraub, H. *et al.*, Antisense RNA as a molecular tool for genetic analysis, *Reviews - Trends in Genetics*, Vol. 1(1) 1986; Askari, F.K. and McDonnell, W.M. (1996) *N. Eng. J. Med.* 334:316-318; Bennett, M.R. and Schwartz, S.M. (1995) *Circulation* 92:1981-1993;

Mercola, D. and Cohen, J.S. (1995) *Cancer Gene Ther.* 2:47-59; Rossi, J.J. (1995) *Br. Med. Bull.* 51:217-225; Wagner, R.W. (1994) *Nature* 372:333-335). An antisense nucleic acid molecule comprises a nucleotide sequence that is complementary to the coding strand of another nucleic acid molecule (*e.g.*, an mRNA sequence) and accordingly is capable of hydrogen bonding to the coding strand of the other nucleic acid molecule. Antisense sequences complementary to a sequence of an mRNA can be complementary to a sequence found in the coding region of the mRNA, the 5' or 3' untranslated region of the mRNA or a region bridging the coding region and an untranslated region (*e.g.*, at the junction of the 5' untranslated region and the coding region). Furthermore, an antisense nucleic acid can be complementary in sequence to a regulatory region of the gene encoding the mRNA, for instance a transcription initiation sequence or regulatory element. Preferably, an antisense nucleic acid is designed so as to be complementary to a region preceding or spanning the initiation codon on the coding strand or in the 3' untranslated region of an mRNA.

Given the coding strand sequences encoding NIP45 or a NIP45-interacting molecule disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NIP45 or a NIP45-interacting molecule mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of NIP45 or a NIP45-interacting molecule mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NIP45 or a NIP45-interacting molecule mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, *e.g.*, phosphorothioate derivatives and acridine substituted nucleotides may be used. Examples of modified nucleotides which may be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine,

inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a NIP45 or a NIP45-interacting molecule protein to thereby inhibit expression of the protein, *e.g.*, by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention include direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, *e.g.*, by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gaultier *et al.* (1987) *Nucleic Acids*.

Res. 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue *et al.* (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.* (1987) *FEBS Lett.* 215:327-330).

In another embodiment, an antisense nucleic acid of the invention is a compound that
 5 mediates RNAi. RNA interfering agents include, but are not limited to, nucleic acid molecules including RNA molecules which are homologous to the target gene or genomic sequence, *e.g.*, NIP45 or PRMT, or a fragment thereof, "short interfering RNA" (siRNA), "short hairpin" or "small hairpin RNA" (shRNA), and small molecules which interfere with or inhibit expression of a target gene by RNA interference (RNAi). RNA interference is a
 10 post-transcriptional, targeted gene-silencing technique that uses double-stranded RNA (dsRNA) to degrade messenger RNA (mRNA) containing the same sequence as the dsRNA (Sharp, P.A. and Zamore, P.D. 287, 2431-2432 (2000); Zamore, P.D., *et al.* *Cell* 101, 25-33 (2000). Tuschl, T. *et al.* *Genes Dev.* 13, 3191-3197 (1999)). The process occurs when an endogenous ribonuclease cleaves the longer dsRNA into shorter, 21- or 22-nucleotide-long
 15 RNAs, termed small interfering RNAs or siRNAs. The smaller RNA segments then mediate the degradation of the target mRNA. Kits for synthesis of RNAi are commercially available from, *e.g.* New England Biolabs and Ambion. In one embodiment one or more of the chemistries described above for use in antisense RNA can be employed.

In still another embodiment, an antisense nucleic acid of the invention is a
 20 ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (*e.g.*, hammerhead ribozymes (described in Haselhoff and Gerlach, 1988, *Nature* 334:585-591) may be used to catalytically cleave NIP45 or a NIP45-interacting molecule mRNA transcripts to thereby inhibit translation of
 25 NIP45 mRNA. A ribozyme having specificity for a NIP45- or a NIP45-interacting molecule-encoding nucleic acid can be designed, *e.g.*, based upon the nucleotide sequence of SEQ ID NO:1 or another nucleic acid molecule encoding another NIP45 or a NIP45-interacting molecule family polypeptide. For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is
 30 complementary to the nucleotide sequence to be cleaved in a NIP45- or a NIP45-interacting molecule -encoding mRNA. See, *e.g.*, Cech *et al.* U.S. Patent No. 4,987,071; and Cech *et al.* U.S. Patent No. 5,116,742. Alternatively, NIP45 mRNA may be used to select a

catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, *e.g.*, Bartel, D. and Szostak, J.W., 1993, *Science* 261:1411-1418.

Alternatively, gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of NIP45 or a NIP45-interacting molecule (*e.g.*, the NIP45 promoter and/or enhancers) to form triple helical structures that prevent transcription of the NIP45 gene in target cells. See generally, Helene, C., 1991, *Anticancer Drug Des.* 6(6):569-84; Helene, C. *et al.*, 1992, *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher, L.J., 1992, *Bioassays* 14(12):807-15.

In yet another embodiment, the NIP45 or a NIP45-interacting molecule nucleic acid molecules of the present invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g.*, the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup B. *et al.*, 1996, *Bioorganic & Medicinal Chemistry* 4 (1): 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, *e.g.*, DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup B. *et al.*, 1996, *supra*; Perry-O'Keefe *et al.*, 1996, *Proc. Natl. Acad. Sci. USA* 93: 14670-675.

PNAs of NIP45 or a NIP45-interacting molecule nucleic acid molecules may be used in therapeutic and diagnostic applications. For example, PNAs may be used as antisense or antigene agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNAs of NIP45 or a NIP45-interacting molecule nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene, (*e.g.*, by PNA-directed PCR clamping); as 'artificial restriction enzymes' when used in combination with other enzymes, (*e.g.*, S1 nucleases (Hyrup B., 1996, *supra*)); or as probes or primers for DNA sequencing or hybridization (Hyrup B. *et al.*, 1996, *supra*; Perry-O'Keefe *supra*).

In another embodiment, PNAs of NIP45 or a NIP45-interacting molecule can be modified, (*e.g.*, to enhance their stability or cellular uptake), by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of

liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NIP45 nucleic acid molecules can be generated which may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, (*e.g.*, RNase H and DNA polymerases), to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup B., 1996, *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup B., 1996, *supra* and Finn P.J. *et al.*, 1996, *Nucleic Acids Res.* 24 (17): 3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs, *e.g.*, 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, may be used as a between the PNA and the 5' end of DNA (Mag, M. *et al.*, 1989, *Nucleic Acid Res.* 17: 5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn P.J. *et al.*, 1996, *supra*). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment (Peterser, K.H. *et al.*, 1975, *Bioorganic Med. Chem. Lett.* 5: 1119-11124).

In other embodiments, the oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger *et al.*, 1989, *Proc. Natl. Acad. Sci. US.* 86:6553-6556; Lemaitre *et al.*, 1987, *Proc. Natl. Acad. Sci. USA* 84:648-652; PCT Publication No. W088/09810) or the blood-brain barrier (see, *e.g.*, PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (See, *e.g.*, Krol *et al.*, 1988, *Bio-Techniques* 6:958-976) or intercalating agents. (See, *e.g.*, Zon, 1988, *Pharm. Res.* 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, (*e.g.*, a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent).

Antisense polynucleotides may be produced from a heterologous expression cassette in a transfectant cell or transgenic cell. Alternatively, the antisense polynucleotides may comprise soluble oligonucleotides that are administered to the external milieu, either in the culture medium *in vitro* or in the circulatory system or in interstitial fluid *in vivo*. Soluble antisense polynucleotides present in the external milieu have been shown to gain access to the cytoplasm and inhibit translation of specific mRNA species.

b. Intracellular Antibodies

Another type of inhibitory compound that may be used to inhibit the expression and/or activity of cytokine production in a cell is an intracellular antibody specific for NIP45 or a NIP45-interacting molecule discussed herein. The use of

5 intracellular antibodies to inhibit protein function in a cell is known in the art (see *e.g.*, Carlson, J. R. (1988) *Mol. Cell. Biol.* 8:2638-2646; Biocca, S. *et al.* (1990) *EMBO J.* 9:101-108; Werge, T.M. *et al.* (1990) *FEBS Letters* 274:193-198; Carlson, J.R. (1993) *Proc. Natl. Acad. Sci. USA* 90:7427-7428; Marasco, W.A. *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:7889-7893; Biocca, S. *et al.* (1994) *Bio/Technology* 12:396-399; Chen, S-Y. *et al.* (1994) *Human Gene Therapy* 5:595-601; Duan, L *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:5075-5079; Chen, S-Y. *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:5932-5936; Beerli, R.R. *et al.* (1994) *J. Biol. Chem.* 269:23931-23936; Beerli, R.R. *et al.* (1994) *Biochem. Biophys. Res. Commun.* 204:666-672; Mhashilkar, A.M. *et al.* (1995) *EMBO J.* 14:1542-1551; Richardson, J.H. *et al.* (1995) *Proc. Natl. Acad. Sci. USA* 92:3137-3141; PCT

15 Publication No. WO 94/02610 by Marasco *et al.*; and PCT Publication No. WO 95/03832 by Duan *et al.*).

To inhibit protein activity using an intracellular antibody, a recombinant expression vector is prepared which encodes the antibody chains in a form such that, upon introduction of the vector into a cell, the antibody chains are expressed as a functional

20 antibody in an intracellular compartment of the cell. For inhibition of transcription factor activity according to the inhibitory methods of the invention, preferably an intracellular antibody that specifically binds the transcription factor is expressed within the nucleus of the cell. Nuclear expression of an intracellular antibody can be accomplished by removing from the antibody light and heavy chain genes those nucleotide sequences that encode the

25 N-terminal hydrophobic leader sequences and adding nucleotide sequences encoding a nuclear localization signal at either the N- or C-terminus of the light and heavy chain genes (see *e.g.*, Biocca, S. *et al.* (1990) *EMBO J.* 9:101-108; Mhashilkar, A. M. *et al.* (1995) *EMBO J.* 14:1542-1551). A preferred nuclear localization signal to be used for nuclear targeting of the intracellular antibody chains is the nuclear localization signal of SV40

30 Large T antigen (see Biocca, S. *et al.* (1990) *EMBO J.* 9:101-108; Mhashilkar, A. M. *et al.* (1995) *EMBO J.* 14:1542-1551).

To prepare an intracellular antibody expression vector, antibody light and heavy chain cDNAs encoding antibody chains specific for the target protein of interest, *e.g.*,

NIP45 or a NIP45-interacting molecule protein, is isolated, typically from a hybridoma that secretes a monoclonal antibody specific for NIP45 or a NIP45-interacting molecule protein. For example, antibodies can be prepared by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with a NIP45 or a NIP45-interacting molecule protein immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed NIP45 or a NIP45-interacting molecule protein or a chemically synthesized NIP45 or a NIP45-interacting molecule peptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory compound. Antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975, *Nature* 256:495-497) (see also, Brown *et al.* (1981) *J. Immunol* 127:539-46; Brown *et al.* (1980) *J Biol Chem* 255:4980-83; Yeh *et al.* (1976) *PNAS* 76:2927-31; and Yeh *et al.* (1982) *Int. J. Cancer* 29:269-75). The technology for producing monoclonal antibody hybridomas is well known (see generally R. H. Kenneth, in *Monoclonal Antibodies: A New Dimension In Biological Analyses*, Plenum Publishing Corp., New York, New York (1980); E. A. Lerner (1981) *Yale J. Biol. Med.*, 54:387-402; M. L. Gefter *et al.* (1977) *Somatic Cell Genet.*, 3:231-36). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with a NIP45 protein immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds specifically to the NIP45 or a NIP45-interacting molecule protein. Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-NIP45 protein monoclonal antibody (see, e.g., G. Galfre *et al.* (1977) *Nature* 266:550-52; Gefter *et al.* *Somatic Cell Genet.*, cited *supra*; Lerner, *Yale J. Biol. Med.*, cited *supra*; Kenneth, *Monoclonal Antibodies*, cited *supra*). Moreover, the ordinary skilled artisan will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). Any of a number of myeloma cell lines may

be used as a fusion partner according to standard techniques, *e.g.*, the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Ag14 myeloma lines. These myeloma lines are available from the American Type Culture Collection (ATCC), Rockville, Md. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG").

5 Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody that specifically binds the maf protein are identified by screening the hybridoma culture supernatants for such antibodies, *e.g.*, using a standard ELISA assay.

10 Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal antibody that binds to a NIP45 or a NIP45-interacting molecule can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (*e.g.*, an antibody phage display library) with the protein, or a peptide thereof, to thereby isolate immunoglobulin library members that bind specifically to the protein. Kits for
15 generating and screening phage display libraries are commercially available (*e.g.*, the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAPTM Phage Display Kit*, Catalog No. 240612). Additionally, examples of methods and compounds particularly amenable for use in generating and screening antibody display library can be found in, for example, Ladner *et al.* U.S. Patent No.
20 5,223,409; Kang *et al.* International Publication No. WO 92/18619; Dower *et al.* International Publication No. WO 91/17271; Winter *et al.* International Publication WO 92/20791; Markland *et al.* International Publication No. WO 92/15679; Breitling *et al.* International Publication WO 93/01288; McCafferty *et al.* International Publication No. WO 92/01047; Garrard *et al.* International Publication No. WO 92/09690; Fuchs *et al.*
25 (1991) *Bio/Technology* 9:1370-1372; Hay *et al.* (1992) *Hum Antibod Hybridomas* 3:81-85; Huse *et al.* (1989) *Science* 246:1275-1281; Griffiths *et al.* (1993) *EMBO J* 12:725-734; Hawkins *et al.* (1992) *J Mol Biol* 226:889-896; Clarkson *et al.* (1991) *Nature* 352:624-628; Gram *et al.* (1992) *PNAS* 89:3576-3580; Garrad *et al.* (1991) *Bio/Technology* 9:1373-1377; Hoogenboom *et al.* (1991) *Nuc Acid Res* 19:4133-4137; Barbas *et al.* (1991) *PNAS*
30 88:7978-7982; and McCafferty *et al.* *Nature* (1990) 348:552-554.

Once a monoclonal antibody of interest specific for NIP45 or a NIP45-interacting molecule has been identified (*e.g.*, either a hybridoma-derived monoclonal antibody or a recombinant antibody from a combinatorial library, including monoclonal

antibodies to NIP45 or a NIP45-interacting molecule that are already known in the art), DNAs encoding the light and heavy chains of the monoclonal antibody are isolated by standard molecular biology techniques. For hybridoma derived antibodies, light and heavy chain cDNAs can be obtained, for example, by PCR amplification or cDNA library screening. For recombinant antibodies, such as from a phage display library, cDNA encoding the light and heavy chains can be recovered from the display package (*e.g.*, phage) isolated during the library screening process. Nucleotide sequences of antibody light and heavy chain genes from which PCR primers or cDNA library probes can be prepared are known in the art. For example, many such sequences are disclosed in Kabat, E.A., *et al.* (1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human Services, NIH Publication No. 91-3242 and in the "Vbase" human germline sequence database.

Once obtained, the antibody light and heavy chain sequences are cloned into a recombinant expression vector using standard methods. As discussed above, the sequences encoding the hydrophobic leaders of the light and heavy chains are removed and sequences encoding a nuclear localization signal (*e.g.*, from SV40 Large T antigen) are linked in-frame to sequences encoding either the amino- or carboxy terminus of both the light and heavy chains. The expression vector can encode an intracellular antibody in one of several different forms. For example, in one embodiment, the vector encodes full-length antibody light and heavy chains such that a full-length antibody is expressed intracellularly. In another embodiment, the vector encodes a full-length light chain but only the VH/CH1 region of the heavy chain such that a Fab fragment is expressed intracellularly. In the most preferred embodiment, the vector encodes a single chain antibody (scFv) wherein the variable regions of the light and heavy chains are linked by a flexible peptide linker (*e.g.*, (Gly₄Ser)₃) and expressed as a single chain molecule. To inhibit transcription factor activity in a cell, the expression vector encoding the NIP45-specific intracellular antibody is introduced into the cell by standard transfection methods as described hereinbefore.

c. NIP45- and NIP45-Interacting Molecule Derived Peptidic Compounds

In another embodiment, an inhibitory compound of the invention is a peptidic compound derived from the NIP45 or a NIP45-interacting molecule amino acid sequence. In particular, the inhibitory compound comprises a portion of NIP45 or a NIP45-

interacting molecule (or a mimetic thereof) that mediates interaction of NIP45 or a NIP45-interacting molecule with a target molecule such that contact of NIP45 or a NIP45-interacting molecule with this peptidic compound competitively inhibits the interaction of NIP45 or a NIP45-interacting molecule with the target molecule. In an exemplary
5 embodiment, the peptide compound is designed based on the region of NIP45 that mediates interaction of NIP45 with, for example, PRMT1. As described herein, amino acid residues 1-32 of the NIP45 protein mediate the interaction of the NIP45 proteins with PRMT1 and peptides spanning the region inhibit the ability of PRMT1 to bind to and methylate NIP45 proteins, without affecting the methylase activity of PRMT1 against other substrates.

10 In a preferred embodiment, a NIP45 or a NIP45-interacting molecule inhibitory compound is a peptidic compound, which is prepared based on a PRMT1-interacting region of NIP45. A peptide can be derived from the PRMT1-interacting region of NIP45 having an amino acid sequence that comprises the amino acid residues 1-32 of NIP45. Alternatively, longer or shorter regions of human NIP45 may be used such as a
15 peptide.

The peptidic compounds of the invention can be made intracellularly in immune cells by introducing into the immune cells an expression vector encoding the peptide. Such expression vectors can be made by standard techniques, using, for example, oligonucleotides that encode the amino acid sequences of SEQ ID NO: 2. The peptide can
20 be expressed intracellularly as a fusion with another protein or peptide (*e.g.*, a GST fusion). Alternative to recombinant synthesis of the peptides in the cells, the peptides can be made by chemical synthesis using standard peptide synthesis techniques. Synthesized peptides can then be introduced into cells by a variety of means known in the art for introducing peptides into cells (*e.g.*, liposome and the like).

25 Other inhibitory agents that may be used to specifically inhibit the activity of an NIP45 or a NIP45-interacting molecule protein are chemical compounds that directly inhibit NIP45 or a NIP45-interacting molecule activity or inhibit the interaction between NIP45 or a NIP45-interacting molecule and target molecules. Such compounds can be identified using screening assays that select for such compounds, as described in detail
30 above.

B. Upregulation of Immune Responses

Stimulation of cytokine production as a means of upregulating immune responses is also useful in therapy. Upregulation of immune responses can be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through enhancing of cytokine production (in particular TH1 cytokine production) is useful in cases of infections with microbes, *e.g.*, bacteria (*e.g.*, intracellular bacteria), viruses, or parasites. For example, in one embodiment, an agent that enhances NIP45 or a NIP45-interacting molecule activity, *e.g.*, a small molecule or a NIP45 or a NIP45-interacting molecule peptide, is therapeutically useful in situations where upregulation of humoral and/or cell-mediated responses, resulting in more rapid or thorough clearance of a virus, would be beneficial. These conditions include viral skin diseases such as Herpes or shingles, in which case such an agent can be delivered topically to the skin. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of such agents systemically. In certain instances, it may be desirable to further administer other agents that upregulate immune responses, for example, agents that transduce signals via costimulatory receptors, in order further augment the immune response.

Alternatively, immune responses can be enhanced in an infected patient by removing immune cells from the patient, contacting immune cells *in vitro* with an agent (*e.g.*, a small molecule) that enhances NIP45 or a NIP45-interacting molecule activity, and reintroducing the *in vitro*-stimulated immune cells into the patient. In another embodiment, a method of enhancing immune responses involves isolating infected cells from a patient, *e.g.*, virally infected cells, transfecting them with a nucleic acid molecule encoding a form of NIP45 or a NIP45-interacting molecule that is more active than the wild-type NIP45 or a NIP45-interacting molecule, such that the cells express all or a portion of the NIP45 or a NIP45-interacting molecule on their surface, and reintroducing the transfected cells into the patient. The transfected cells may be capable of preventing an inhibitory signal to, and thereby activating, immune cells *in vivo*.

An agent that enhances NIP45 or a NIP45-interacting molecule activity may be used prophylactically in therapy against various polypeptides, *e.g.*, polypeptides derived from pathogens for vaccination. Immunity against a pathogen, *e.g.*, a virus, can be induced by vaccinating with a viral polypeptide along with an agent that enhances NIP45 or a NIP45-interacting molecule activity. Nucleic acid vaccines can be administered by a

variety of means, for example, by injection (*e.g.*, intramuscular, intradermal, or the biolistic injection of DNA-coated gold particles into the epidermis with a gene gun that uses a particle accelerator or a compressed gas to inject the particles into the skin (Haynes *et al.* (1996) *J. Biotechnol.* 44:37)). Alternatively, nucleic acid vaccines can be administered by
5 non-invasive means. For example, pure or lipid-formulated DNA can be delivered to the respiratory system or targeted elsewhere, *e.g.*, Peyer patches by oral delivery of DNA (Schubert (1997) *Proc. Natl. Acad. Sci. USA* 94:961). Attenuated microorganisms may be used for delivery to mucosal surfaces (Sizemore *et al.* (1995) *Science* 270:29).

Stimulation of an immune response to tumor cells can also be achieved by
10 enhancing NIP45 or a NIP45-interacting molecule activity by treating a patient with an agent that for example, enhances NIP45-PRMT1 interaction. Preferred examples of such agents include, *e.g.*, and compounds identified in the subject screening assays and peptides.

In another embodiment, the immune response can be stimulated by stimulating the expression and/or activity of NIP45 or a NIP45-interacting molecule. For
15 example, immune responses against antigens to which a subject cannot mount a significant immune response, *e.g.*, tumor-specific antigens, can be enhanced by administering an agent that stimulates the expression and/or activity of NIP45 or a NIP45-interacting molecule. Other NIP45 or a NIP45-interacting molecule agonists may be used as adjuvants to boost responses to foreign antigens in the process of active immunization.

20 In one embodiment, immune cells are obtained from a subject and cultured *ex vivo* in the presence of an agent that enhances NIP45 or a NIP45-interacting molecule activity to expand the population of immune cells. In a further embodiment the immune cells are then administered to a subject. Immune cells can be stimulated to proliferate *in vitro* by, for example, providing the immune cells with a primary activation
25 signal and a costimulatory signal, as is known in the art. Various forms of NIP45 or a NIP45-interacting molecule polypeptides or agents that enhance NIP45 or a NIP45-interacting molecule activity can also be used to costimulate proliferation of immune cells. In one embodiment immune cells are cultured *ex vivo* according to the method described in PCT Application No. WO 94/29436. The agent can be soluble, attached to a cell membrane
30 or attached to a solid surface, such as a bead.

In an additional embodiment, in performing any of the methods described herein, it is within the scope of the invention to upregulate an immune response by administering one or more additional agents. For example, the use of other agents known to

stimulate the immune response, such as cytokines, adjuvants, or stimulatory forms of costimulatory molecules or their ligands may be used in conjunction with an agent that enhances, *e.g.*, NIP45 activity. Examples of other immunomodulating reagents include antibodies that provide a costimulatory signal, (*e.g.*, agonists of CD28 or ICOS),
 5 stimulating antibodies against immune cell markers, and/or cytokines and the like.

i. Exemplary Stimulatory Compounds

Since upregulation of cytokine production is associated with an increased immune response, a compound that specifically stimulates NIP45 or a NIP45-interacting
 10 molecule activity and/or expression may be used to enhance or upmodulate an immune response. In the stimulatory methods of the invention, a subject is treated with a stimulatory compound that stimulates expression and/or activity of a NIP45 or a NIP45-interacting molecule. The methods of the invention using NIP45 or a NIP45-interacting molecule stimulatory compounds may be used in the treatment of disorders in which the
 15 immune response is enhanced, promoted, stimulated, upregulated or the like.

Examples of stimulatory compounds include active NIP45 or a NIP45-interacting molecule protein, expression vectors encoding NIP45 or a NIP45-interacting molecule and chemical agents that specifically stimulate NIP45 or a NIP45-interacting molecule activity.

20 A preferred stimulatory compound is a nucleic acid molecule encoding NIP45 or a NIP45-interacting molecule, wherein the nucleic acid molecule is introduced into the subject (*e.g.*, T cells of the subject) in a form suitable for expression of the NIP45 protein in the cells of the subject. The amino acid sequence of NIP45 protein has been determined (shown in SEQ ID NO: 2) and a cDNA encoding NIP45 protein has been
 25 isolated (the nucleotide sequence of which is shown in SEQ ID NO: 1) (GI No.:1747518). The nucleotide sequence of NFATc1 is shown in SEQ ID NO:3, the amino acid sequence in SEQ ID NO:4 (GI No.:3643194). The nucleotide sequence of NFATc2 is shown in SEQ ID NO:5, the amino acid sequence in SEQ ID NO:6 (GI No.:1353236). The nucleotide sequence of NFATc3 is shown in SEQ ID NO:7, the amino acid sequence in SEQ ID NO:8
 30 (GI No.:1906311). The nucleotide sequence of PRMT1 is shown in SEQ ID NO:9, the amino acid sequence in SEQ ID NO:10 (GI No.:7141325).

For example, a NIP45 or a NIP45-interacting molecule cDNA (full length or partial NIP45 or a NIP45-interacting molecule cDNA sequence) is cloned into a

recombinant expression vector and the vector is transfected into the immune cell using standard molecular biology techniques. The NIP45 or a NIP45-interacting molecule cDNA can be obtained, for example, by amplification using the polymerase chain reaction (PCR) or by screening an appropriate cDNA library. The nucleotide sequences of NIP45 or a
5 NIP45-interacting molecule cDNA is known in the art and may be used for the design of PCR primers that allow for amplification of a cDNA by standard PCR methods or for the design of a hybridization probe that may be used to screen a cDNA library using standard hybridization methods.

Following isolation or amplification of NIP45 or a NIP45-interacting
10 molecule cDNA, the DNA fragment is introduced into a suitable expression vector, as described above. Nucleic acid molecules encoding NIP45 or a NIP45-interacting molecule in the form suitable for expression of the NIP45 or a NIP45-interacting molecule in a host cell, can be prepared as described above using nucleotide sequences known in the art. The nucleotide sequences may be used for the design of PCR primers that allow for
15 amplification of a cDNA by standard PCR methods or for the design of a hybridization probe that may be used to screen a cDNA library using standard hybridization methods.

Another form of a stimulatory compound for stimulating expression of NIP45 or a NIP45-interacting molecule in a cell is a chemical compound that specifically stimulates the expression or activity of endogenous NIP45 or a NIP45-interacting molecule
20 in the cell. Such compounds can be identified using screening assays that select for compounds that stimulate the expression or activity of NIP45 as described herein.

The method of the invention for modulating NIP45 or a NIP45-interacting molecule activity in a subject can be practiced either *in vitro* or *in vivo* (the latter is discussed further in the following subsection). For practicing the method *in vitro*, cells
25 (*e.g.*, T cells) can be obtained from a subject by standard methods and incubated (*i.e.*, cultured) *in vitro* with a stimulatory or inhibitory compound of the invention to stimulate or inhibit, respectively, the activity of NIP45 or a NIP45-interacting molecule. Methods for isolating immune cells are known in the art.

Cells treated *in vitro* with either a stimulatory or inhibitory compound can be
30 administered to a subject to influence the growth and/or differentiation of immune cells in the subject. For example, immune cells can be isolated from a subject, expanded in number *in vitro* by enhancing NIP45 or a NIP45-interacting molecule activity in the cells using an enhancing agent (thereby promoting the proliferation of the cells), and then the immune

cells can be readministered to the same subject, or another subject tissue compatible with the donor of the immune cells. Accordingly, in another embodiment, the modulatory method of the invention comprises culturing immune cells *in vitro* with a NIP45 or a NIP45-interacting molecule modulator and further comprises administering the immune cells to a subject to thereby modulate T growth and/or differentiation in a subject. Upon culture *in vitro*, the immune cells can differentiate into mature immune cells and thus the methods encompass administering this mature immune cells to the subject. For administration of cells or T to a subject, it may be preferable to first remove residual compounds in the culture from the cells or T before administering them to the subject. This can be done for example by gradient centrifugation of the cells or by washing of the T tissue. For further discussion of *ex vivo* genetic modification of cells followed by readministration to a subject, see also U.S. Patent No. 5,399,346 by W.F. Anderson *et al.*

In other embodiments, a stimulatory or inhibitory compound is administered to a subject *in vivo*, such as directly to an articulation site of a subject. For stimulatory or inhibitory agents that comprise nucleic acids (*e.g.*, recombinant expression vectors encoding NIP45 or a NIP45-interacting molecule, antisense RNA, intracellular antibodies or NIP45- or a NIP45-interacting molecule -derived peptides), the compounds can be introduced into cells of a subject using methods known in the art for introducing nucleic acid (*e.g.*, DNA) into cells *in vivo*. Examples of such methods include:

Direct Injection: Naked DNA can be introduced into cells *in vivo* by directly injecting the DNA into the cells (see *e.g.*, Acsadi *et al.* (1991) *Nature* 332:815-818; Wolff *et al.* (1990) *Science* 247:1465-1468). For example, a delivery apparatus (*e.g.*, a "gene gun") for injecting DNA into cells *in vivo* may be used. Such an apparatus is commercially available (*e.g.*, from BioRad).

Receptor-Mediated DNA Uptake: Naked DNA can also be introduced into cells *in vivo* by complexing the DNA to a cation, such as polylysine, which is coupled to a ligand for a cell-surface receptor (see for example Wu, G. and Wu, C.H. (1988) *J. Biol. Chem.* 263:14621; Wilson *et al.* (1992) *J. Biol. Chem.* 267:963-967; and U.S. Patent No. 5,166,320). Binding of the DNA-ligand complex to the receptor facilitates uptake of the DNA by receptor-mediated endocytosis. A DNA-ligand complex linked to adenovirus capsids which naturally disrupt endosomes, thereby releasing material into the cytoplasm may be used to avoid degradation of the complex by intracellular lysosomes (see for

example Curiel *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:8850; Cristiano *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:2122-2126).

Retroviruses: Defective retroviruses are well characterized for use in gene transfer for gene therapy purposes (for a review see Miller, A.D. (1990) *Blood* 76:271). A recombinant retrovirus can be constructed having a nucleotide sequences of interest incorporated into the retroviral genome. Additionally, portions of the retroviral genome can be removed to render the retrovirus replication defective. The replication defective retrovirus is then packaged into virions which may be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells *in vitro* or *in vivo* with such viruses can be found in *Current Protocols in Molecular Biology*, Ausubel, F.M. *et al.* (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art. Examples of suitable packaging virus lines include ψ Crip, ψ Cre, ψ 2 and ψ Am. Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells, endothelial cells, lymphocytes, myoblasts, hepatocytes, bone marrow cells, *in vitro* and/or *in vivo* (see for example Eglitis, *et al.* (1985) *Science* 230:1395-1398; Danos and Mulligan (1988) *Proc. Natl. Acad. Sci. USA* 85:6460-6464; Wilson *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:3014-3018; Armentano *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87:6141-6145; Huber *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:8039-8043; Ferry *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:8377-8381; Chowdhury *et al.* (1991) *Science* 254:1802-1805; van Beusechem *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:7640-7644; Kay *et al.* (1992) *Human Gene Therapy* 3:641-647; Dai *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:10892-10895; Hwu *et al.* (1993) *J. Immunol.* 150:4104-4115; U.S. Patent No. 4,868,116; U.S. Patent No. 4,980,286; PCT Application WO 89/07136; PCT Application WO 89/02468; PCT Application WO 89/05345; and PCT Application WO 92/07573). Retroviral vectors require target cell division in order for the retroviral genome (and foreign nucleic acid inserted into it) to be integrated into the host genome to stably introduce nucleic acid into the cell. Thus, it may be necessary to stimulate replication of the target cell.

Adenoviruses: The genome of an adenovirus can be manipulated such that it encodes and expresses a gene product of interest but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. See for example Berkner *et al.* (1988)

BioTechniques 6:616; Rosenfeld *et al.* (1991) *Science* 252:431-434; and Rosenfeld *et al.* (1992) *Cell* 68:143-155. Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (*e.g.*, Ad2, Ad3, Ad7 *etc.*) are well known to those skilled in the art. Recombinant adenoviruses are advantageous in that they do not

5 require dividing cells to be effective gene delivery vehicles and may be used to infect a wide variety of cell types, including airway epithelium (Rosenfeld *et al.* (1992) cited *supra*), endothelial cells (Lemarchand *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:6482-6486), hepatocytes (Herz and Gerard (1993) *Proc. Natl. Acad. Sci. USA* 90:2812-2816) and muscle cells (Quantin *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:2581-2584).

10 Additionally, introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis in situations where introduced DNA becomes integrated into the host genome (*e.g.*, retroviral DNA). Moreover, the carrying capacity of the adenoviral genome for foreign DNA is large (up to 8

15 kilobases) relative to other gene delivery vectors (Berkner *et al.* cited *supra*; Haj-Ahmand and Graham (1986) *J. Virol.* 57:267). Most replication-defective adenoviral vectors currently in use are deleted for all or parts of the viral E1 and E3 genes but retain as much as 80 % of the adenoviral genetic material.

Adeno-Associated Viruses: Adeno-associated virus (AAV) is a naturally

20 occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle. (For a review see Muzyczka *et al.* *Curr. Topics in Micro. and Immunol.* (1992) 158:97-129). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration (see for example Flotte *et al.* (1992) *Am. J. Respir. Cell.*

25 *Mol. Biol.* 7:349-356; Samulski *et al.* (1989) *J. Virol.* 63:3822-3828; and McLaughlin *et al.* (1989) *J. Virol.* 62:1963-1973). Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate. Space for exogenous DNA is limited to about 4.5 kb. An AAV vector such as that described in Tratschin *et al.* (1985) *Mol. Cell. Biol.* 5:3251-3260 may be used to introduce DNA into cells. A variety of nucleic acids have been introduced

30 into different cell types using AAV vectors (see for example Hermonat *et al.* (1984) *Proc. Natl. Acad. Sci. USA* 81:6466-6470; Tratschin *et al.* (1985) *Mol. Cell. Biol.* 4:2072-2081; Wondisford *et al.* (1988) *Mol. Endocrinol.* 2:32-39; Tratschin *et al.* (1984) *J. Virol.* 51:611-619; and Flotte *et al.* (1993) *J. Biol. Chem.* 268:3781-3790).

The efficacy of a particular expression vector system and method of introducing nucleic acid into a cell can be assessed by standard approaches routinely used in the art. For example, DNA introduced into a cell can be detected by a filter hybridization technique (*e.g.*, Southern blotting) and RNA produced by transcription of introduced DNA can be detected, for example, by Northern blotting, RNase protection or reverse transcriptase-polymerase chain reaction (RT-PCR). The gene product can be detected by an appropriate assay, for example by immunological detection of a produced protein, such as with a specific antibody, or by a functional assay to detect a functional activity of the gene product, such as an enzymatic assay.

VI. Diagnostic Assays

In another aspect, the invention features a method of diagnosing a subject for a disorder that would benefit from modulation of the activity of one or more of: a NIP45-binding molecule, *e.g.*, a PRMT (such as a NIP45 related activity of a PRMT); or from modulation of NIP45. Exemplary disorders include those that would benefit from modulation of cytokine production, *e.g.*, modulation of IL-2, IFN- γ , IL-4, IL-5 and/or IL-13 production, modulation of the relative number of Th1 and Th2 cells, modulation of effector T cell function, and modulation of T cell differentiation.

In one embodiment, the expression of NIP45 or a NIP45-interacting molecule or a molecule in cells of a subject may be measured and compared to a control and a difference in expression of NIP45 or a NIP45-interacting molecule in cells of the subject as compared to the control could be used to diagnose the subject as one that would benefit from modulation of cytokine activity.

The "change in expression" or "difference in expression" may be detected by assaying levels of mRNA, for example, by isolating cells from the subject and determining the level of mRNA expression in the cells by standard methods known in the art, including Northern blot analysis, microarray analysis, reverse-transcriptase PCR analysis and *in situ* hybridizations. For example, a biological specimen can be obtained from the patient and assayed for, *e.g.*, expression or activity of NIP45 or a NIP45-interacting molecule.

In another embodiment, protein expression may be measured using standard methods known in the art, including Western blot analysis, immunoprecipitations, enzyme linked immunosorbent assays (ELISAs) and immunofluorescence. Antibodies for use in

such assays can be made using techniques known in the art and/or as described herein for making intracellular antibodies.

In another embodiment, a change in expression of NIP45 or a NIP45-interacting molecule or a molecule in a signal transduction pathway involving NIP45 or a NIP45-interacting molecule in cells of the subject results from one or more mutations (*i.e.*, alterations from wild-type), *e.g.*, the NIP45 or a NIP45-interacting molecule gene and mRNA leading to one or more mutations (*i.e.*, alterations from wild-type) in the amino acid sequence of the protein. In one embodiment, the mutation(s) leads to a form of the molecule with increased activity (*e.g.*, partial or complete constitutive activity). In another embodiment, the mutation(s) leads to a form of the molecule with decreased activity (*e.g.*, partial or complete inactivity). The mutation(s) may change the level of expression of the molecule for example, increasing or decreasing the level of expression of the molecule in a subject with a disorder. Alternatively, the mutation(s) may change the regulation of the protein, for example, by modulating the interaction of the mutant protein with one or more targets *e.g.*, resulting in a form of NIP45 that cannot be methylated or cannot interact with a NIP45-binding partner or resulting in a form that is unable to methylate. Mutations in the nucleotide sequence or amino acid sequences of proteins can be determined using standard techniques for analysis of DNA or protein sequences, for example for DNA or protein sequencing, RFLP analysis, and analysis of single nucleotide or amino acid polymorphisms. For example, in one embodiment, mutations can be detected using highly sensitive PCR approaches using specific primers flanking the nucleic acid sequence of interest. In one embodiment, detection of the alteration involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, *e.g.*, U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, *e.g.*, Landegran *et al.* (1988) *Science* 241:1077-1080; and Nakazawa *et al.* (1994) *PNAS* 91:360-364). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (*e.g.*, genomic, DNA) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically amplify a sequence under conditions such that hybridization and amplification of the sequence (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample.

In one embodiment, the complete nucleotide sequence for NIP45 or a NIP45-interacting molecule or a molecule in a signal transduction pathway involving NIP45

or a NIP45-interacting molecule can be determined. Particular techniques have been developed for determining actual sequences in order to study polymorphism in human genes. See, for example, Proc. Natl. Acad. Sci. U.S.A. 85, 544-548 (1988) and Nature 330, 384-386 (1987); Maxim and Gilbert. 1977. *PNAS* 74:560; Sanger 1977. *PNAS* 74:5463. In addition, any of a variety of automated sequencing procedures can be utilized when performing diagnostic assays ((1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, *e.g.*, PCT International Publication No. WO 94/16101; Cohen *et al.* (1996) *Adv. Chromatogr.* 36:127-162; and Griffin *et al.* (1993) *Appl. Biochem. Biotechnol.* 38:147-159).

10 Restriction fragment length polymorphism mappings (RFLPS) are based on changes at a restriction enzyme site. In one embodiment, polymorphisms from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Moreover, the use of sequence specific ribozymes (see, for example, U.S. Patent No. 5,498,531) may be used to score for the presence of a specific ribozyme cleavage site.

 Another technique for detecting specific polymorphisms in particular DNA segment involves hybridizing DNA segments which are being analyzed (target DNA) with a complimentary, labeled oligonucleotide probe. See Nucl. Acids Res. 9, 879-894 (1981). Since DNA duplexes containing even a single base pair mismatch exhibit high thermal instability, the differential melting temperature may be used to distinguish target DNAs that are perfectly complimentary to the probe from target DNAs that only differ by a single nucleotide. This method has been adapted to detect the presence or absence of a specific restriction site, U.S. Pat. No. 4,683,194. The method involves using an end-labeled oligonucleotide probe spanning a restriction site which is hybridized to a target DNA. The hybridized duplex of DNA is then incubated with the restriction enzyme appropriate for that site. Reformed restriction sites will be cleaved by digestion in the pair of duplexes between the probe and target by using the restriction endonuclease. The specific restriction site is present in the target DNA if shortened probe molecules are detected.

 Other methods for detecting polymorphisms in nucleic acid sequences include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers *et al.* (1985) *Science* 230:1242).

In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the polymorphic sequence with potentially polymorphic RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent which cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S1 nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels. See, for example, Cotton *et al.* (1988) *Proc. Natl Acad Sci USA* 85:4397; Saleeba *et al.* (1992) *Methods Enzymol.* 217:286-295. In a preferred embodiment, the control DNA or RNA can be labeled for detection.

In another embodiment, alterations in electrophoretic mobility may be used to identify polymorphisms. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild-type nucleic acids (Orita *et al.* (1989) *Proc Natl. Acad. Sci USA*: 86:2766, see also Cotton (1993) *Mutat Res* 285:125-144; and Hayashi (1992) *Genet Anal Tech Appl* 9:73-79). Single-stranded DNA fragments of sample and control nucleic acids can be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In a preferred embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen *et al.* (1991) *Trends Genet* 7:5).

In yet another embodiment, the movement of nucleic acid molecule comprising polymorphic sequences in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers *et al.* (1985) *Nature* 313:495). When DGGE is used as the method of analysis, DNA can be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a

temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) *Biophys Chem* 265:12753).

5 Examples of other techniques for detecting polymorphisms include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the polymorphic region is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki *et al.* (1986) *Nature* 324:163); Saiki *et al.* (1989) *Proc. Natl Acad. Sci USA* 86:6230). Such allele specific
10 oligonucleotides are hybridized to PCR amplified target DNA or a number of different polymorphisms when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Another process for studying differences in DNA structure is the primer extension process which consists of hybridizing a labeled oligonucleotide primer to a
15 template RNA or DNA and then using a DNA polymerase and deoxynucleoside triphosphates to extend the primer to the 5' end of the template. Resolution of the labeled primer extension product is then done by fractionating on the basis of size, *e.g.*, by electrophoresis via a denaturing polyacrylamide gel. This process is often used to compare homologous DNA segments and to detect differences due to nucleotide insertion or
20 deletion. Differences due to nucleotide substitution are not detected since size is the sole criterion used to characterize the primer extension product.

Another process exploits the fact that the incorporation of some nucleotide analogs into DNA causes an incremental shift of mobility when the DNA is subjected to a size fractionation process, such as electrophoresis. Nucleotide analogs may be used to
25 identify changes since they can cause an electrophoretic mobility shift. See, U.S. Pat. No. 4,879,214.

Many other techniques for identifying and detecting polymorphisms are known to those skilled in the art, including those described in "DNA Markers: Protocols, Applications and Overview," G. Caetano-Anolles and P. Gresshoff ed., (Wiley-VCH, New
30 York) 1997, which is incorporated herein by reference as if fully set forth.

In addition, many approaches have also been used to specifically detect SNPs. Such techniques are known in the art and many are described *e.g.*, in DNA Markers: Protocols, Applications, and Overviews. 1997. Caetano-Anolles and Gresshoff, Eds.

Wiley-VCH, New York, pp199-211 and the references contained therein). For example, in one embodiment, a solid phase approach to detecting polymorphisms such as SNPs may be used. For example an oligonucleotide ligation assay (OLA) may be used. This assay is based on the ability of DNA ligase to distinguish single nucleotide differences at positions complementary to the termini of co-terminal probing oligonucleotides (see, *e.g.*, Nickerson *et al.* 1990. *Proc. Natl. Acad. Sci. USA* 87:8923. A modification of this approach, termed coupled amplification and oligonucleotide ligation (CAL) analysis, has been used for multiplexed genetic typing (see, *e.g.*, Eggerding 1995 *PCR Methods Appl.* 4:337; Eggerding *et al.* 1995 *Hum. Mutat.* 5:153).

In another embodiment, genetic bit analysis (GBA) may be used to detect a SNP (see, *e.g.*, Nikiforov *et al.* 1994. *Nucleic Acids Res.* 22:4167; Nikiforov *et al.* 1994. *PCR Methods Appl.* 3:285; Nikiforov *et al.* 1995. *Anal Biochem.* 227:201). In another embodiment, microchip electrophoresis may be used for high-speed SNP detection (see *e.g.*, Schmalzing *et al.* 2000. *Nucleic Acids Research*, 28). In another embodiment, matrix-assisted laser desorption/ionization time-of-flight mass (MALDI TOF) mass spectrometry may be used to detect SNPs (see, *e.g.*, Stoerker *et al.* *Nature Biotechnology* 18:1213).

In another embodiment, a difference in a biological activity of NIP45 or a NIP45-interacting molecule between a subject and a control can be detected. For example, an activity of NIP45 or a NIP45-interacting molecule or a molecule in a signal transduction pathway involving NIP45 or a NIP45-interacting molecule can be detected in cells of a subject suspected of having a disorder associated with aberrant biological activity of NIP45. The activity of NIP45 or a NIP45-interacting molecule or a molecule in a signal transduction pathway involving NIP45 or a NIP45-interacting molecule in cells of the subject could then be compared to a control and a difference in activity of NIP45 or a NIP45-interacting molecule or a molecule in a signal transduction pathway involving NIP45 or a NIP45-interacting molecule in cells of the subject as compared to the control could be used to diagnose the subject as one that would benefit from modulation of an NIP45 or a NIP45-interacting molecule activity. Activities of NIP45 or a NIP45-interacting molecule or molecules in a signal transduction pathway involving NIP45 or a NIP45-interacting molecule can be detected using methods described herein or known in the art.

In preferred embodiments, the diagnostic assay is conducted on a biological sample from the subject, such as a cell sample or a tissue section (for example, a freeze-dried or fresh frozen section of tissue removed from a subject). In another embodiment, the

level of expression of NIP45 or a NIP45-interacting molecule or a molecule in a signal transduction pathway involving NIP45 or a NIP45-interacting molecule in cells of the subject can be detected *in vivo*, using an appropriate imaging method, such as using a radiolabeled antibody.

5 In one embodiment, the level of expression of NIP45 or a NIP45-interacting molecule or a molecule in a signal transduction pathway involving NIP45 or a NIP45-interacting molecule in cells of the test subject may be elevated (*i.e.*, increased) relative to the control not associated with the disorder or the subject may express a constitutively active (partially or completely) form of the molecule. This elevated expression level of,
10 *e.g.*, NIP45 or a NIP45-interacting molecule or expression of a constitutively active form of NIP45 or a NIP45-interacting molecule, may be used to diagnose a subject for a disorder associated with increased NIP45 or a NIP45-interacting molecule activity.

 In another embodiment, the level of expression of NIP45 or a NIP45-interacting molecule or a molecule in a signal transduction pathway involving NIP45 or a
15 NIP45-interacting molecule in cells of the subject may be reduced (*i.e.*, decreased) relative to the control not associated with the disorder or the subject may express an inactive (partially or completely) mutant form of NIP45 or a NIP45-interacting molecule. This reduced expression level of NIP45 or a NIP45-interacting molecule or expression of an inactive mutant form of NIP45 or a NIP45-interacting molecule may be used to diagnose a
20 subject for a disorder, such as immunodeficiency disorders characterized by insufficient cytokine production.

 In one embodiment, the level of expression of gene whose expression is regulated by NIP45 or a NIP45-interacting molecule can be measured (*e.g.*, IL-4).

 In another embodiment, an assay diagnosing a subject as one that would
25 benefit from modulation of cytokine expression, post-translational modification, and/or activity (or a molecule in a signal transduction pathway involving NIP45 or a NIP45-interacting molecule) is performed prior to treatment of the subject.

 The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe/primer nucleic acid or other
30 reagent (*e.g.*, antibody), which may be conveniently used, *e.g.*, in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving cytokine production, NIP45 or a NIP45-interacting molecule or a molecule in a signal transduction pathway involving NIP45 or a NIP45-interacting molecule.

VII. Kits of the Invention

Another aspect of the invention pertains to kits for carrying out the screening assays, modulatory methods or diagnostic assays of the invention. For example, a kit for carrying out a screening assay of the invention may include an indicator composition comprising NIP45 or a NIP45-interacting molecule, means for measuring a readout (*e.g.*, protein secretion) and instructions for using the kit to identify modulators of biological effects of NIP45 or a NIP45-interacting molecule. In another embodiment, a kit for carrying out a screening assay of the invention may include cells deficient in NIP45 or a NIP45-interacting molecule, means for measuring the readout and instructions for using the kit to identify modulators of a biological effect of NIP45 or a NIP45-interacting molecule, *e.g.*, cytokine production.

In another embodiment, the invention provides a kit for carrying out a modulatory method of the invention. The kit can include, for example, a modulatory agent of the invention (*e.g.*, NIP45 or a NIP45-interacting molecule inhibitory or stimulatory agent) in a suitable carrier and packaged in a suitable container with instructions for use of the modulator to modulate a biological effect of NIP45 or a NIP45-interacting molecule, *e.g.*, cytokine production.

Another aspect of the invention pertains to a kit for diagnosing a disorder associated with a cytokine production, expression and/or activity in a subject. The kit can include a reagent for determining expression of NIP45 or a NIP45-interacting molecule (*e.g.*, a nucleic acid probe for detecting NIP45 or a NIP45-interacting molecule mRNA or an antibody for detection of NIP45 or a NIP45-interacting molecule protein), a control to which the results of the subject are compared, and instructions for using the kit for diagnostic purposes.

VIII. Immunomodulatory compositions

Agents that modulate a NIP45 or a NIP45-interacting molecule activity, (*e.g.*, that modulate one or more of the expression, processing, post-translational modifications, or activity, expression, processing, post-translational modification NIP45 or a NIP45-interacting molecule) are also appropriate for use in immunomodulatory compositions. Stimulatory or inhibitory agents of the invention may be used to up or down regulate the immune response in a subject.

The modulating agents of the invention can be given alone, or in combination with an antigen to which an enhanced immune response or a reduced immune response is desired.

In one embodiment, agents which are known adjuvants can be administered with the subject modulating agents. At this time, the only adjuvant widely used in humans has been alum (aluminum phosphate or aluminum hydroxide). Saponin and its purified component Quil A, Freund's complete adjuvant and other adjuvants used in research and veterinary applications have potential use in human vaccines. However, new chemically defined preparations such as muramyl dipeptide, monophosphoryl lipid A, phospholipid conjugates such as those described by Goodman-Snitkoff *et al.* J. Immunol. 147:410-415 (1991) resorcinols, non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether, enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol can also be used. In embodiments in which antigen is administered, the antigen can *e.g.*, be encapsulated within a proteoliposome as described by Miller *et al.*, J. Exp. Med. 176:1739-1744 (1992) and incorporated by reference herein, or in lipid vesicles, such as Novasome TM lipid vesicles (Micro Vesicular Systems, Inc., Nashua, N. H.), to further enhance immune responses.

In one embodiment, a nucleic acid molecule encoding NIP45 or a NIP45-interacting molecule (*e.g.*, a sense or antisense or siRNA molecule or a NIP45-interacting molecule or portion thereof) is administered as a DNA vaccine. This can be done using a plasmid DNA construct which is similar to those used for delivery of reporter or therapeutic genes. Such a construct preferably comprises a bacterial origin of replication that allows amplification of large quantities of the plasmid DNA; a prokaryotic selectable marker gene; a nucleic acid sequence encoding, *e.g.*, a NIP45 polypeptide or portion thereof; eukaryotic transcription regulatory elements to direct gene expression in the host cell; and a polyadenylation sequence to ensure appropriate termination of the expressed mRNA (Davis. 1997. *Curr. Opin. Biotechnol.* 8:635). Vectors used for DNA immunization may optionally comprise a signal sequence (Michel *et al.* 1995. *Proc. Natl. Acad. Sci USA.* 92:5307; Donnelly *et al.* 1996. *J. Infect Dis.* 173:314). DNA vaccines can be administered by a variety of means, for example, by injection (*e.g.*, intramuscular, intradermal, or the biolistic injection of DNA-coated gold particles into the epidermis with a gene gun that uses a particle accelerator or a compressed gas to inject the particles into the skin (Haynes *et al.* 1996. *J. Biotechnol.* 44:37)). Alternatively, DNA vaccines can be administered by non-

invasive means. For example, pure or lipid-formulated DNA can be delivered to the respiratory system or targeted elsewhere, *e.g.*, Peyer's patches by oral delivery of DNA (Schubbert. 1997. *Proc. Natl. Acad. Sci. USA* 94:961). Attenuated microorganisms may be used for delivery to mucosal surfaces. (Sizemore *et al.* 1995. *Science*. 270:29)

5 In one embodiment, plasmids for DNA vaccination can express NIP45 or a NIP45-interacting molecule (or antagonist of NIP45 or a NIP45-interacting molecule as well as the antigen against which the immune response is desired or can encode modulators of immune responses such as lymphokine genes or costimulatory molecules (Iwasaki *et al.* 1997. *J. Immunol.* 158:4591).

10 IX. Administration of Modulating Agents

Modulatory agents of the invention are administered to subjects in a biologically compatible form suitable for pharmaceutical administration *in vivo* to either enhance or suppress immune responses (*e.g.*, T cell mediated immune responses). By
15 "biologically compatible form suitable for administration *in vivo*" is meant a form of the protein to be administered in which any toxic effects are outweighed by the therapeutic effects of the modulating agent. The term subject is intended to include living organisms in which an immune response can be elicited, *e.g.*, mammals. Examples of subjects include humans, dogs, cats, mice, rats, and transgenic species thereof, including but not limited to
20 the transgenic NIP45 or a NIP45-interacting molecule mouse described herein. Administration of an agent as described herein can be in any pharmacological form including a therapeutically active amount of an agent alone or in combination with a pharmaceutically acceptable carrier.

Administration of a therapeutically active amount of the therapeutic
25 compositions of the present invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example, a therapeutically active amount of a cytokine production modulating agent may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of peptide to elicit a desired response in the individual. Dosage regimen may be adjusted to provide the
30 optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

The therapeutic or pharmaceutical compositions of the present invention can be administered by any suitable route known in the art including for example intravenous, subcutaneous, intramuscular, transdermal, intrathecal or intracerebral or administration to cells in ex vivo treatment protocols. Administration can be either rapid as by injection or
5 over a period of time as by slow infusion or administration of slow release formulation. For treating tissues in the central nervous system, administration can be by injection or infusion into the cerebrospinal fluid (CSF). When it is intended that a cytokine production modulator be administered to cells in the central nervous system, administration can be with one or more agents capable of promoting penetration of cytokine production modulator across the
10 blood-brain barrier.

The cytokine production modulator can also be linked or conjugated with agents that provide desirable pharmaceutical or pharmacodynamic properties. For example, cytokine production modulator can be coupled to any substance known in the art to promote penetration or transport across the blood-brain barrier such as an antibody to the transferrin
15 receptor, and administered by intravenous injection. (See for example, Friden *et al.*, 1993, *Science* 259: 373-377 which is incorporated by reference). Furthermore, cytokine production modulator can be stably linked to a polymer such as polyethylene glycol to obtain desirable properties of solubility, stability, half-life and other pharmaceutically advantageous properties. (See for example Davis *et al.*, 1978, *Enzyme Eng* 4: 169-73;
20 Burnham, 1994, *Am J Hosp Pharm* 51: 210-218, which are incorporated by reference).

Furthermore, the cytokine production modulator can be in a composition which aids in delivery into the cytosol of a cell. For example, the agent may be conjugated with a carrier moiety such as a liposome that is capable of delivering the peptide into the
25 cytosol of a cell. Such methods are well known in the art (for example see Amselem *et al.*, 1993, *Chem Phys Lipids* 64: 219-237, which is incorporated by reference). Alternatively, the NIP45 or a NIP45-interacting molecule modulator can be modified to include specific transit peptides or fused to such transit peptides which are capable of delivering the cytokine production modulator into a cell. In addition, the agent can be delivered directly
30 into a cell by microinjection.

The compositions are usually employed in the form of pharmaceutical preparations. Such preparations are made in a manner well known in the pharmaceutical art. One preferred preparation utilizes a vehicle of physiological saline solution, but it is

contemplated that other pharmaceutically acceptable carriers such as physiological concentrations of other non-toxic salts, five percent aqueous glucose solution, sterile water or the like may also be used. As used herein "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the therapeutic compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions. It may also be desirable that a suitable buffer be present in the composition. Such solutions can, if desired, be lyophilized and stored in a sterile ampoule ready for reconstitution by the addition of sterile water for ready injection. The primary solvent can be aqueous or alternatively non-aqueous. NIP45 or a NIP45-interacting molecule can also be incorporated into a solid or semi-solid biologically compatible matrix which can be implanted into tissues requiring treatment.

The carrier can also contain other pharmaceutically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation. Similarly, the carrier may contain still other pharmaceutically-acceptable excipients for modifying or maintaining release or absorption or penetration across the blood-brain barrier. Such excipients are those substances usually and customarily employed to formulate dosages for parenteral administration in either unit dosage or multi-dose form or for direct infusion by continuous or periodic infusion.

Dose administration can be repeated depending upon the pharmacokinetic parameters of the dosage formulation and the route of administration used. It is also provided that certain formulations containing the cytokine production modulator are to be administered orally. Such formulations are preferably encapsulated and formulated with suitable carriers in solid dosage forms. Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, gelatin, syrup, methyl cellulose, methyl- and propylhydroxybenzoates, talc, magnesium, stearate, water, mineral oil, and the like. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents. The compositions may be formulated so as to provide rapid, sustained, or delayed release of the active ingredients after administration

to the patient by employing procedures well known in the art. The formulations can also contain substances that diminish proteolytic degradation and/or substances which promote absorption such as, for example, surface active agents.

It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals. The specific dose can be readily calculated by one of ordinary skill in the art, *e.g.*, according to the approximate body weight or body surface area of the patient or the volume of body space to be occupied. The dose will also be calculated dependent upon the particular route of administration selected. Further refinement of the calculations necessary to determine the appropriate dosage for treatment is routinely made by those of ordinary skill in the art. Such calculations can be made without undue experimentation by one skilled in the art in light of the activity disclosed herein in assay preparations of target cells. Exact dosages are determined in conjunction with standard dose-response studies. It will be understood that the amount of the composition actually administered will be determined by a practitioner, in the light of the relevant circumstances including the condition or conditions to be treated, the choice of composition to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that

targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies may be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method for the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information may be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

In one embodiment of this invention, a modulatory agent may be therapeutically administered by implanting into patients vectors or cells capable of producing, for example a biologically-active form of NIP45 or a NIP45-interacting molecule or a precursor of NIP45 or a NIP45-interacting molecule, *i.e.* a molecule that can be readily converted to a biological-active form of or a NIP45-interacting molecule by the body. In one approach cells that secrete NIP45 or a NIP45-interacting molecule may be encapsulated into semipermeable membranes for implantation into a patient. The cells can be cells that normally express NIP45 or a NIP45-interacting molecule or a precursor thereof or the cells can be transformed to express NIP45 or a NIP45-interacting molecule or a biologically active fragment thereof or a precursor thereof. It is preferred that the cell be of human origin and that the NIP45 or a NIP45-interacting molecule polypeptide be human NIP45 or a NIP45-interacting molecule when the patient is human. However, the formulations and methods herein may be used for veterinary as well as human applications and the term "patient" or "subject" as used herein is intended to include human and veterinary patients.

Monitoring the influence of agents (*e.g.*, drugs or compounds) on the expression or activity of a cytokine gene can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase cytokine gene expression, protein levels, or upregulate cytokine activity, can be monitored in clinical trials of subjects exhibiting

decreased cytokine gene expression, protein levels, or downregulated cytokine activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease cytokine gene expression, protein levels, or downregulate cytokine activity, can be monitored in clinical trials of subjects exhibiting increased cytokine gene expression,
5 protein levels, or upregulated cytokine activity. In such clinical trials, the expression or activity of a cytokine gene, and preferably, other genes that have been implicated in a disorder may be used as a "read out" or markers of the phenotype of a particular cell.

For example, and not by way of limitation, genes, including NIP45 and NIP45-interacting molecules, that are modulated in cells by treatment with an agent (*e.g.*,
10 compound, drug or small molecule) which modulates NIP45 or NIP45-interacting molecule activity (*e.g.*, identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on a NIP45 or NIP45-interacting molecule associated disorder, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of NIP45 or NIP45-interacting molecule and other genes implicated in
15 the NIP45 associated disorder, respectively. The levels of gene expression (*i.e.*, a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NIP45 or NIP45-interacting molecule or other genes. In this way, the gene expression pattern can serve as a marker,
20 indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during treatment of the individual with the agent.

In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (*e.g.*, an agonist,
25 antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a cytokine protein, mRNA, or genomic DNA in the pre-administration sample; (iii) obtaining one or more post-administration samples from the
30 subject; (iv) detecting the level of expression or activity of the NIP45 or NIP45-interacting molecule protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the NIP45 or NIP45-interacting molecule protein, mRNA, or genomic DNA in the pre-administration sample with the NIP45 or

NIP45-interacting molecule protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NIP45 or NIP45-interacting molecule to higher levels than detected, *i.e.*, to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NIP45 or NIP45-interacting molecule to lower levels than detected, *i.e.* to decrease the effectiveness of the agent. According to such an embodiment, NIP45 or NIP45-interacting molecule expression or activity may be used as an indicator of the effectiveness of an agent, even in the absence of an observable phenotypic response.

In a preferred embodiment, the ability of a cytokine modulating agent to modulate inflammation or apoptosis in a epithelial cell of a subject that would benefit from modulation of the expression and/or activity of a cytokine gene can be measured by detecting an improvement in the condition of the patient after the administration of the agent. Such improvement can be readily measured by one of ordinary skill in the art using indicators appropriate for the specific condition of the patient. Monitoring the response of the patient by measuring changes in the condition of the patient is preferred in situations where the collection of biopsy materials would pose an increased risk and/or detriment to the patient.

It is likely that the level of a cytokine may be altered in a variety of conditions and that quantification of cytokine levels would provide clinically useful information. Furthermore, because it has been demonstrated herein that increased levels of cytokine expressed by a cell can shift the cell death regulatory mechanism of that cell to decrease viability, it is believed that measurement of the level of cytokine in a cell or cells such as in a group of cells, tissue or neoplasia, or the like will provide useful information regarding apoptotic state of that cell or cells.

Furthermore, in the treatment of disease conditions, compositions containing cytokine production modulators can be administered exogenously and it would likely be desirable to achieve certain target levels of cytokine production modulators polypeptide in sera, in any desired tissue compartment or in the affected tissue. It would, therefore, be advantageous to be able to monitor the levels of NIP45 polypeptide in a patient or in a biological sample including a tissue biopsy sample obtained from a patient and, in some cases, also monitoring the levels of NIP45 and, in some circumstances, also monitoring

levels of TRAF, NFAT and/or PRMT or another NIP45-interacting polypeptide.

Accordingly, the present invention also provides methods for detecting the presence of NIP45 or NIP45-interacting molecule in a sample from a patient.

5 The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, Molecular Cloning A Laboratory Manual, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis
10 (Cold Spring Harbor Laboratory Press: 1989); DNA Cloning, Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis *et al.* U.S. Patent NO: 4,683,195; Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes
15 (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Methods In Enzymology, Vols. 154 and 155 (Wu *et al.* eds.), Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press,
20 London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

 This invention is further illustrated by the following examples which should
25 not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are hereby incorporated by reference. Nucleotide and amino acid sequences deposited in public databases as referred to herein are also hereby incorporated by reference.

30

**EXAMPLE 1: Isolation of a NIP45 cDNA Using a Yeast
Two-Hybrid Interaction Trap Assay**

A yeast two-hybrid interaction trap assay was used to isolate proteins that
5 could directly bind to the RHD of NFATp. An NFATp(RHD)-Gal4 fusion protein was
prepared for use as the "bait" in the yeast two-hybrid assay by cloning a 900 bp fragment of
murine NFATp (McCaffrey, P.G. *et al.* (1993) *Science* 262:750-754), spanning amino acids
228 to 520, into the BamHI site of vector pEG202 (Gyuris, J. *et al.* (1993) *Cell* 75:791-
803). In frame fusion of the NFAT(p) polypeptide sequences to the Gal4 sequences was
10 confirmed by DNA sequence analysis. This bait was used to screen a cDNA library
prepared from the murine T cell line D10, constructed in the plasmid pJG4-5, to select for
clones encoding polypeptides that interacted with the bait, using methodologies known in
the art (see Gyuris, J. *et al.* (1993) *Cell* 75:791-803).

One class of interactors encoding a fusion protein with apparently high
15 affinity for the NFATp(RHD)-Gal4 bait, as exhibited by high level of β -galactosidase
activity and ability to confer leucine prototrophy, was isolated and termed NIP45 (NFAT
Interacting Protein 45). Figure 1 shows a photograph of yeast colonies (three
representatives for each plasmid combination), cotransformed with the NIP45 plasmid and
either the NFATp-RHD bait or control baits (Max-Gal4, CDK2-Gal4 and the control vector
20 pEG202, expressing only an epitope tagged Gal4 protein), together with the LacZ reporter
plasmid pSH18. The yeast colonies had been selected on appropriate media and were
spotted onto plates containing Xgal and the nonrepressing carbon source galactose. Yeast
colonies cotransformed with the NIP45 plasmid and the NFATp-RHD bait were blue in
color, demonstrating expression of the LacZ reporter plasmid (indicative of NIP45/NFATp-
25 RHD interaction), whereas yeast colonies transformed with the NIP45 plasmid and the
control baits were white in color, indicating no interaction of NIP45 with the control baits.
Transformants were also tested on galactose containing media lacking leucine, and only
those containing the NIP45 plasmid and the NFATp-RHD bait grew, further indicating the
specific interaction of NIP45 with NFATp-RHD. The NIP45 cDNA isolated by the two-
30 hybrid assay was a 1.9 kb DNA fragment.

EXAMPLE 2: Interaction of NIP45 and NFATp *In vivo* in Mammalian Cells

The ability of the NIP45 polypeptide to interact specifically with NFATp *in vivo* was tested in mammalian cells. The 1.9 kb NIP45 cDNA insert selected in the yeast two-hybrid system (described in Example 1) was subcloned into a mammalian expression vector which fuses the coding region to an epitope tag from a influenza hemagglutinin (HA) peptide, vector pCEP4-HA (Herrscher, R.F. *et al.* (1995) *Genes Dev.* 9:3067-3082), to create the expression vector NIP45-HA. This tagged construct was then cotransfected with an NFATp expression plasmid into HepG2 cells (which express low levels of NFATp). As controls, HepG2 cells also were cotransfected with NIP45-HA along with the parental expression vector for the NFATp construct (*i.e.*, the expression vector without the NFATp insert) or with the NFATp expression vector along with an out of frame fusion of NIP45 with the epitope tag. Lysates were prepared from the transfected cells and immunoprecipitated with anti-NFATp antibody. Western blot analysis was then performed on the immunoprecipitated material using either anti-NFATp or anti-HA antibodies.

The results of this experiment are shown in Figure 2. Western blot analysis of these samples using an HA-specific monoclonal antibody (mAb) demonstrated that the anti-NFATp antibody used for immunoprecipitation coimmunoprecipitated the HA-tagged NIP45 polypeptide. The lane showing transfection with only NIP45-HA (middle lane) reveals the low endogenous level of NFATp present in these cells. The amount of HA-tagged NIP45 protein immunoprecipitated was further increased by cotransfection with the NFATp expression plasmid demonstrating the specificity of this interaction (right lane). Western blot analysis of untreated lysates demonstrated that equivalent levels of NIP45-HA polypeptide were expressed in the samples tested for coimmunoprecipitation of NIP45-HA anti-NFATp antibodies. Furthermore, no immunoreactive material for either NFATp or the HA tagged protein was detected when performing immunoprecipitation using normal rabbit serum. These experiments demonstrate that NFAT and NIP45 physically associate *in vivo* in mammalian cells.

EXAMPLE 3: Structural Analysis of NIP45 cDNAs

The 1.9 kb NIP45 cDNA insert from the clone isolated using the two-hybrid assay (described in Example 1) was used to screen a D10.G4 T cell lambda zap II cDNA

library (Stratagene) to identify full length clones. Screening of a library containing approximately 8×10^5 clones yielded 7 hybridizing clones most of which did not extend as far towards the 5' end as the original isolate. Sequence analysis of the longest clone (2.8 kb), however, demonstrated identity to the original clone at the 5' end. The structures of the original 1.9 kb cDNA isolate and the longest 2.8 kb cDNA isolate are compared in Figure 3. The 2.8 kb cDNA isolate contained an additional segment of 180 bp located 868 bp downstream from the 5' end of the original clone. Junction sequences at the ends of this 180 nucleotide segment indicate it to be an unspliced intron and conceptual translation of the nucleotide sequence within this region revealed an in-frame stop codon. Much of the additional sequence in this clone was at the 3' end and represented an extensive 3' untranslated region followed by a poly-A⁺ tail (see Figure 3). Such extensive 3' untranslated regions have been observed in many genes. Allowing for the splicing of the small intron and translation of the single large open reading frame, the 2.8 kb cDNA clone is predicted to encode an identical polypeptide to that of the original 1.9 kb isolate.

The nucleotide and predicted amino acid sequences of the 1.9 kb cDNA isolate are shown in Figure 4 (and in SEQ ID NOs: 1 and 2, respectively). The coding region is shown from the first initiation codon through the first in frame stop codon. The nucleotide and amino acid positions are indicated to the right of the primary sequence. Conceptual translation of the 1.9 kb nucleotide sequence predicted a polypeptide of 412 amino acids with a molecular mass of 45 Kd, and hence the protein has been termed NFAT Interacting Protein 45 (NIP45). Inspection of the amino acid sequence of NIP45 revealed a highly basic domain at the N-terminus, in which 13 of 32 amino acid are basic. This region is underlined in Figure 4. This basic region appears as a hydrophilic stretch in the hydrophobicity plot shown in Figure 5.

EXAMPLE 4: Tissue Expression of NIP45 mRNA

Northern blot analysis of RNA from different murine tissues was performed to investigate the tissue expression of NIP45 mRNA. 10 µg of total RNA from various tissues was separated on denaturing agarose gels, blotted and hybridized with a radiolabelled 1.4 kb NIP45 cDNA fragment. Samples were controlled for equivalent loading of RNA by comparison of ethidium bromide fluorescence. The results of the Northern blot analysis are shown in Figure 6. The hybridizations revealed a transcript of

approximately 3.1 kb, which is of comparable size to the longest cDNA clones. RNA from testis contained an additional 1.4 Kb hybridizing species. The highest levels of NIP45 transcripts were seen in spleen, thymus and testis. The preferential expression in lymphoid organs may indicate a specific function for NIP45 in the immune system. The low intensity hybridization signal and the rare occurrence of NIP45 cDNA clones in the T cell cDNA library indicate that the NIP45 RNA is a relatively rare message.

EXAMPLE 5: Subcellular Localization of NIP45

Subcellular localization of epitope tagged NIP45 protein was determined by indirect immunofluorescence. BHK cells were transfected with 1 µg of an expression construct encoding an HA-epitope tagged NIP45 (pCEP4-HA), using methodologies known in the art (see Heald, R. *et al.* (1993) *Cell* 74:463-474). Transfected cells were incubated overnight, fixed, permeabilized as described (Heald, R. *et al.* (1993) *supra*) and probed with an anti-HA mAb 12CA5 (Boehringer Mannheim) plus indocarbocyanine labeled donkey anti-mouse antibody (Jackson ImmunoResearch) and then counterstained with the dye Hoechst 33258. The results are shown in Figures 7A-B. Nuclear staining of NIP45 was observed with the indocarbocyanine labeled secondary reagent (see Figure 7A) by comparison to the same cells counterstained with the DNA staining dye Hoechst 33258 (see Figure 7B). The fluorescence pattern indicates that NIP45 is evenly distributed throughout the nucleus. Furthermore, this pattern matched that seen for cells transfected with NFAT4 and stimulated with ionomycin (Shibasaki, F. *et al.* (1996) *Nature* 382:370-373; see also below). Stimulation with PMA and/or ionomycin did not affect the subcellular localization of this NIP45.

Control experiments were also performed on BHK cells transfected with NFAT4. Cells were incubated overnight in culture media and either fixed directly or first stimulated with 1 mM ionomycin for 10 minutes before fixation and then processed as described above. The results are shown in Figures 7C-F. Unstimulated (Figs. 7C and 7D) or ionomycin treated (Figs. 7E and 7F) NFAT4 transfectants were probed with an anti-NFAT4 specific antibody followed by a indocarbocyanine labeled secondary reagent and Hoechst 33258. Indocarbocyanine fluorescence demonstrates the pattern of staining for cytoplasmic localized NFAT4 in unstimulated transfectants (Fig. 7C) and nuclear localized

NFAT4 in stimulated cells (Fig. 7E). Adjacent panels (Fig. 7D and 7F, respectively) show the same field exposed for detection of nuclei by staining with Hoechst 33258.

The effect of NIP45 on the nuclear translocation of NFAT4 also was investigated. HepG2 cells were transfected with either NFAT4 or NFAT4 plus NIP45 and stimulated the following day with 1 μ M ionomycin for 0, 2, 4, 8 or 15 minutes. For one sample, the cells were stimulated for 15 minutes with ionomycin and then washed with fresh media and allowed to rest for an additional 15 minutes (indicated as "15 min. + 15 min. rest" in Table 1). This analysis is designed to examine the function of NIP45 as a nuclear retention factor. Fifteen minutes has been shown to be sufficient time for NFAT4 to be exported to the cytoplasm (Shibasaki, F. *et al.* (1996) *Nature* 382:370-373). All samples were then fixed and analyzed by immunofluorescence for translocation of NFAT4 as described above. The results are summarized below in Table 1. Subcellular localization of NFAT4 in the cytoplasm is indicated by a (-) and nuclear translocation of NFAT4 is indicated by (+).

Table 1: Nuclear Translocation of NFAT4

<u>Time</u>	<u>Ionomycin</u>	<u>Ionomycin + NIP45</u>
0 min.	-	-
2 min.	+/-	+/-
4 min.	+/-	+/-
8 min.	+	+
15 min.	+	+
15 min. + 15 min. rest	-	-

No difference in the rate of nuclear import or export of NFAT4 was observed in the presence of NIP45, indicating that nuclear trafficking of NFAT4 in response to changes in intracellular calcium levels was not affected by the overexpression of exogenous NIP45.

EXAMPLE 6: Functional Activity of NIP45 in Regulating Gene Expression

To test for a functional role of NIP45 in NFAT-driven transcription, NIP45 was expressed at high levels in HepG2 cells. HepG2 cells were chosen because they have low levels of endogenous NFAT, and ectopic expression of NFAT family member proteins has been shown to transactivate NFAT-driven transcription in this cell line in the absence of exogenous stimulation (Hoey, T. *et al.* (1995) *Immunity* 2:461-472). HepG2 cells were transfected with a 3X NFAT-CAT reporter from the IL-2 gene (Venkataraman, L. *et al.* (1994) *Immunity* 1:189-196) and control or expression plasmids for a NIP45 and NFAT family members (NFATp, NFATc, NFAT3, NFAT4). HepG2 cells were transfected by the DEAE-Dextran method as described in Hoey, T. *et al.* (1995) *supra*, and CAT assays were performed according to standard methodologies. The results are shown in Figure 8. One representative assay for each combination is shown adjacent to a bar graph representing relative CAT activity for each group. Fold induction was calculated by normalizing the CAT activity of cells transfected with the CAT reporter and each parental expression vector to one. Values represent the relative level of CAT expression above this control transfection. All transfections were performed at least three times with one representative autoradiograph shown.

Transfection of NIP45 alone into HepG2 cells with a 3X NFAT-CAT

reporter did not lead to a significant increase in CAT expression demonstrating that NIP45 cannot act on its own to transactivate an NFAT target sequence. Overexpression of NFATp alone resulted in substantial (6-fold over vector control) transactivation of the NFAT-CAT reporter, consistent with previous reports (Hoey, T. *et al.* (1995) *supra*). Cotransfection of NIP45 plus NFATp resulted in a 4-5 fold increase in CAT activity relative to transfection with NFATp alone and a 25-30 fold increase over that seen with vector alone. This increase was not observed when a mutant 3X NFAT-CAT reporter or a control MHC class II promoter reporter was used thus demonstrating its target site specificity. To confirm that the polypeptide product encoded by the NIP45 cDNA was responsible for this enhanced transactivation, a frame shift mutation was introduced in the coding region by creating a two base deletion at nucleotide 50. This alteration results in the introduction of missense mutations at amino acid 13 and termination of the polypeptide after an additional 22 residues. Assays using this NIP45 Δ construct demonstrated its failure to transactivate the NFAT reporter in the presence or absence of NFATp thus confirming that the enhanced transactivation observed was due to the polypeptide expressed from NIP45 cDNA. Transactivation experiments were also performed in the B cell line M12 and the T cell clone D10 with similar although less dramatic results, which may be due to higher levels of endogenous NIP45 or NFATp in these latter cell lines. These experiments demonstrate that NIP45 substantially and specifically potentiates transcription induced by NFATp, an activity that requires interaction with NFATp.

NFAT proteins share approximately 70% identity within the RHD, raising the possibility that NIP45 could also interact with other NFAT family members. To test this, NIP45 was cotransfected as above with expression constructs encoding either NFATc, NFAT3 or NFAT4 plus the 3X NFAT-CAT reporter plasmid. The results of these experiments are also shown in Figure 8. It has previously been demonstrated that all NFAT family members can transactivate a reporter gene containing 3 copies of an NFAT/AP1 site when overexpressed in HepG2 cells, although to different levels (Hoey, T. *et al.* (1995) *supra*). In the absence of NIP45, NFATp was the most potent transactivator of the NFAT-CAT reporter followed by NFATc and NFAT3 with only weak transactivation by NFAT4, consistent with previous data (McCaffrey, P.G. *et al.* (1993) *Science* 262:750-754). When NFATc, NFAT3 or NFAT4 were cotransfected with NIP45, NIP45 substantially potentiated both NFATc and NFAT3-driven transactivation and weakly potentiated NFAT4-mediated

transactivation (Figure 8). Cooperation with NFATc in HepG2 cells is consistent with the observation that NIP45 interacts with an NFATc RHD bait in yeast cells. Overall, NIP45 overexpression resulted in a 4-fold increase in transactivation by NFATc, a 3-fold increase in NFAT3-driven transactivation and a 2-fold increase in NFAT4-driven transcription. The ability of NIP45 to potentiate the activity of all NFAT family members is not surprising given the high degree of sequence conservation of the RHD of the NFAT family members. A sequence comparison of the NFAT RHD domains reveals a higher level of sequence identity in the amino terminal portion compared to that of the carboxyl terminus (Hoey, T. *et al.* (1995) *supra*). Thus it is likely that the NIP45/NFAT interaction site is located in the 5' portion of the RHD.

Although a reporter construct containing multiple copies of the NFAT binding site provides a sensitive method for measuring transactivation by NFAT and NIP45, it was determined if NIP45 was functional in the context of a native NFAT-dependent promoter. IL-4 expression is highly tissue specific and restricted to the Th2 subset of T cells and to mast cells. The IL-4 promoter contains multiple NFAT binding sites which have been shown to be critical for expression of IL-4 (Rooney, J.W. *et al.* (1995) *Immunity* 2:473-483). Furthermore, the proto-oncogene c-maf has been shown to direct tissue specific expression of IL-4 (U.S. Serial No. 08/636,602). Thus, the IL-4 promoter is not active in the HepG2 cell line but can be activated by the introduction of NFATp and c-maf. In cotransfection experiments carried out as described above, HepG2 cells were transfected with an IL-4-CAT reporter construct (extending to -732 bp of the IL-4 promoter) and expression vectors or controls for NIP45, NFATp and c-Maf. The controls for NIP45 was a frame shift mutant at amino acid 13. Controls for NFATp and c-Maf were the empty expression vectors pREP4 and pMEX respectively (Ho, I.C. *et al.* (1996) *Cell* 85:973-983). The results of these experiments are shown in Figure 9 (representative CAT assays and bar graphs are depicted as in Figure 8). The data indicate that introduction of NIP45 together with NFATp and c-Maf results in an additional 9-fold increase in the activity of the IL-4 promoter relative to that seen for NFATp and c-Maf alone. NIP45 also increased the activity of the IL-4 promoter in the absence of transfected NFATp, an effect likely due to interaction with endogenous NFATp.

**EXAMPLE 7: Transient Overexpression of NIP45 with NFATp
and c-Maf Results in Endogenous IL-4 Production**

To determine whether the combination of NIP45, NFATp and c-Maf was
5 sufficient to induce endogenous IL-4 expression by cells that do not normally produce IL-4,
M12 B lymphoma cells were transiently cotransfected with expression plasmids for NFATp
and
c-Maf together with NIP45 or pCI vector control. M12 cells were transiently transfected by
electroporation as previously described (Ho, I.C. *et al.* (1996) *Cell* 85:973-983) by
10 incubating 3×10^6 cells in 0.4 ml of PBS with 5 μ g of each plasmid for 10 minutes at room
temperature prior to electroporation at 975 μ F, 280 V. Levels of IL-4 in the supernatants
harvested 72 hours later were measured by a commercially available IL-4 ELISA
(Pharmingen), performed according to the manufacturer's instructions except with
modification as described (Ho, I.C. *et al.* (1996) *supra*). Four independent sets of transient
15 transfections were done and assayed for secretion of IL-4 into the culture supernatant.
Results from a representative experiment from one of the four independent transfections is
shown in Figure 10. For each set of transfections, inclusion of NIP45 led to a dramatic
increase in IL-4 production. Cells transfected with NIP45 produced 50-200 fold more
endogenous IL-4 than cells that did not receive NIP45, in which IL-4 production was near
20 the limit of detection.

**EXAMPLE 8: Inhibition of Arginine Methylation Influences T helper
Cytokine Production**

25 To test whether protein arginine methylation could play a role in T helper cell
cytokine production, 5'-methyl-thioadenosine (MTA), a specific inhibitor of protein
methyltransferases (Williams-Ashman, H. G., *et al.* (1982) *Biochem Pharmacol* 31: 277-
288) was utilized. Previous studies demonstrated that incubation of cells with MTA
reduced the total amount of cellular protein methylation (Maher, P. A. (1993) *J Biol Chem*
30 268: 4244-4249). DO11.10 TCR transgenic CD4⁺ lymph node cells were stimulated under
Th1 or Th2 differentiating conditions for one week. Pretreatment with 1mM MTA for 1
hour prior to a 3 hour stimulation with PMA/ionomycin led to a decrease in select cytokine

mRNAs as detected by RNase protection analysis. Specifically, decreases in IFN γ and IL-2 transcripts in Th1 cells were observed as were decreases in IL4, IL5, and IL-13 transcripts in Th2 cells, but IL-10 and IL-6 mRNA levels in Th2 cells were not affected (Figure 11A). Because the BALB/c Th2-prone strain was used, the Th1 cultures are incompletely

5 polarized and still generate MTA-sensitive IL-4 transcripts (Guler, M. L., *et al.* (1997) *J Immunol* 159: 1767-1774; Launois, P., *et al.* (1997) *J Immunol* 158: 3317-3324). Inhibition of methyltransferase activity resulted not only in decreased levels of cytokine transcripts but also in reduction of the number of IFN γ -producing Th1 cells and IL-4 producing Th2 cells (Figure 11B). Importantly, MTA treatment of Th1 and Th2 cells did not result in increased

10 cell death as measured by annexin V staining (data not shown). These results suggest that PRMT directed arginine methylation regulates T helper cytokine production.

Because PRMTs could affect levels of cytokine RNA through altering promoter activation or through affecting RNA stability, the effect of MTA treatment on the activity of a Th2 selective portion of the IL4 promoter (-760 to +68) was tested. This portion

15 of the IL-4 promoter is very responsive to transactivation by the Th2 specific factor, c-Maf, in conjunction with NFAT (. Szabo, S. J., *et al.* (1993) *Mol Cell Biol* 13: 4793-4805; Wenner, C. A., *et al.* (1997) *J Immunol* 158: 765-773). Jurkat cells, a human T cell line were transfected with an IL-4 luciferase reporter along with NFATc2 and c-Maf expression vectors. Coexpression of NFATc2 and c-Maf greatly induced IL-4 promoter activity under

20 PMA/Ionomycin stimulation conditions; however, pretreatment with MTA prior to PMA/Ionomycin stimulation inhibited NFATc2 and c-Maf-driven IL-4 promoter transactivation (Figure 11C), suggesting that the decrease in IL4 RNA in Th2 cells was at least partly due to inhibition of IL4 promoter activation.

25 **EXAMPLE 9: PRMT is Highly Expressed in T helper Cells**

The data in Example 8 revealed an important role for arginine methylation in regulating cytokine gene expression. To determine which protein arginine methyltransferase(s) (PRMT) was the target of MTA inhibition the expression pattern of

30 PRMTs in T helper cells as they differentiated was characterized. Cell lysates from T helper precursors (Thp) and from cells stimulated under Th1 or Th2 conditions for seven days were subjected to immunoblot analysis for PRMT, PRMT2, PRMT3, CARM1, PRMT5, and PRMT6. CARM1 and PRMT6 were expressed at low levels although

CARM1 was not detected at the Thp stage; PRMT2, PRMT3, and PRMT5 were expressed at moderate levels in Thp, Th1, and Th2 cell lysates (Figure 12A). Not only was PRMT the most highly expressed PRMT but its expression was upregulated in Th1 and Th2 cells (Figure 12A). Induction of CARM1 expression in Th1 and Th2 cells was also observed.

5 Because PRMT expression was both robust and regulated during Th differentiation its control was further studied. CD4⁺ T cells were isolated from DO11.10 TCR transgenic mice and were left unstimulated or stimulated with α -CD3/ α -CD28 polyclonal antibody for the indicated times. PRMT transcripts were present in unstimulated CD4⁺ T cells, but were dramatically upregulated 24 hrs after TCR stimulation (Figure 12B). After 3 and 5 days in
10 culture PRMT transcripts declined to levels slightly above baseline Thp expression, and when Day 5 cultures were restimulated with α -CD3, PRMT transcripts were again upregulated (sample D6R, Figure 12B). Upregulation of PRMT transcripts was observed by 6 hours after α -CD3/ α -CD28 polyclonal antibody stimulation and was cyclosporin A sensitive (Figure 12C), indicating that PRMT1 expression was induced through TCR
15 signaling in an NFAT-dependent manner.

These data support earlier findings that PRMT1 accounts for the majority of PRMT activity in mammalian cells (Tang, J., *et al.* (2000) *J Biol Chem* 275: 7723-7730) as further evidenced by a greater than 50% reduction in the level of asymmetric dimethylarginine in deficient ES cells (Pawlak, M. R., *et al.* (2002) *J Cell Biochem* 87: 394-
20 407). Thus, PRMT1 seemed likely to be the primary methyl transferase responsible for modulating TCR-regulated cytokine production.

EXAMPLE 10: PRMT Augments IFN γ and IL-4 Promoter Activity

25 To determine whether PRMT1 could induce IFN γ and IL-4 promoter activity on its own or in conjunction with T helper transcription factors was examined. Jurkat cells were cotransfected with a 9.2kb IFN γ luciferase reporter construct and PRMT1 alone or together with T-bet, a Th1 specific factor which regulates IFN γ expression (Szabo, S. J., *et al.* (2000) *Cell* 100: 655-669). Transfection of PRMT1 alone did not transactivate
30 the IFN γ promoter even with PMA/Ionomycin stimulation, and, as described previously, provision of T-bet induced IFN γ promoter activity under unstimulated and PMA/Ionomycin stimulation conditions (Figure 13A). Notably, cotransfection of PRMT1 and T-bet resulted

in an enhancement of T-bet regulated IFN γ reporter activity (Figure 13A). Similarly, Jurkat cells transfected with PRMT1 only exhibited little induction of the IL-4 promoter over baseline even with PMA/Ionomycin stimulation (Figure 13B) while coexpression of NFATc2 and c-Maf greatly induced IL-4 luciferase activity (Figure 13B). Similar to T-bet, provision of PRMT1 along with NFATc2 and c-Maf substantially augmented IL-4 promoter activity under PMA/ionomycin stimulation conditions (5-fold over NFATc2/c-Maf only) (Figure 13B).

The IL-4 promoter contains several composite NFAT/AP-1 sites. Whether PRMT1 coactivation is mediated through NFAT or AP-1 factors was investigated as both NFAT and JunB are involved in the regulation of IL-4 promoter activity (Li, B., *et al.* (1999) *EMBO J* 18: 420-432). C-Maf, also a member of the AP-1 family, synergizes with JunB to induce IL-4 promoter activity, likely as a result of cooperative DNA binding (Li, B., *et al.* (1999) *EMBO J* 18: 420-432). To test whether PRMT1 augmented JunB/c-Maf transactivation of the IL-4 promoter, PRMT1, JunB, and c-Maf were cotransfected with the IL-4 luciferase reporter. Expression of JunB, or c-Maf alone with the IL-4 promoter had little effect on PMA/ionomycin stimulated reporter activity (20-30 fold compared to 20-fold vector control), however, as previously reported, under PMA/ionomycin stimulation, cotransfection of JunB and c-Maf led to a 50 fold increase compared to vector control. PRMT1 expression alone, as shown in Figure 13B, had no effect on promoter activity or on JunB/c-Maf induced IL-4 reporter activity (Figure 13C). In contrast, PRMT1 synergized with NFATc2 to augment NFATc2 transactivation of an NFAT reporter element by approximately 10-fold (Figure 13D). Thus, PRMT1-induced transcriptional enhancement occurs with both the IFN γ and IL-4 promoters and at least in the case of IL-4 promoter induction, is mediated through the NFAT transcription factor.

EXAMPLE 11: NIP45 is a Potential PRMT Target in T helper Cells

Potential targets of PRMT1 methyltransferase activity were identified. The effects of PRMT1 on the IFN γ and IL-4 promoter were reminiscent of an NFAT-interacting factor previously isolated (Hodge, M. *Ret al.* (1996) *Immunity* 4: 1-20). NFAT interacting protein (NIP) 45kd is a cofactor in NFATc2/c-Maf driven IL-4 promoter activity and endogenous IL-4 expression (Figure 14A and Hodge, M. *Ret al.* (1996) *Immunity* 4: 1-20), and has subsequently been observed to have a similar synergy between NIP45 and T-bet in

transactivating an IFN γ reporter construct (Figure 14A). Furthermore, the amino-terminus (a.a. 6-32) of NIP45 contains several RXR and RG motifs which have been shown to be favorable for methylation by Type I PRMTs (McBride, A. E., and Silver, P. A. (2001) *Cell* 106: 5-8) (Figure 14B). Within the amino-terminus, NIP45 contains eleven arginine residues which are potentially methylated. Whether PRMT1 could methylate NIP45, NFATc2, T-bet or c-Maf was tested. Transfected cell lysates were harvested and immunoprecipitated with indicated antibodies to isolate NIP45, NFATc2, T-bet, or c-Maf. Immunoprecipitates were subjected to an *in vitro* methylation assay using recombinant PRMT1. PRMT1 methylated immunoprecipitated NIP45 but not Δ N-NIP45 in which amino acids 1-32 are deleted (Figure 14C lanes 2 and 3 upper panel). Additionally, PRMT1 did not methylate NFATc2, c-Maf, or T-bet immunoprecipitates, indicating that of these factors NIP45 is the only potential target of PRMT1 (Figure 14C lanes 2,4,5,6 top panel).

EXAMPLE 12:**NIP45 Is Methylated By PRMT**

15

Although it was shown that PRMT1 can methylate NIP45, this did not rule out the possibility that other PRMTs can methylate NIP45 as well. *In vitro* methylation assays were utilized to compare the ability of affinity purified PRMT1, PRMT3, CARM1, and PRMT5 to methylate a bacterially expressed GST-NIP45 fusion protein. In this assay, only PRMT1 was capable of methylating NIP45 (Figure 15A lane 2 upper panel). As PRMT1 is known to form homodimers, the possibility exists that it may form heterodimers with other PRMTs as well; thus the methylation of NIP45 observed in immunoprecipitates from cell lysates could be due to the methyltransferase activity of another PRMT that is recruited by PRMT1. Therefore whether PRMT1 could directly methylate NIP45 using recombinant proteins was tested. As shown in Figure 15B, recombinant PRMT1 was able to methylate bacterially expressed GST-NIP45 (lane 2) whereas CARM1 did not (lane 5), although CARM1 did methylate histone H3 (lane 7) as described previously (chen 1999). These data suggest that PRMT1 methylation of NIP45 is direct and specific. To prove that the amino terminus of NIP45 was the target for methylation by PRMT1, a GST- Δ N-NIP45 fusion protein in which amino acids 1-32 were deleted was created. Elimination of the amino terminus resulted in a loss of PRMT1 induced methylation (Figure 15B lane 3). Others have shown that methylation of proteins *in vitro* by PRMT1 correlates well with their methylation by PRMT1 *in vivo* (Pawlak, M. R., *et al.* (2002) *J Cell Biochem* 87: 394-

30

407). To test this notion directly, wildtype and PRMT1 deficient ES cells were transfected with NIP45 and Western blot analysis was performed using an antibody specific for asymmetrically methylated arginines within RG repeats similar to those found in the amino-terminus of NIP45. Methylation of NIP45 was greatly reduced in PRMT1 deficient ES cells (Figure 15C upper panel). Next, in order to determine whether NIP45 was methylated in T helper cells, endogenous NIP45 was precipitated from lysates generated from cells grown under Th1 or Th2 conditions for seven days and immunoprecipitates probed with the anti-methylated arginine antibody. NIP45 was methylated in both Th1 and Th2 skewed lysates and the methylation status of NIP45 did not change after PMA/Ionomycin stimulation for 60 minutes (Figure 15D upper panel). Therefore, NIP45 is a substrate of PRMT1, the amino terminus of NIP45 is necessary for methylation by PRMT and NIP45 is methylated *in vivo*.

EXAMPLE 13: Association Between NIP45 and PRMT

Because PRMT1 methylates NIP45, their interaction was examined more closely. To determine specificity of interaction GST-NIP45 and GST-ΔN-NIP45 fusion proteins were used in pulldown assays of Jurkat cell lysates. Similar to the *in vitro* methylation results, PRMT1 but not CARM1 associated with full length NIP45 (Figure 16A lanes 2 and 6 upper panel). Furthermore, the interaction between NIP45 and PRMT1 was dependent on the amino-terminus of NIP45 (Figure 16A lane 3). To parallel the pulldown assays, 293T cells were transfected with HA-PRMT1, FLAG-NIP45, and FLAG-ΔN NIP45 mutant. PRMT1 coimmunoprecipitated with full length NIP45 but not with the amino-terminal deletion mutant (Figure 16B), indicating that not only is this region a potential site of PRMT1 methylation but that it is also necessary for a physical NIP45/PRMT1 interaction. Thus, the selectivity and amino-terminus dependence of the NIP45 interaction with PRMT1 *in vivo* mirrors the specificity observed in the *in vitro* methylation assays.

In order to evaluate the physiologic significance of the PRMT1 and NIP45 interaction, coimmunoprecipitation assays were performed using lysates from primary T helper cells differentiated for 7 days under Th1 or Th2 conditions unstimulated, or stimulated for 60 minutes with PMA/ionomycin. Lysates were immunoprecipitated using an anti-PRMT1 antibody as well as the appropriate isotype control and immunoblotted using anti-NIP45 monoclonal antibodies to detect the associated NIP45 protein (Figure 16C upper panel). Blots were reprobed with anti-PRMT1 antibody to determine equal

protein loading (Figure 16C lower panel). These experiments revealed that endogenous PRMT1 and NIP45 proteins associate with each other within primary T helper cells, and that this association does not change under conditions mimicking TCR stimulation.

5 **EXAMPLE 14: The Amino-Terminus of NIP45 is Important for its Function**

Since the amino-terminus of NIP45 is methylated and important for interaction with PRMT1, whether the arginine methylation domain of NIP45 within the amino-terminus was necessary for NIP45 function as an NFAT cofactor was investigated. Jurkat cells were transfected with different combinations of PRMT1, NFATc2, c-Maf, NIP45, and Δ N-NIP45 to test their effects on IL-4 promoter activity. As above, PRMT1 did not transactivate the IL-4 promoter on its own but instead synergized with NFATc2 and c-Maf (Figure 17A). Also, as shown previously, NIP45 augmented NFATc2 and c-Maf-induced IL-4 promoter activity. Deletion of the NIP45 amino terminus reduced the transactivation ability of NIP45 under unstimulated and PMA/ionomycin stimulation conditions (Figure 17A). To ensure that deletion of the NIP45 amino terminus did not alter its subcellular localization, Δ N-NIP45 was expressed fused to green fluorescent protein in mouse embryonic fibroblasts and found nuclear localization was still intact (data not shown). Therefore, the impaired function of Δ N-NIP45 was not due to aberrant cellular localization. When NIP45 and PRMT1 were cotransfected with NFATc2 and c-Maf, reporter activity was not stimulated beyond that seen with just PRMT1, NFATc2, and c-Maf; however, when Δ N-NIP45 was expressed in conjunction with PRMT1, NFATc2, and c-Maf, the dramatic augmentation of IL-4 promoter activity by PRMT1 was lost (Fig 7A). These data suggest that the amino-terminus of NIP45 is necessary for potent NIP45-induced augmentation of NFAT transactivation and is responsible for PRMT1 coactivation of the IL-4 promoter.

The function of arginine methylation in regulating NIP45 activity was investigated. Arginine methylation has previously been shown to regulate subcellular localization and protein-protein interactions. Because Δ N-NIP45 is still localized to the nucleus, it was unlikely that arginine methylation of the amino-terminus of NIP45 was necessary for its presence in the nucleus (data not shown). Since NIP45 binds to NFATc2 and augments NFATc2 driven IL-4 promoter activity (Hodge, M. *et al.* (1996) *Immunity* 4: 1-20), the effects of MTA treatment on the interaction between NIP45 and NFATc2 was tested.

cMyc-tagged NIP45 and HA-tagged NFATc2 were coexpressed in 293T cells which were left untreated or treated with 1mM MTA for 60 minutes. Inhibition of arginine methylation reduced the association between NIP45 and NFATc2 (Fig 7B), suggesting that the function of arginine methylation of NIP45 is to modulate this interaction.

5

EXAMPLE 15: NIP45 deficient mice have defects in Th cell cytokine production as well as non-T cell cytokine production

NIP45^{-/-} mice were generated by standard techniques used previously in our laboratory and the absence of NIP45 protein in lymphoid cells confirmed. There were normal numbers of T and B cells and phenotypic analysis and receptor-induced proliferation of these populations revealed no obvious defects. The ability of NIP45^{-/-} Th cells to produce cytokines was tested. (A) Intracellular cytokine (ICC) FACS of naive CD4⁺ T cells isolated by FACS sorting for CD4⁺ Mel14⁺ cells and stimulated under Th1 (IL-12 and anti-IL4) and Th2 (IL-4 and anti-IFN γ) conditions with platebound antiCD3/antiCD28. Cells were split out with IL2 on day 3 and analyzed on day 7 after stimulation with PMA/ionomycin by ICC. (B -D) NIP45 deficient mice have profound defects in mast cell cytokine production and function.

BMMC from NIP45^{+/+} (wt) and ^{-/-} (ko) mice were cultured for 3 weeks in IL3 and 1x10⁶ cells/ml were stimulated with PMA/ionomycin. Supernatants were collected 24 hrs later and assayed for cytokine production (A and B). NIP45 wt and ko mice were infected with *T. spiralis* larvae. 12 days later mice were sacrificed and intestinal worm burden was determined (C). Wild-type animals had an average of slightly greater than 20 worms/intestine, while knock out animals had slightly greater than 70 worms/intestine.

25

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

30

CLAIMS

What is claimed is:

- 5 1. A method of identifying a compound that modulates cytokine
production, comprising:
 a) providing an indicator composition comprising a type I polypeptide arginine
methyltransferase (PRMT1) polypeptide;
 b) contacting the indicator composition with a plurality of
10 test compounds;
 c) selecting from the library of test compounds a compound of interest
that modulates an activity of PRMT1;
 to thereby identify a compound that modulates cytokine production.
- 15 2. A method of identifying a compound that modulates T cell receptor-
mediated signaling, comprising:
 a) providing an indicator composition comprising a type I polypeptide arginine
methyltransferase (PRMT1) polypeptide;
 b) contacting the indicator composition with a plurality of
20 test compounds;
 c) selecting from the library of test compounds a compound of interest
that modulates an activity of PRMT1;
 to thereby identify a compound that modulates T cell receptor-mediated signaling.
- 25 3. The method of claim 1 or 2, wherein the activity of PRMT1 is a NIP45-
related activity.
4. A method of identifying a compound that modulates cytokine
production, comprising:
30 a) providing an indicator composition comprising the upstream regulatory
regions controlling expression of a type I polypeptide arginine methyltransferase (PRMT1)
polypeptide operably linked to a reporter gene;
 b) contacting the indicator composition with a plurality of
test compounds;
35 c) selecting from the library of test compounds a compound of interest
that modulates the expression of the reporter gene;
 to thereby identify a compound that modulates cytokine production.

5. The method of claim 4, further comprising determining the effect of the compound of interest on a NIP45-related activity of PRMT1.

5 6. The method of claim 1 or 2, wherein the indicator composition is a cell that expresses the PRMT1 polypeptide.

7. The method of claim 6, wherein the cell has been engineered to express the PRMT1 polypeptide by introducing into the cell an expression vector encoding the PRMT1 polypeptide.

10

8. The method of claim 1 or 2, wherein the indicator composition is a cell free composition.

9. The method of claim 1 or 2, wherein the step of determining the effect of the compound of interest on an activity of PRMT1 comprises measuring the ability of the PRMT1 to methylate one or more arginine residues of a target polypeptide.

15

10. The method of claim 9, wherein the target polypeptide is NIP45.

20

11. The method of claim 6, wherein the cell further comprises a NIP45 polypeptide.

12. The method of claim 6, wherein the cell further comprises an NFAT polypeptide.

25

13. The method of claim 3, wherein the step of determining the effect of the compound of interest on a NIP45-related activity of PRMT1 comprises measuring cytokine production or cytokine gene transcription.

30

14. The method of claim 13, wherein the cytokine is IFN- γ or IL-4.

15. A method for identifying a compound that modulates cytokine production in a non-T cell, comprising;

35

- a) providing non-T cell comprising a NIP45 molecule;
- b) contacting the non-T cell with a plurality of test compounds; and
- c) selecting from the library of test compounds a compound of interest that modulates the activity of NIP45;

to thereby identify a compound that modulates cytokine production in a non-T cell.

16. The method of claim 15, wherein the cell further comprises PRMT1.

17. The method of claim 15, wherein the cell further comprises NFAT.

18. The method of claim 15, wherein the activity of NIP45 is selected from the group consisting of: binding to NFAT, binding to PRMT1, and activation of gene transcription.

19. The method of claim 18, wherein the gene is selected from the group consisting of: IL-4, IFN- γ , Egr2, Egr3, c-Rel, and p65.

20. A method for identifying a compound that modulates gene expression comprising:

a) contacting an indicator composition comprising a first polypeptide comprising amino acids 1-32 of NIP45 and a second polypeptide which is a PRMT1 polypeptide with a plurality of test compounds;

b) detecting an activity of the first polypeptide or a NIP45-related activity of the second polypeptide in the presence and absence of a test compound, and

c) selecting a compound of interest that modulates an activity of the first or second polypeptide;

to thereby identify a compound that modulates gene expression.

21. The method of claim 20, wherein the indicator composition is a cell.

22. The method of claim 20, wherein the cell further comprises an NFAT polypeptide and the activity of the first polypeptide is detected by measuring the binding of the first polypeptide to the NFAT polypeptide.

23. The method of claim 22, wherein the NFAT polypeptide is selected from the group consisting of: NFATc1, NFATc2, and NFATc3.

24. The method of claim 20, wherein the activity of the first polypeptide is detected by measuring transcription from a promoter.

25. The method of claim 24, wherein the promoter is an IL-4 or IFN- γ promoter.

5 26. The method of claim 24, wherein the promoter is selected from the group consisting of: the Egr2, Egr3, c-Rel, and p65 promoter.

27. The method of claim 20, wherein the indicator composition is present in a cell free system.

10 28. The method of claim 20, wherein the NIP45-related activity of the second polypeptide is detected by measuring the methylation of one or more arginine residues of NIP45.

15 29. The method of claim 20, wherein the NIP45-related activity of the second polypeptide is detected by measuring the interaction between the second polypeptide and the first polypeptide.

30. The method of claim 20, wherein the test compounds are present in a library of small molecules.

20 31. The method of claim 28, wherein the test compound decreases the degree of arginine methylation of NIP45 as compared to the degree of arginine methylation of NIP45 in the absence of the test compound, and the test compound is identified as an agent that reduces cytokine production.

25 32. The method of claim 28; wherein the test compound increases the degree of arginine methylation of NIP45 as compared to the degree of arginine methylation of NIP45 in the absence of the test compound, and the test compound is identified as an agent that increases cytokine production.

30 33. A method for identifying a compound that modulates an interaction between NIP45 and a PRMT polypeptide, comprising:

- 35 a) contacting an indicator composition comprising a polypeptide comprising amino acids 1-32 of NIP45 and a PRMT polypeptide with a plurality of test compounds;
- b) detecting a readout of the interaction between the NIP45 and PRMT polypeptides in the presence and absence of a test compound, and
- c) selecting a compound of interest that modulates the interaction between the NIP45 and PRMT polypeptides;

to thereby identify a compound that modulates an interaction between NIP45 and PRMT polypeptide.

5 34. The method of claim 33, wherein the indicator composition is a cell based composition.

 35. The method of claim 33, wherein the indicator composition is a cell free composition.

10 36. The method of claim 33 wherein the readout of the interaction between the NIP45 and PRMT1 polypeptides is the binding of NIP45 to PRMT1 or the methylation of one or more arginine residues of NIP45.

15 37. The method of claim 33, wherein the readout of the interaction between the first and second polypeptides is modulation of gene transcription.

 38. The method of claim 37, wherein the gene is selected from the group consisting of IL-4 and IFN- γ .

20 39. The method of claim 33, wherein said test compounds are present in a library of small molecules.

 40. The method of claim 33, wherein the test compound decreases the interaction between NIP45 and PRMT1 as compared to the interaction between NIP45 and PRMT1 in the absence of the test compound, and the test compound is identified as an agent that reduces interaction between NIP45 and PRMT1.

30 41. The method of claim 33, wherein the test compound increases the interaction between NIP45 and PRMT1 as compared to the interaction between NIP45 and PRMT1 in the absence of the test compound, and the test compound is identified as an agent that increases interaction between NIP45 and PRMT1.

 42. A method for identifying a compound that modulates cytokine production in a cell, comprising;

35 a) providing a cell containing one or more constructs which comprise: a cytokine promoter operably linked to a reporter gene, a nucleotide sequence encoding PRMT1, and a nucleotide sequence encoding at least one activator of cytokine gene transcription;

- b) stimulating the cell with an activating signal;
- c) contacting the cell with a plurality of test compounds;
- d) measuring the expression or activity of the reporter gene; and
- e) selecting a compound of interest that modulates the expression or activity

5 of the reporter gene,
to thereby identify a compound that modulates cytokine production in a cell.

43. The method of claim 42, wherein the cytokine promoter is an IFN γ
10 promoter.

44. The method of claim 42, wherein the activator of cytokine gene
transcription is T-bet.

45. The method of claim 42, wherein the cytokine promoter is an IL-4
15 promoter.

46. The method of claim 42, wherein the activator of cytokine gene
transcription is selected from the group consisting of NFATc2 and NIP45.

20 47. The method of claim 42, wherein the cell further comprises a
construct comprising a nucleotide sequence encoding c-maf.

48. A method for modulating cytokine production in a non-T cell
comprising contacting a non-T cell with an agent that modulates the expression and/or
25 activity of at least one molecule selected from the group consisting of: NIP45, PRMT1, and
NFAT, such that cytokine production in the non-T cell is modulated.

49. The method of claim 48, wherein the cell is selected from the group
consisting of: a dendritic cell, an NK cell, and a mast cell.
30

50. A method for modulating cytokine production comprising contacting
a T cell with an agent that modulates PRMT1 expression and/or activity such that cytokine
production is modulated.

35 51. The method of claim 50, wherein the T cell is a CD4⁺ T cell.

52. The method of claim 50, wherein the T cell is a CD8⁺ T cell.

53. The method of claim 48 or 50, wherein IFN γ production is modulated.

54. The method of claim 48 or 50, wherein IL-4 production is modulated.

55. The method of claim 48 or 50, wherein PRMT1 activity is increased, thereby increasing cytokine production.

56. The method of claim 48 or 50, wherein PRMT1 activity is decreased, thereby decreasing cytokine production.

57. A method for modulating IFN γ production, comprising contacting a cell with an agent that modulates PRMT1 expression and/or activity such that IFN γ production is modulated.

58. The method of claim 56, wherein the cell is an NK cell or a dendritic cell.

59. A method for modulating IL-4, comprising contacting a cell with an agent that modulates PRMT1 expression and/or activity such that IL-4 production is modulated.

60. The method of claim 58, wherein the cell is an NK cell or a mast cell.

61. A method for modulating the relative number of Th1 or Th2 cell, comprising contacting a population of T cells with an agent that modulates PRMT1 activity such that the relative number of Th1 or Th2 cells is modulated.

62. A method of treating a subject that would benefit from the modulation of cytokine production comprising contacting an immune cell from the subject with an agent that modulates PRMT1 expression and/or activity in the immune cell such that cytokine production is modulated and the subject that would benefit from the modulation of cytokine production is treated.

63. The method of claim 61, wherein PRMT1 activity is increased, thereby increasing cytokine production.

64. The method of claim 63, wherein the patient is suffering from an immunodeficiency.

5 65. The method of claim 61, wherein PRMT1 activity is decreased, thereby decreasing cytokine production.

66. The method of claim 65, wherein the subject is suffering from an autoimmune or allergic condition.

10

**MODULATION OF IMMUNE SYSTEM FUNCTION BY MODULATION OF
POLYPEPTIDE ARGININE METHYLTRANSFERASES**

5

Abstract

The instant invention pertains to, *e.g.*, method of identifying a compound that modulates cytokine production or T cell receptor-mediated signaling, by identifying modulators of the expression and/or activity of PRMT polypeptides. The invention further pertains to methods for identifying a compound that modulates cytokine production in a non-T cell, by identifying compounds that modulate the expression and/or activity of NIP45. Methods for modulating cytokine production in cells by modulating the expression and/or activity of at least one molecule selected from the group consisting of: NIP45, PRMT1, and NFAT are also provided. The invention also pertains to methods for modulating the relative number of Th1 or Th2 cells is modulated and to methods of treating a subject that would benefit from the modulation of cytokine production comprising contacting an immune cell from the subject with an agent that modulates PRMT1 expression and/or activity in the immune cell.


20

App No.: Not Yet Assigned
Inventor: Laurie H. Glimcher

Docket No.: HUI-054-1


Title: MODULATION OF IMMUNE SYSTEM FUNCTION BY
MODULATION OF POLYPEPTIDE ARGININE
METHYLTRANSFERASES

FIG. 1



BEST AVAILABLE COPY

FIG. 2



BEST AVAILABLE COPY




FIG. 3

ACAGTGTGGGAGATGGCGGAACCACTGAGGGGACGTGGTCCGAGGTCC	48
TGTCACACCCTCTACCGCCTTGGTGACTCCCCTGCACCAGGCTCCAGG	
<u>M A E P L R G R G P R S</u>	12
CGCGGTGGCCGAGGCGCTCGGAGAGCCCGAGGCGCCCGTGGCCGGTGT	96
GCGCCACCGGCTCCGCGAGCCTCTCGGGCTCCGCGGGCACC GGCCACA	
<u>R G G R G A R R A R G A R G R C</u>	28
CCTCGCGCCCGGCAGTCTCCGGCTAGGCTCATTCCAGACACCGTGCTT	144
GGAGCGCGGGCCGTCAGAGGCCGATCCGAGTAAGGTCTGTGGCACGAA	
<u>P R A R Q S P A R L I P D T V L</u>	44
GTGGACTTGGTCAGTGACAGCGACGAAGAGGTCTTGAAGTCGCAGAC	192
CACCTGAACCAGTCACTGTGCTGCTTCTCCAGAACCTTCAGCGTCTG	
<u>V D L V S D S D E E V L E V A D</u>	60
CCAGTAGAGGTGCCGGTCGCCCGCCTCCCCGCGCCGGCTAAACCTGAG	240
GGTCATCTCCACGGCCAGCGGGCGGAGGGGCGCGGCCGATTTGGACTC	
<u>P V E V P V A R L P A P A K P E</u>	76
CAGGACAGCGACAGTGACAGTGAAGGGGCGGCCGAGGGGCCTGCGGGA	288
GTCCTGTGCTGTCACTGTCACTTCCCCGCCGGCTCCCCGGACGCCCT	
<u>Q D S D S D S E G A A E G P A G</u>	92
GCCCCGCGTACATTGGTGCGACGGCGGCGGCGGCGGCTGCTGGATCCC	336
CGGGGCGCATGTAAACCACGCTGCCGCCGCCGCCGACGACCTAGGG	
<u>A P R T L V R R R R R R L L D P</u>	108
GGAGAGGCGCCGGTGGTCCCAGTGTACTCCGGAAGGTACAGAGCAGC	384
CCTCTCCGCGGCCACCAGGGTCACATGAGGCCCTTCCATGTCTCGTCG	
<u>G E A P V V P V Y S G K V Q S S</u>	124
CTCAACCTCATTCCAGATAATTCATCCCTCTTGAAACTGTGCCCTTCA	432
GAGTTGGAGTAAGGTCTATTAAGTAGGGAGAACTTTGACACGGGAAGT	
<u>L N L I P D N S S L L K L C P S</u>	140
GAGCCTGAAGATGAGGCAGATCTGACAAATTCTGGCAGTTCTCCCTCT	480
CTCGGACTTCTACTCCGTCTAGACTGTTTAAGACCGTCAAGAGGGAGA	
<u>E P E D E A D L T N S G S S P S</u>	156
GAGGATGATGCCCTGCCTTCAGGTTCTCCCTGGAGAAAGAAGCTCAGA	528
CTCCTACTACGGGACGGAAGTCCAAGAGGGACCTCTTTCTTCGAGTCT	
<u>E D D A L P S G S P W R K K L R</u>	172

FIGURE 4A

AAGAAGTGTGAGAAAGAAGAAAAGAAAATGGAAGAGTTTCCGGACCAG TTCTTCACACTCTTTCTTCTTTTCTTTTACCTTCTCAAAGGCCTGGTC K K C E K E E K K M E E F P D Q	576 188
GACATCTCTCCTTTGCCCCAACCTTCGTCAAGGAACAAAAGCAGAAAG CTGTAGAGAGGAAACGGGGTTGGAAGCAGTTCCTTGTTTTCTGCTTTTC D I S P L P Q P S S R N K S R K	624 204
CATACGGAGGCGCTCCAGAAGCTAAGGGAAGTGAACAAGCGTCTCCAA GTATGCCTCCGCGAGGTCTTCGATTCCCTTCACTTGTTTCGAGAGGTT H T E A L Q K L R E V N K R L Q	672 220
GATCTCCGCTCCTGCCTGAGCCCCAAGCAGCACCAGAGTCCAGCCCTT CTAGAGGCGAGGACGGACTCGGGGTTTCGTTCGTGGTCTCAGGTCGGGAA D L R S C L S P K Q H Q S P A L	720 236
CAGAGCACAGATGATGAGGTGGTCCCTAGTGGAAGGGCCTGTCTTGCCA GTCTCGTGTCTACTACTCCACCAGGATCACCTTCCCGGACAGAACGGT Q S T D D E V V L V E G P V L P	768 252
CAGAGCTCTCGACTCTTTACACTCAAGATCCGGTGCCGGGCTGACCTA GTCTCGAGAGCTGAGAAATGTGAGTTCTAGGCCACGGCCCGACTGGAT Q S S R L F T L K I R C R A D L	816 268
GTGAGACTGCCTGTCAGGATGTCGGAGCCCCTTCAGAATGTGGTGGAT CACTCTGACGGACAGTCCTACAGCCTCGGGGAAGTCTTACACCACCTA V R L P V R M S E P L Q N V V D	864 284
CACATGGCCAATCATCTTGGGGTGTCTCCAAACAGGATTCTTTTGCTT GTGTACCGGTTAGTAGAACCCACAGAGGTTTGTCTTAAGAAAACGAA H M A N H L G V S P N R I L L L	912 300
TTTGGAGAGAGTGAAGTGTCTCCTACTGCCACCCCTAGTACCCTAAAG AAACCTCTCTCACTTGACAGAGGATGACGGTGGGGATCATGGGATTTC F G E S E L S P T A T P S T L K	960 316
CTTGGAGTGGCTGACATCATTTGATTGTGTGGTGTCTAGCAAGCTCTTCA GAACCTCACCAGCTGTAGTAACACACACACGATCGTTCGAGAAGT L G V A D I I D C V V L A S S S	1008 332
GAGGCCACAGAGACATCCCAGGAGCTCCGGCTCCGGGTGCAGGGGAAG CTCCGGTGTCTCTGTAGGGTCTCGAGGCCGAGGCCACGTCCCCTTC E A T E T S Q E L R L R V Q G K	1056 348

FIGURE 4B

Title: MODULATION OF IMMUNE SYSTEM FUNCTION BY
MODULATION OF POLYPEPTIDE ARGININE
METHYLTRANSFERASES

GAGAAACACCAGATGTTGGAGATCTCACTGTCTCCTGATTCTCCTCTT CTCTTTGTGGTCTACAACCTCTAGAGTGACAGAGGACTAAGAGGAGAA E K H Q M L E I S L S P D S P L	1104 364
AAGGTTCTCATGTCACTATGAGGAAGCCATGGGACTCTCTGGACAC TTCCAAGAGTACAGTGTGATACTCCTTCGGTACCCTGAGAGACCTGTG K V L M S H Y E E A M G L S G H	1152 380
AAGCTCTCCTTCTTCTTTGATGGGACAAAGCTTTCAGGCAAGGAGCTG TTCGAGAGGAAGAAGAACTACCCTGTTTCGAAAGTCCGTTCTCGAC K L S F F F D G T K L S G K E L	1200 396
CCAGCTGATCTGGGCCTGGAATCCGGAGATCTCATCGAAGTCTGGGGC GGTCGACTAGACCCGGACCTTAGGCCTCTAGAGTAGCTTCAGACCCCG P A D L G L E S G D L I E V W G	1248 412
TGAAGCTCTCACCCGTGTCGGACGCAAAGCCAAGACATGGAGACAATA ACTTCGAGAGTGGGACAAGCCTGCGTTTCGGTCTGTACCTCTGTTAT	1296
GCTCCCAATTTTATTATTGTGATTTTTTCGCCCCATAAGGGCTAACAGA CGAGGGTTAAAATAATAACACTAAAAAGCGGGGTATTCCCGATTGTCT	1344
AACTGAATTAGAACTTGTTTACTTATTTATTTCTGGTGCTGGGGATTG TTGACTTAATCTTGAACAAATGAATAAATAAAGACCACGACCCCTAAC	1392
AACCCAGACTATGCACATGCTAAGGATGTATGAAGTGGAGGCAAAAC TTGGGGTCTGATACGTGTACGATTCTACATACTTCACCTCCGTTTTG	1440
CAAGGCATTACCTTTAGCCAGCCTCTAGTAGACTGTAGTGTCAAGCAA GTTCCGTAATGGAAATCGGTCTGGAGATCATCTGACATCACAGTTCGTT	1488
GTGGCTACTTGGTAGTTGTGTGGCTCTGTGTATGTTTGTGCTGTATTT CACCGATGAACCATCAACACACCGAGACACATACAAACACGACATAAA	1536
GGCAGCCCCTGGGGCACATAGAAGGGACCTTGGCTTCCCTACCATTTC CCGTCTGGGGACCCCGTGTATCTTCCCTGGAACCGAAGGGATGGTAAAG	1584

FIGURE 4C

ACGTTGCTGGTGCCCTTTCCTTCATCAGATGACTTCTGTGAAGCTGC TGCAAGCGACCACGGGAAAGGAAGTAGTCTACTGAAGACACTTCGACG	1632
CTATGTTGAGTGTGTTGAACTAAATGAGCTCTGCTTTGGGTGTCCAGG GATACAACTCACACAACCTTGATTTACTCGAGACGAAACCCACAGGTCC	1680
CCTGGGGTTTGTGCCGCAGTTGGAGCCAGCAGTGACTTCACTCTGACT GGACCCCAAACACGGCGTCAACCTCGGTCGTCACTGAAGTGAGACTGA	1728
TGGGACTGAGAATGCATTTCTGGTGGAGACACTCGGGTGCAGAAATA ACCCTGACTCTTACGTAAAGGACCACCTCTGTGAGCCACGTCTTTAT	1776
TAACAGAAGGTGACATACATGCTGAAGCTGAGGACTAGGTCGAAAGTT ATTGTCTTCCACTGTATGTACGACTTCGACTCCTGATCCAGCTTTCAA	1824
AACGACGTTGCATTTTCAGCCTTGGGTATCCTCTCTGCCTGCCAGGAC TTGCTGCAACGTAAAAGTCGGAACCCATAGGAGAGACGGACGGTCCTG	1872
TCTAGCCAGTGTCTGGTACACACTTCTTGGCATGGACACCTAGGTCGA AGATCGGTACAGACCATGTGTGAAGAACCGTACCTGTGGATCCAGCT	1920
CGCGGGCGCGATTTCGGCCGACTCGAG GCGCCCGCGCTAAGCCGGCTGAGCTC	1946

FIGURE4D





FIG. 5

FIG. 6



App No.: Not Yet Assigned
Inventor: Laurie H. Glimcher

Docket No.: HUI-054-1

Title: MODULATION OF IMMUNE SYSTEM FUNCTION BY
MODULATION OF POLYPEPTIDE ARGININE
METHYLTRANSFERASES

FIG. 7A





FIG. 7B



BEST AVAILABLE COPY

FIG. 7C




FIG. 7D






FIG. 7E

FIG. 7F

Title: MODULATION OF IMMUNE SYSTEM FUNCTION BY
MODULATION OF POLYPEPTIDE ARGININE
METHYLTRANSFERASES

FIG. 8





FIG. 9



App No.: Not Yet Assigned

Docket No.: HUI-054-1

Inventor: Laurie H. Glimcher

Title: MODULATION OF IMMUNE SYSTEM FUNCTION BY
MODULATION OF POLYPEPTIDE ARGININE
METHYLTRANSFERASES







FIG.10

BEST AVAILABLE COPY


Figure 11**A****B****C**

BEST AVAILABLE COPY


Figure 12

Title: MODULATION OF IMMUNE SYSTEM FUNCTION BY
 MODULATION OF POLYPEPTIDE ARGININE
 METHYLTRANSFERASES

A



B



C




Figure 13








Figure 14



B.

MAEPLRGRGPRSRGGRGARRARGARGRCPRARQ
SPARLIPDTVLDLVSDSDEEVLEVADPVEVPVARLP
APAKPEQDSDSDSEGAAGPAGAPRTLVRRRRRRL
LDPGEAPVVPVYSGKVQSSNLNIPDNSSLLKLPSE
PEDEADLTNSGSSPSEDDALPSGSPWRKKLRKKCE
KEEKKMEEFPDQDISPLPQPSSRNKSRKHTEALQKL
REVNKRQLQDLRSCLSPKQHQSALQSTDDEVVLVE
GPVLPQSSRLFTLKIRCRADLVRLPVRMSEPLQNVV
DHMANHLGVSPNRILLFGESELSPTATPSTLKLQVA
DIIDCVVLASSEATETSQELRLRVQGKEKHQMLEIS
LSPDSPLKVLMSHYEAMGLSGHKLSFFFDGTKLS
GKELPADLGLESGDLIEVWG

C.





Figure 15



BEST AVAILABLE COPY

Figure 16








Figure 17

A



B




BEST AVAILABLE COPY


Title: MODULATION OF IMMUNE SYSTEM FUNCTION BY
 MODULATION OF POLYPEPTIDE ARGININE
 METHYLTRANSFERASES

Figure 18


A




B



D



C



BEST AVAILABLE COPY

Application Data Sheet

Application Information

Application Type::	Provisional
Subject Matter::	Utility
Suggested Group Art Unit::	N/A
CD-ROM or CD-R?::	None
Sequence submission?::	Paper
Computer Readable Form (CRF)?::	No
Title::	MODULATION OF IMMUNE SYSTEM FUNCTION BY MODULATION OF POLYPEPTIDE ARGININE METHYLTRANSFERASES
Attorney Docket Number::	HUI-054-1
Request for Early Publication?::	No
Request for Non-Publication?::	No
Suggested Drawing Figure::	1
Total Drawing Sheets::	22
Small Entity?::	Yes
Petition included?::	No
Licensed US Govt. Agency::	NIH
Contract or Grant Numbers::	AI37833
Secrecy Order in Parent Appl.?::	No

Applicant Information

Applicant Authority Type::	Inventor
Primary Citizenship Country::	US
Status::	Full Capacity
Given Name::	Laurie
Middle Name::	H.
Family Name::	Glimcher
City of Residence::	West Newton

State or Province of Residence:: MA
Country of Residence:: US
Street of mailing address:: 51 Hampshire Street
City of mailing address:: West Newton
State or Province of mailing address:: MA
Postal or Zip Code of mailing address:: 02165

Correspondence Information

Correspondence Customer Number:: 00959

Representative Information

Representative Customer Number:: 00959

Assignee Information

Assignee name:: President and Fellows of Harvard College
Street of mailing address:: 1350 Massachusetts Avenue, Suite 727
City of mailing address:: Cambridge
State or Province of mailing address:: MA
Postal or Zip Code of mailing address:: 02138

SEQUENCE LISTING

<110> Glimcher, Laurie

<120> MODULATION OF IMMUNE SYSTEM FUNCTION BY
MODULATION OF POLYPEPTIDE ARGININE METHYLTRANSFERASES

<130> HUI-054-1

<160> 10

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1946

<212> DNA

<213> Mus musculus

<400> 1

```

acagtgtggg agatggcgga accactgagg ggacgtgggc cgagggtcccg cgggtggccga 60
ggcgctcgga gagcccgagg cgcccgtggc cgggtgtcctc gcgcccggca gtctccggct 120
aggctcattc cagacaccgt gcttgtggac ttggtcagtg acagcgacga agagggtcttg 180
gaagtcgcag acccagtaga ggtgcccgtc gccgcctcc ccgcgcccgc taaacctgag 240
caggacagcg acagtgcag tgaaggggcg gccgaggggc ctgcgggagc cccgcgtaca 300
ttggtgcgac ggcgggcgcg gcggtgctg gatcccggag aggcgcccgt ggtcccagtg 360
tactccggga aggtacagag cagcctcaac ctcatccag ataattcatc cctcttgaaa 420
ctgtgccctt cagagcctga agatgaggca gatctgacaa attctggcag ttctccctct 480
gaggatgatg ccctgccttc aggttctccc tggagaaaga agctcagaaa gaagtgtgag 540
aaagaagaaa agaaaatgga agagtttccg gaccaggaca tctctccttt gcccacact 600
tcgtcaagga acaaaagcag aaagcatagc gaggcgctcc agaagctaag ggaagtgaac 660
aagcgtctcc aagatctccg ctctgcctg agccccaagc agcaccagag tccagccctt 720
cagagcacag atgatgaggt ggtcctagtg gaagggcctg tcttgccaca gagctctcga 780
ctctttacac tcaagatccg gtgccgggct gacctagtga gactgcctgt caggatgtcg 840
gagcccttc agaattgtgt ggatcacatg gccaatcatc ttgggggtgt tccaaacagg 900
attcttttgc tttttggaga gagtgaactg tctcctactg ccaccctag taccctaaag 960
cttgagtggt ctgacatcat tgattgtgtg gtgctagcaa gctcttcaga ggccacagag 1020
acatcccagg agctccggct ccgggtgcag ggggaaggaga aacaccagat gttggagatc 1080
tactgtctc ctgattctcc tcttaaggtt ctcatgtcac actatgagga agccatggga 1140
ctctctggac acaagctctc ctctctctt gatgggacaa agctttcagg caaggagctg 1200
ccagctgac tgggcctgga atccggagat ctcatcgaag tctggggctg aagctctcac 1260
cctgttcgga cgcaaagcca agacatggag acaatagctc ccaattttat tattgtgatt 1320
tttcgcccc taagggctaa cagaaactga attagaactt gtttacttat ttatttcttg 1380
tgctggggat tgaaccccag actatgcaca tgctaaggat gtatgaagtg gaggcaaac 1440
caaggcatta cctttagcca gcctctagta gactgtagt tcaagcaagt ggctacttg 1500
tagttgtgtg gctctgtgta tgtttgtgct gtatttgga gccctgggg cacatagaag 1560
ggaccttggt ttcctacca ttccagttc gctgggtgcc ttctcttcac cagatgactt 1620
ctgtgaagct gcctatgttg agtgtgttga actaaatgag ctctgctttg ggtgtccagg 1680
cctgggggtt gtgccgagc tggagccagc agtgacttca ctctgacttg ggactgagaa 1740
tgcatttcct ggtggagaca ctcggtgca gaaatataac agaaggtgac atacatgctg 1800
aagctgagga ctaggctgaa agttaacgac gttgcatttt cagccttggg tatcctctct 1860
gcctgccagg actctagcca gtgtctggt cacacttctt ggcattggaca cctaggtcga 1920
cgcgggcgcg attcggccga ctcgag

```

<210> 2

<211> 412

<212> PRT

<213> Mus musculus

<400> 2

```

Met Ala Glu Pro Leu Arg Gly Arg Gly Pro Arg Ser Arg Gly Gly Arg
 1           5           10           15
Gly Ala Arg Arg Ala Arg Gly Ala Arg Gly Arg Cys Pro Arg Ala Arg
      20           25           30
Gln Ser Pro Ala Arg Leu Ile Pro Asp Thr Val Leu Val Asp Leu Val
      35           40           45
Ser Asp Ser Asp Glu Glu Val Leu Glu Val Ala Asp Pro Val Glu Val
      50           55           60
Pro Val Ala Arg Leu Pro Ala Pro Ala Lys Pro Glu Gln Asp Ser Asp
      65           70           75           80
Ser Asp Ser Glu Gly Ala Ala Glu Gly Pro Ala Gly Ala Pro Arg Thr
      85           90           95
Leu Val Arg Arg Arg Arg Arg Arg Leu Leu Asp Pro Gly Glu Ala Pro
      100          105          110
Val Val Pro Val Tyr Ser Gly Lys Val Gln Ser Ser Leu Asn Leu Ile
      115          120          125
Pro Asp Asn Ser Ser Leu Leu Lys Leu Cys Pro Ser Glu Pro Glu Asp
      130          135          140
Glu Ala Asp Leu Thr Asn Ser Gly Ser Ser Pro Ser Glu Asp Asp Ala
      145          150          155          160
Leu Pro Ser Gly Ser Pro Trp Arg Lys Lys Leu Arg Lys Lys Cys Glu
      165          170          175
Lys Glu Glu Lys Lys Met Glu Glu Phe Pro Asp Gln Asp Ile Ser Pro
      180          185          190
Leu Pro Gln Pro Ser Ser Arg Asn Lys Ser Arg Lys His Thr Glu Ala
      195          200          205
Leu Gln Lys Leu Arg Glu Val Asn Lys Arg Leu Gln Asp Leu Arg Ser
      210          215          220
Cys Leu Ser Pro Lys Gln His Gln Ser Pro Ala Leu Gln Ser Thr Asp
      225          230          235          240
Asp Glu Val Val Leu Val Glu Gly Pro Val Leu Pro Gln Ser Ser Arg
      245          250          255
Leu Phe Thr Leu Lys Ile Arg Cys Arg Ala Asp Leu Val Arg Leu Pro
      260          265          270
Val Arg Met Ser Glu Pro Leu Gln Asn Val Val Asp His Met Ala Asn
      275          280          285
His Leu Gly Val Ser Pro Asn Arg Ile Leu Leu Leu Phe Gly Glu Ser
      290          295          300
Glu Leu Ser Pro Thr Ala Thr Pro Ser Thr Leu Lys Leu Gly Val Ala
      305          310          315          320
Asp Ile Ile Asp Cys Val Val Leu Ala Ser Ser Ser Glu Ala Thr Glu
      325          330          335
Thr Ser Gln Glu Leu Arg Leu Arg Val Gln Gly Lys Glu Lys His Gln
      340          345          350
Met Leu Glu Ile Ser Leu Ser Pro Asp Ser Pro Leu Lys Val Leu Met
      355          360          365
Ser His Tyr Glu Glu Ala Met Gly Leu Ser Gly His Lys Leu Ser Phe
      370          375          380
Phe Phe Asp Gly Thr Lys Leu Ser Gly Lys Glu Leu Pro Ala Asp Leu
      385          390          395          400
Gly Leu Glu Ser Gly Asp Leu Ile Glu Val Trp Gly
      405          410

```

<210> 3
 <211> 3469
 <212> DNA
 <213> Mus musculus

<400> 3
 atgccaaata ccagcttttcc agtcccttcc aagttttccac tcggccctcc ggccgcagtc 60
 tgcgggagcg gagaaacttt gcggccccgc cgcctcccg gcggcaccat gaaggcggcc 120
 gaggaagaac actacagtta tgtgtccctt agtgtcacct cgacctgcc ccttcccaca 180

 gcacactctg ccttgccagc agcatgccac gacctccaga cgtccacccc gggatatctca 240
 gctgttccct cagccaatca tccccccagt tacggagggg ctgtggacag cgggccttcg 300
 ggatacttcc tgtcctctgg caacaccaga cccaacgggg ccccgactct ggagagtccg 360
 agaatcgaga tcacctccta cctgggccta caccatggca gcggccagtt tttccacgac 420
 gtggaggtgg aagacgtact tcctagctgc aagcgctcac cgtctacagc aacctgcac 480
 ctgcccagcc tggaaagccta cagagacccc tcctgctga gccagccag cagtctctcc 540
 tccagaagct gtaactctga ggctcctcc tacaggtcca actactccta ccatacgcg 600
 tccccccaga cctctccgtg gcagtcaccc tgcgtgtctc ccaagaccac ggaccggag 660
 gagggttttc cccgaagcct ggggtgcctgc cactgctag gatcgccag gcactcccca 720
 tccacctctc ctcgggcaag catcacggag gagagctggc tcggtgcccg cggctcccgg 780
 cccacgtccc cctgcaaca gcgcaagtac agtctcaatg gccggcagcc ctctgtctca 840
 cccaccact caccacacc atcccccat ggctccctc gggtcagtgt gaccgaagat 900
 acctggctcg gtaacaccac ccagtatacc agctctgcca ttgtggcagc catcaacgcc 960
 ctgaccaccg atagcactct ggacctgggt gatggggtcc ctatcaagtc tcgaaagaca 1020
 gcaactggagc atgcgcctc tgtggccctc aaagtagagc cagctgggga agacctgggc 1080
 accactccac ccacttctga cttcccaccc gaggagtaca ccttccagca ccttcggaag 1140
 ggtgcctttt gcgagcagta tctgtcgggt ccacaggcct cgtatcagtg ggcgaagccc 1200
 aagtctcttt ccccgacatc atatatgagc ccactccttg ctgcccttga ctggcagctc 1260
 ccgtcacatt ctggtccata cgagcttcgg atcgaggtgc agcccaagtc tcaccacagg 1320
 gctcactatg agacggaagg cagccggggg gctgtgaagg cttcagctgg aggacacccc 1380
 attgtgcagc tacacggtta cttggagaat gaacctctca cgctacagct gttcattggg 1440
 acggctgacg accgcctgct gaggccccac gccttctacc aggtccaccg gatcacgggg 1500
 aagactgtct ccaccaccag ccacgagatc atcctgtcca acaccaaagt cctggagatc 1560
 ccgttgcttc cagaaaataa catgagagcc atcatcgact gtgctgggat cctgaagctc 1620
 agaaactctg atattgagct gaggaaggag gagacagaca tcgggaggaa gaacaccagg 1680
 gtgaggtctg tcttccgagt tcacatccca cagcccaatg gccggacgct gtctctccag 1740
 gtggcctcga accctatcga gtgttcccag cggtcagccc aggagctgcc cctcgtggag 1800
 aagcagagca cagacagcta cccagtcac ggccgggaaga agatggtgct gtctggccat 1860
 aactttctgc aagactccaa agtcattttc gtggagaagg ctccagatgg ccaccacgtc 1920
 tgggagatgg aagcaaaagc tgaccgggac ctgtgcaagc caaattccct ggtggttgag 1980
 ataccacctt tccgcaacca gaggataacc agccccgcc aagtcagttt ctatgtctgc 2040
 aacgggaaac ggaagagaag ccagtaccag cgtttcacgt accttctgc caatggtaac 2100
 tctgtctttc taaccttaag ctctgagagt gagctgagag gaggttttta ctgagcagcc 2160
 ccccgaggct ataagaggat gttgttgtaa acaaaacaaa acaaaacaaa acatacctgt 2220
 agcctcttca caccacgtga tagccctatt cacaagacca agtcgcccac cccctcaaag 2280
 aaaagcgaag cctgggtgtg ttttctgtg actggtgcat gctggggtca tcacttgctc 2340
 gccttttgca aatacagcag cgcggccaac caagcagctc tgctgcgctc aggggctgat 2400
 gcggtctggg ggtgtatatc taacctctgt gactctttgg gttagaagaa agtatttgct 2460
 aacgcagttt tgtaagtagc ttcgaaaata agcctgccgt ggtcactggg gaacatacat 2520
 gatgttgtcc tcatggtgac gcttctacac agcgtgcggg gtgtctccac tgaataatgc 2580
 tgtcccctgg tgacgtgaga ctttcagatg gaagctcttc tgctcgagtt tactcattta 2640
 gggaaatggc tctttcattc agaagtgate ggctcgctt ttcaactttc taggggtgtt 2700
 tatttacgaa aataccgttt ttaactgctc cccgccccgc aagcttctag aaagggtgtg 2760
 cccaggcgtc cagggttttc tgtgtggtgc aggccattct cctgcagcag gatgtataaa 2820
 cagagagcag agtcggttgt tatcctgagt tctattgtat tttgagtaag ctaggctatg 2880
 tcaacaacct ttttaaatgt ctactttttt ttttctctca aaaacttaag atagtcatgt 2940

```

aatttaagag ggaagttata caataaatac tagccatgaa agcagccata ttgctatctt 3000
agtaaaatca aggtgggtttt gttgttggtta ttttgttttg ttttttgttt ttttaagggttt 3060
caagggtttt tggttttgaa gtgtaaaggc atttggaaca gtttagacag tacgaaaagt 3120
tggtattaaa attctgaaac caattgtctt atcaggaaac ccctagaaat gccctttaaa 3180
aatgaggaca atagctttgt tgcattctca aacaaggaca tcagtgaag ggcagcaact 3240
gtctgtgctg tgggtgaccc cagaacagcg gcccatcccc catcccgtct ctgctcttca 3300
gattatttca caggcctctt cctttcgga aataatgcac actctctctt acaaaaaaac 3360
caaacatttg gtcttttatt ttattttatt ttattttttg aaagtgcaat gattgtgtcc 3420
tacctatact tcaagcatgg ttgatctaag atttttgaaa ggtctaaac 3469

```

<210> 4

<211> 717

<212> PRT

<213> Mus musculus

<400> 4

```

Met Pro Asn Thr Ser Phe Pro Val Pro Ser Lys Phe Pro Leu Gly Pro
1          5          10          15
Pro Ala Ala Val Cys Gly Ser Gly Glu Thr Leu Arg Pro Ala Pro Pro
20          25          30
Ser Gly Gly Thr Met Lys Ala Ala Glu Glu Glu His Tyr Ser Tyr Val
35          40          45
Ser Pro Ser Val Thr Ser Thr Leu Pro Leu Pro Thr Ala His Ser Ala
50          55          60
Leu Pro Ala Ala Cys His Asp Leu Gln Thr Ser Thr Pro Gly Ile Ser
65          70          75          80
Ala Val Pro Ser Ala Asn His Pro Pro Ser Tyr Gly Gly Ala Val Asp
85          90          95
Ser Gly Pro Ser Gly Tyr Phe Leu Ser Ser Gly Asn Thr Arg Pro Asn
100         105         110
Gly Ala Pro Thr Leu Glu Ser Pro Arg Ile Glu Ile Thr Ser Tyr Leu
115         120         125
Gly Leu His His Gly Ser Gly Gln Phe Phe His Asp Val Glu Val Glu
130         135         140
Asp Val Leu Pro Ser Cys Lys Arg Ser Pro Ser Thr Ala Thr Leu His
145         150         155         160
Leu Pro Ser Leu Glu Ala Tyr Arg Asp Pro Ser Cys Leu Ser Pro Ala
165         170         175
Ser Ser Leu Ser Ser Arg Ser Cys Asn Ser Glu Ala Ser Ser Tyr Glu
180         185         190
Ser Asn Tyr Ser Tyr Pro Tyr Ala Ser Pro Gln Thr Ser Pro Trp Gln
195         200         205
Ser Pro Cys Val Ser Pro Lys Thr Thr Asp Pro Glu Glu Gly Phe Pro
210         215         220
Arg Ser Leu Gly Ala Cys His Leu Leu Gly Ser Pro Arg His Ser Pro
225         230         235         240
Ser Thr Ser Pro Arg Ala Ser Ile Thr Glu Glu Ser Trp Leu Gly Ala
245         250         255
Arg Gly Ser Arg Pro Thr Ser Pro Cys Asn Lys Arg Lys Tyr Ser Leu
260         265         270
Asn Gly Arg Gln Pro Ser Cys Ser Pro His His Ser Pro Thr Pro Ser
275         280         285
Pro His Gly Ser Pro Arg Val Ser Val Thr Glu Asp Thr Trp Leu Gly
290         295         300
Asn Thr Thr Gln Tyr Thr Ser Ser Ala Ile Val Ala Ala Ile Asn Ala
305         310         315         320
Leu Thr Thr Asp Ser Thr Leu Asp Leu Gly Asp Gly Val Pro Ile Lys

```


				325					330					335		
Ser	Arg	Lys	Thr	Ala	Leu	Glu	His	Ala	Pro	Ser	Val	Ala	Leu	Lys	Val	
			340					345					350			
Glu	Pro	Ala	Gly	Glu	Asp	Leu	Gly	Thr	Thr	Pro	Pro	Thr	Ser	Asp	Phe	
		355					360					365				
Pro	Pro	Glu	Glu	Tyr	Thr	Phe	Gln	His	Leu	Arg	Lys	Gly	Ala	Phe	Cys	
		370				375					380					
Glu	Gln	Tyr	Leu	Ser	Val	Pro	Gln	Ala	Ser	Tyr	Gln	Trp	Ala	Lys	Pro	
385					390					395					400	
Lys	Ser	Leu	Ser	Pro	Thr	Ser	Tyr	Met	Ser	Pro	Ser	Leu	Pro	Ala	Leu	
				405					410					415		
Asp	Trp	Gln	Leu	Pro	Ser	His	Ser	Gly	Pro	Tyr	Glu	Leu	Arg	Ile	Glu	
			420					425					430			
Val	Gln	Pro	Lys	Ser	His	His	Arg	Ala	His	Tyr	Glu	Thr	Glu	Gly	Ser	
		435					440					445				
Arg	Gly	Ala	Val	Lys	Ala	Ser	Ala	Gly	Gly	His	Pro	Ile	Val	Gln	Leu	
		450				455					460					
His	Gly	Tyr	Leu	Glu	Asn	Glu	Pro	Leu	Thr	Leu	Gln	Leu	Phe	Ile	Gly	
465					470					475					480	
Thr	Ala	Asp	Asp	Arg	Leu	Leu	Arg	Pro	His	Ala	Phe	Tyr	Gln	Val	His	
				485					490					495		
Arg	Ile	Thr	Gly	Lys	Thr	Val	Ser	Thr	Thr	Ser	His	Glu	Ile	Ile	Leu	
			500					505					510			
Ser	Asn	Thr	Lys	Val	Leu	Glu	Ile	Pro	Leu	Leu	Pro	Glu	Asn	Asn	Met	
		515					520					525				
Arg	Ala	Ile	Ile	Asp	Cys	Ala	Gly	Ile	Leu	Lys	Leu	Arg	Asn	Ser	Asp	
		530				535					540					
Ile	Glu	Leu	Arg	Lys	Gly	Glu	Thr	Asp	Ile	Gly	Arg	Lys	Asn	Thr	Arg	
545					550					555					560	
Val	Arg	Leu	Val	Phe	Arg	Val	His	Ile	Pro	Gln	Pro	Asn	Gly	Arg	Thr	
				565					570					575		
Leu	Ser	Leu	Gln	Val	Ala	Ser	Asn	Pro	Ile	Glu	Cys	Ser	Gln	Arg	Ser	
			580					585					590			
Ala	Gln	Glu	Leu	Pro	Leu	Val	Glu	Lys	Gln	Ser	Thr	Asp	Ser	Tyr	Pro	
		595					600					605				
Val	Ile	Gly	Gly	Lys	Lys	Met	Val	Leu	Ser	Gly	His	Asn	Phe	Leu	Gln	
		610				615					620					
Asp	Ser	Lys	Val	Ile	Phe	Val	Glu	Lys	Ala	Pro	Asp	Gly	His	His	Val	
625					630					635					640	
Trp	Glu	Met	Glu	Ala	Lys	Thr	Asp	Arg	Asp	Leu	Cys	Lys	Pro	Asn	Ser	
				645					650					655		
Leu	Val	Val	Glu	Ile	Pro	Pro	Phe	Arg	Asn	Gln	Arg	Ile	Thr	Ser	Pro	
			660					665					670			
Ala	Gln	Val	Ser	Phe	Tyr	Val	Cys	Asn	Gly	Lys	Arg	Lys	Arg	Ser	Gln	
		675					680									

```
<210> 5
<211> 3419
<212> DNA
<213> Mus musculus
```

<400> 5

```

cacagatacg gtgacccctg ctctgcgccc cgcgactcta tacgaaccgg catcccgaa 60
gccccgagcc atggacgtcc cggagccgca gccccacccc gatggcgggg acggcccccg 120
ccacgagccc gggggcagtc cccaagacga gctggacttt tccatcctct tcgattatga 180
ctatctgaac cctatcgaag aagaaccgat cgcacataag gccatcagct caccctccgg 240
actcgcatat ccggatgatg tcttgacta tggcctcaag ccatgcaacc cccttgccag 300
tctctctggc gagccccctg gccgggttcgg agagccggat agtatagggt tccagaactt 360
tctgagcccc gtcaagccag caggggcttc gggcccgagc cctcggatcg agatcactcc 420
atcccacgaa ctgatgcagg cagggggggc cctccgtggg agagacgccc gcctgtcccc 480
cgagcagccc gccctggccc tggccggcgt ggcgcgcagc ccgaggttca cactgcccgt 540
gccccgctac gagggctacc gcgagccgtt ttgcttgagc cccgctagca gcggctcctc 600
tgccagcttc atttctgaca ccttctcccc ctacacctcg cctgcgtct caccataa 660
cgccgggccc gacgacctgt gtccccagtt tcaaaacatc cctgctcatt attccccag 720
aacctctcca ataattgtac ctogaaccag cctcgccgag gacagctgcc tgggcccaga 780
ctcgcccggtg ccccgctccg catcccgctc ctctcaccg ggtgccaagc ggaggcattc 840
gtgcgcagag gctttgggtg ctctctgccc cgcagcctca ccccgcgct cccggagccc 900
ctcgccacag ccctcgctc acgtggcacc gcaggacgac agcatccccg ctgggtaccc 960
ccccacggcc ggtctgctg ttctcatgga tgccctcaac accctggcca ccgactcgcc 1020
ctgcgggata ccctccaaga tatggaagac cagtcctgac ccgacgctg tgtccaccgc 1080
tccgtccaag gctggcctgg cccgccacat ctaccctact gtggagttcc tggggccatg 1140
tgagcaggag gagaggagga attccgctcc agagtccatc ctgctggtac cacctacttg 1200
gccaagcag ttggtgcccg ccattcccat ctgcagcatc cctgtgactg catccctccc 1260
accactcgag tggccactct ccaatcagtc gggctcctat gagctacgga ttgaggtcca 1320
accaagccc catcacggg ccactatga cagggagggc agccgtggcg ctgtcaaagc 1380
ccccacagga ggacacctg tgggtgcagct ccacggctac atggagaaca agcctctggg 1440
gcttcagatc ttcatggga cagcagatga gaggatcctt aagccgcacg ccttctacca 1500
agtacacagg atcactggga aaacggtcac caccacgagc tatgagaaga tcgtaggcaa 1560
caccaaggte ctggagatcc ccctggagcc aaagaacaac atgagagcca ccatcgactg 1620
tgcaggcatc ctgaagctcc gaaacgctga catcgagctg cggaaggggc agacggacat 1680
cggcaggaag aacacgcgtg tgcgcctggt gttccgcgtg cagctcccag agcccagtgg 1740
gcgcacgtc tcctgcagg ctgcgtccaa ccccatcgag tgctctcagc gctctgccc 1800
cgagctgccc atggtggaga gacaagacat ggacagctgc ctggtctacg ggggcccagc 1860
gatgatcctc acgggccaga acttcacagc ggagtccaag gttgtgttca tggagaagac 1920
tacagatggg cagcagattt gggagatgga agctacggtg gataaagaca agagccagcc 1980
taacatgctt tttgttgaga tccccgagta tcggaacaag cacatccgcg tgcccgtgaa 2040
agtcaacttc tacgtcatca acggaaagag gaaacgaagt cagccacagc actttacct 2100
ccaccagtc cctgccatca agacagagcc cagcgatgag tatgaacct ctttgatctg 2160
cagccccgcc catggaggcc tggggagcca gccatattac ccacagcacc caatgctggc 2220
cgagtcccc tcctgccttg tggctacctt gggccctgc caacagttcc gctcggggct 2280
ctcatcccc gatgctcgt accaacagca gagccccgca gctgccctct accagagaag 2340
caagagctg agtccccgcc tgcctgggcta ccagcagccg tccctcctgg cagcaccct 2400
gggtctggct gatccccacc gctctgtgct ggtgcagctg ggttctcagg ggcaggggca 2460
gggtccacc ctccgacaca catcctcggc cagccagcag gcctcaccgg tgatccacta 2520
ctcaccacc aaccagcagc ttgcgggtgg gggtcaccag gagttccagc atatcatgta 2580
ctgtgaaaac ttcgccccca gctctgccag gcctggccc cctcccatca accaaggtea 2640
gaggctgagc cggggcgctt accccacagt catccaacaa cagactgccc cgagccaaag 2700
agtgccaaa aacggacca gtgaccagaa ggaagctctg cccacgggag tgaccgtcaa 2760
acaggaacag aacctggacc agacctacct ggatgacgca gccacttcag aaagctgggt 2820
tgggacagaa aggtatatag agagaaaatt ttggaagaag acccttgtgc agcctgggct 2880
cctgccctca tttttacttc ttggctccct gtctgctgga ccaaggtcac agacaccatc 2940
agaaagaaag cccatagagg aagacgtgcc cttgagttgc agccagatag cctggtgttg 3000
tcagcatccc ttggggacct gccctgtcct gccagggct ttagctgtag agtgggtggg 3060
agggcagctc gggcggtggc tggagccaat tccctgggct ccagacagtg ccggcagcct 3120
ccatgaggtg gacagtgtag gcctggcggg agtggctgga atggttctgc tactcttat 3180
gcaccacttc tccatggatc agaaccagac cccctctcct cactggcaaa ggcacaaaga 3240
ggttgctagc ccaggctgga tctgaccoga ggaagctggg gccaggccca gagtctgaag 3300
gggtctgaat catccttctt gacacccac ggggtatggg gccagggatg aaccagaggc 3360
aaccgttctc cagcatggca tctccatcg caatccacag gcccacact cggcctagg 3419

```

<210> 6
 <211> 1064
 <212> PRT
 <213> Mus musculus

<400> 6
 Met Asp Val Pro Glu Pro Gln Pro Asp Pro Asp Gly Gly Asp Gly Pro
 1 5 10 15
 Gly His Glu Pro Gly Gly Ser Pro Gln Asp Glu Leu Asp Phe Ser Ile
 20 25 30
 Leu Phe Asp Tyr Asp Tyr Leu Asn Pro Ile Glu Glu Glu Pro Ile Ala
 35 40 45
 His Lys Ala Ile Ser Ser Pro Ser Gly Leu Ala Tyr Pro Asp Asp Val
 50 55 60
 Leu Asp Tyr Gly Leu Lys Pro Cys Asn Pro Leu Ala Ser Leu Ser Gly
 65 70 75 80
 Glu Pro Pro Gly Arg Phe Gly Glu Pro Asp Ser Ile Gly Phe Gln Asn
 85 90 95
 Phe Leu Ser Pro Val Lys Pro Ala Gly Ala Ser Gly Pro Ser Pro Arg
 100 105 110
 Ile Glu Ile Thr Pro Ser His Glu Leu Met Gln Ala Gly Gly Ala Leu
 115 120 125
 Arg Gly Arg Asp Ala Gly Leu Ser Pro Glu Gln Pro Ala Leu Ala Leu
 130 135 140
 Ala Gly Val Ala Ala Ser Pro Arg Phe Thr Leu Pro Val Pro Gly Tyr
 145 150 155 160
 Glu Gly Tyr Arg Glu Pro Leu Cys Leu Ser Pro Ala Ser Ser Gly Ser
 165 170 175
 Ser Ala Ser Phe Ile Ser Asp Thr Phe Ser Pro Tyr Thr Ser Pro Cys
 180 185 190
 Val Ser Pro Asn Asn Ala Gly Pro Asp Asp Leu Cys Pro Gln Phe Gln
 195 200 205
 Asn Ile Pro Ala His Tyr Ser Pro Arg Thr Ser Pro Ile Met Ser Pro
 210 215 220
 Arg Thr Ser Leu Ala Glu Asp Ser Cys Leu Gly Arg His Ser Pro Val
 225 230 235 240
 Pro Arg Pro Ala Ser Arg Ser Ser Ser Pro Gly Ala Lys Arg Arg His
 245 250 255
 Ser Cys Ala Glu Ala Leu Val Ala Pro Leu Pro Ala Ala Ser Pro Gln
 260 265 270
 Arg Ser Arg Ser Pro Ser Pro Gln Pro Ser Pro His Val Ala Pro Gln
 275 280 285
 Asp Asp Ser Ile Pro Ala Gly Tyr Pro Pro Thr Ala Gly Ser Ala Val
 290 295 300
 Leu Met Asp Ala Leu Asn Thr Leu Ala Thr Asp Ser Pro Cys Gly Ile
 305 310 315 320
 Pro Ser Lys Ile Trp Lys Thr Ser Pro Asp Pro Thr Pro Val Ser Thr
 325 330 335
 Ala Pro Ser Lys Ala Gly Leu Ala Arg His Ile Tyr Pro Thr Val Glu
 340 345 350
 Phe Leu Gly Pro Cys Glu Gln Glu Glu Arg Arg Asn Ser Ala Pro Glu
 355 360 365
 Ser Ile Leu Leu Val Pro Pro Thr Trp Pro Lys Gln Leu Val Pro Ala
 370 375 380
 Ile Pro Ile Cys Ser Ile Pro Val Thr Ala Ser Leu Pro Pro Leu Glu
 385 390 395 400

Trp Pro Leu Ser Asn Gln Ser Gly Ser Tyr Glu Leu Arg Ile Glu Val
 405 410 415
 Gln Pro Lys Pro His His Arg Ala His Tyr Glu Thr Glu Gly Ser Arg
 420 425 430
 Gly Ala Val Lys Ala Pro Thr Gly Gly His Pro Val Val Gln Leu His
 435 440 445
 Gly Tyr Met Glu Asn Lys Pro Leu Gly Leu Gln Ile Phe Ile Gly Thr
 450 455 460
 Ala Asp Glu Arg Ile Leu Lys Pro His Ala Phe Tyr Gln Val His Arg
 465 470 475 480
 Ile Thr Gly Lys Thr Val Thr Thr Thr Ser Tyr Glu Lys Ile Val Gly
 485 490 495
 Asn Thr Lys Val Leu Glu Ile Pro Leu Glu Pro Lys Asn Asn Met Arg
 500 505 510
 Ala Thr Ile Asp Cys Ala Gly Ile Leu Lys Leu Arg Asn Ala Asp Ile
 515 520 525
 Glu Leu Arg Lys Gly Glu Thr Asp Ile Gly Arg Lys Asn Thr Arg Val
 530 535 540
 Arg Leu Val Phe Arg Val His Val Pro Glu Pro Ser Gly Arg Ile Val
 545 550 555 560
 Ser Leu Gln Ala Ala Ser Asn Pro Ile Glu Cys Ser Gln Arg Ser Ala
 565 570 575
 His Glu Leu Pro Met Val Glu Arg Gln Asp Met Asp Ser Cys Leu Val
 580 585 590
 Tyr Gly Gly Gln Gln Met Ile Leu Thr Gly Gln Asn Phe Thr Ala Glu
 595 600 605
 Ser Lys Val Val Phe Met Glu Lys Thr Thr Asp Gly Gln Gln Ile Trp
 610 615 620
 Glu Met Glu Ala Thr Val Asp Lys Asp Lys Ser Gln Pro Asn Met Leu
 625 630 635 640
 Phe Val Glu Ile Pro Glu Tyr Arg Asn Lys His Ile Arg Val Pro Val
 645 650 655
 Lys Val Asn Phe Tyr Val Ile Asn Gly Lys Arg Lys Arg Ser Gln Pro
 660 665 670
 Gln His Phe Thr Tyr His Pro Val Pro Ala Ile Lys Thr Glu Pro Ser
 675 680 685
 Asp Glu Tyr Glu Pro Ser Leu Ile Cys Ser Pro Ala His Gly Gly Leu
 690 695 700
 Gly Ser Gln Pro Tyr Tyr Pro Gln His Pro Met Leu Ala Glu Ser Pro
 705 710 715 720
 Ser Cys Leu Val Ala Thr Met Ala Pro Cys Gln Gln Phe Arg Ser Gly
 725 730 735
 Leu Ser Ser Pro Asp Ala Arg Tyr Gln Gln Gln Ser Pro Ala Ala Ala
 740 745 750
 Leu Tyr Gln Arg Ser Lys Ser Leu Ser Pro Gly Leu Leu Gly Tyr Gln
 755 760 765
 Gln Pro Ser Leu Leu Ala Ala Pro Leu Gly Leu Ala Asp Ala His Arg
 770 775 780
 Ser Val Leu Val His Ala Gly Ser Gln Gly Gln Gly Gln Gly Ser Thr
 785 790 795 800
 Leu Arg His Thr Ser Ser Ala Ser Gln Gln Ala Ser Pro Val Ile His
 805 810 815
 Tyr Ser Pro Thr Asn Gln Gln Leu Arg Gly Gly Gly His Gln Glu Phe
 820 825 830
 Gln His Ile Met Tyr Cys Glu Asn Phe Gly Pro Ser Ser Ala Arg Pro
 835 840 845
 Gly Pro Pro Pro Ile Asn Gln Gly Gln Arg Leu Ser Pro Gly Ala Tyr

850	855	860
Pro Thr Val Ile Gln Gln Thr Ala Pro Ser Gln Arg Ala Ala Lys		
865	870	875
Asn Gly Pro Ser Asp Gln Lys Glu Ala Leu Pro Thr Gly Val Thr Val		
	885	890
Lys Gln Glu Gln Asn Leu Asp Gln Thr Tyr Leu Asp Asp Ala Ala Thr		
	900	905
Ser Glu Ser Trp Val Gly Thr Glu Arg Tyr Ile Glu Arg Lys Phe Trp		
	915	920
Lys Lys Thr Leu Val Gln Pro Gly Leu Leu Pro Ser Phe Leu Leu Leu		
	930	935
Gly Ser Leu Ser Ala Gly Pro Arg Ser Gln Thr Pro Ser Glu Arg Lys		
945	950	955
Pro Ile Glu Glu Asp Val Pro Leu Ser Cys Ser Gln Ile Ala Trp Cys		
	965	970
Cys Gln His Pro Leu Gly Thr Cys Pro Val Leu Pro Gly Pro Leu Ala		
	980	985
Val Glu Trp Trp Glu Gly Gln Leu Gly Arg Gly Leu Glu Pro Ile Pro		
	995	1000
Trp Ala Pro Asp Ser Ala Gly Ser Leu His Glu Val Asp Ser Val Gly		
	1010	1015
Leu Ala Gly Val Val Gly Met Val Leu Leu Thr Leu Met His His Phe		
1025	1030	1035
Ser Met Asp Gln Asn Gln Thr Pro Ser Pro His Trp Gln Arg His Lys		
	1045	1050
Glu Val Ala Ser Pro Gly Trp Ile		1055
	1060	

<210> 7
 <211> 3638
 <212> DNA
 <213> Mus musculus

<400> 7

cacgcccgatg	actactgcaa	actgtggcgc	ccacgacgag	ctcgacttca	aactcgtctt	60
tggcgaggac	ggggcgccgg	cgccgcgcgc	cccgggctcg	cggcctgcag	atcttgagcc	120
agatgattgt	gcatccattt	acatctttta	tgtagatcca	cctccatcta	ctttaaccac	180
accactttgc	ttaccacatc	atggattacc	gtctcactct	tctgttttgt	caccatcggt	240
tcagctccaa	agtcacaaaa	actatgaagg	aacttgtgag	attcctgaat	ctaaatatag	300
cccattaggt	ggtcccaaac	cctttgagtg	cccaagtatc	caattttacat	ctatctctcc	360
taactgtcaa	caagaattag	atgcacatga	agatgacctt	cagataaatg	accagaacg	420
ggaatttttg	gaaaggcctt	ctagagatca	tctctatctt	cctcttgagc	catcctaccg	480
ggagtcttct	cttagtccta	gtcctgccag	cagcatctct	tctaggagtt	ggttctctga	540
tgcattcttct	tgtgaatcgc	tttcacatat	ttatgatgat	gtggactcag	agttgaatga	600
agctgctgca	cgattcactc	ttggttcacc	tctgacttct	ccagggtggc	ctccaggagg	660
ttgccctgga	gaagagtcct	ggcatcaaca	gtatggatct	ggacactcct	tgtaacctag	720
gcaatctcct	tgccactctc	ctagatctag	tatcactgat	gagaattggc	tgagccccag	780
accagcctca	ggaccctcat	caaggcccac	ttctccctgt	ggtaaaccgac	ggcactccag	840
tgctgaagta	tgttatgctg	gttccctttc	accccatcac	tcgcctgttc	catcccctgg	900
tcactctcct	agaggaagtg	taacagaaga	tacctggctc	actgctcctg	tccacactgg	960
atcaggcctc	agccctgcac	cgtttccatt	tcagtactgt	gtagagactg	acatcccttt	1020
gaaaacaagg	aagacttctg	aagatcaagc	tgccatacta	ccaggaaaat	tagagatctg	1080
ttcagatgat	caagggaact	tatccccttc	ccgggagaca	tcagtagatg	atggccttgg	1140
atctcagtat	cctttaaaga	aagattcatc	tggtgaccaa	tttctttcag	ttccttcacc	1200
ctttacctgg	agcaaaccac	agcctggcca	caccctata	tttcgcacat	cttcattacc	1260
tccattagac	tggcctttac	caactcactt	tggacaatgt	gaattgaaaa	tagaagtgca	1320

```

acctaaaact caccatagag cccattatga aactgaaggt agccgagggg cagtgaaagc 1380
ctctactggt ggccatcctg ttgtgaagct cctgggctat agtgaaaagc caataaatct 1440
acagatgttt attggaacag ccgatgatag atatttacga cctcatgcat tttaccaggt 1500
gcctcggatt actggaaaga cagttgctac tgcaagtcaa gagataataa tcgccagcac 1560
aaaagtcttg gaaatccac ttctacctga aaataatatg tcagcgagta ttgactgtgc 1620
aggatattta aagctccgca actcagatat agaacttcga aaaggagaaa ctgatattgg 1680
cagaaaaaat actagagtcc gacttgattt tcgtgtgcac atcccacagc ccagtggaaa 1740
agttctttct ctacagatag catctattcc tgttgagtgc tctcagcgat ctgctcaaga 1800
actccctcat attgagaagt acagtatcaa cagttgctct gtcaatggag gccacgaaat 1860
gattgtgact ggatctaatt ttcttcagca atccaaaata atttttcttg aaaaaggaca 1920
agatggagga cctcattggg aggttgaagg aaaaataatc agggaaaaat gtcaaggggc 1980
tcacattgtc cttgaagttc ctccctatca taaccagca gttacatctg ccgtgcaggt 2040
gcacttttat ctttgcaatg gcaagaggaa aaaaagccag tctcaacgtt ttacttacac 2100
accagttttg atgaagcaag aacaaagaga agacacagat ttgccttcag ttccatcttt 2160
gcctgtgctt cattctgccc agggccagag gccctcctca gagacagggc acccccatga 2220
ccgtgcgatg tcagcacccg gaggttgcct ttgtcaagtg cagccagcat atacatctat 2280

```

```

ggtagcctcc acccatttgc cacagttgca gtgtagggat gaaggtgctg gtaaagagca 2340
gcacatagca acatcttcag tcatgcacca gcctttccaa gttacacca catctcctat 2400
agggctcttc tatcagtcta taaaaactag tatgtataac ggtccaacct gtcttcctgt 2460
gaatcctgcc tctagtcaag aatttgacct agttttgttt cagcaagatg cagctctttc 2520
tagtttagta aatcttggct gtcaaccact gtcaccaata ccatttcatt cttcaaattc 2580
agatgcgaca ggacatctct tagcacattc acctcattct gtgcaaacc caccatctct 2640
gcagtcaatg ggataccatt gttcaaattg aggacaaaca gctctttctt ctccagtggc 2700
agaccagatc acaggtcagc cttcttctca ttacagcct attacatatt gtccttcaca 2760
cccaggatct gctacagcag cttccccagc agcctctcat cctctggcta gttcaccgat 2820
ttctgggcca tcatccctc agctgcagcc tatgccttat caatctccta gctcaggaa 2880
tgccctatca ccatctccaa ctaccagaat gcattctgga cagcactcaa ctcaagcaca 2940
aagtacaggg caaggaggcc tttctgttcc ttcactctta gtatgtcaca gtttgtgtga 3000
cccagcgtca tttccgcctg gtggtgcaac tgtgagcatt aaacctgaac ctgaagatca 3060
agaacctaac tttgcaacca ttggtctaca ggatatcacc ttagatgatg tgaacgagat 3120
tattgggaga gacatgtccc agatttctgt tccccagcc acggaggtga tgagagacac 3180
tctctcccc ggctccggct ctccagatct gatgacctct cacagtgtct actgagcctt 3240
ttgccacca cggactgtct agcctgtctt tctcccgaa ctttaaggct agccagactt 3300
caggatctgt tgcaggagtt ggactcactg tgggaaaagc agcgttccct ctccttaagc 3360
cacaggcaga ttgtgtaaaa caggaacagc agcggtctgt tcagctgtgg gaaacgagct 3420
ttgcttttat atatatatat atatatatat atatatattt aaataggata cttttatatg 3480
atgggtgctt tgagtgtgaa tgcagcaggg tctatctcag aggtgctgct cttgcagggtg 3540
acctggttgc atagctagga ttagtaattt gtactgcttt ctggtcattt gaagagccct 3600
ttagttttga tgatatattt aaaatagaac tttttgat 3638

```

<210> 8

<211> 1075

<212> PRT

<213> Mus musculus

<400> 8

```

Met Thr Thr Ala Asn Cys Gly Ala His Asp Glu Leu Asp Phe Lys Leu
 1             5             10             15
Val Phe Gly Glu Asp Gly Ala Pro Ala Pro Pro Pro Pro Gly Ser Arg
      20             25             30
Pro Ala Asp Leu Glu Pro Asp Asp Cys Ala Ser Ile Tyr Ile Phe Asn
      35             40             45
Val Asp Pro Pro Pro Ser Thr Leu Thr Thr Pro Leu Cys Leu Pro His
      50             55             60
His Gly Leu Pro Ser His Ser Ser Val Leu Ser Pro Ser Phe Gln Leu

```

65					70					75				80
Gln	Ser	His	Lys	Asn	Tyr	Glu	Gly	Thr	Cys	Glu	Ile	Pro	Glu	Ser
				85					90					95
Tyr	Ser	Pro	Leu	Gly	Gly	Pro	Lys	Pro	Phe	Glu	Cys	Pro	Ser	Ile
			100					105					110	Gln
Phe	Thr	Ser	Ile	Ser	Pro	Asn	Cys	Gln	Gln	Glu	Leu	Asp	Ala	His
		115					120					125		Glu
Asp	Asp	Leu	Gln	Ile	Asn	Asp	Pro	Glu	Arg	Glu	Phe	Leu	Glu	Arg
	130					135					140			Pro
Ser	Arg	Asp	His	Leu	Tyr	Leu	Pro	Leu	Glu	Pro	Ser	Tyr	Arg	Glu
145					150					155				160
Ser	Leu	Ser	Pro	Ser	Pro	Ala	Ser	Ser	Ile	Ser	Ser	Arg	Ser	Trp
			165					170					175	Phe
Ser	Asp	Ala	Ser	Ser	Cys	Glu	Ser	Leu	Ser	His	Ile	Tyr	Asp	Asp
		180						185					190	Val
Asp	Ser	Glu	Leu	Asn	Glu	Ala	Ala	Ala	Arg	Phe	Thr	Leu	Gly	Ser
	195						200					205		Pro
Leu	Thr	Ser	Pro	Gly	Gly	Ser	Pro	Gly	Gly	Cys	Pro	Gly	Glu	Glu
	210					215					220			Ser
Trp	His	Gln	Gln	Tyr	Gly	Ser	Gly	His	Ser	Leu	Ser	Pro	Arg	Gln
225				230						235				240
Pro	Cys	His	Ser	Pro	Arg	Ser	Ser	Ile	Thr	Asp	Glu	Asn	Trp	Leu
			245					250					255	Ser
Pro	Arg	Pro	Ala	Ser	Gly	Pro	Ser	Ser	Arg	Pro	Thr	Ser	Pro	Cys
		260					265					270		Gly
Lys	Arg	Arg	His	Ser	Ser	Ala	Glu	Val	Cys	Tyr	Ala	Gly	Ser	Leu
	275						280					285		Ser
Pro	His	His	Ser	Pro	Val	Pro	Ser	Pro	Gly	His	Ser	Pro	Arg	Gly
	290					295				300				Ser
Val	Thr	Glu	Asp	Thr	Trp	Leu	Thr	Ala	Pro	Val	His	Thr	Gly	Ser
305				310					315					Gly
Leu	Ser	Pro	Ala	Pro	Phe	Pro	Phe	Gln	Tyr	Cys	Val	Glu	Thr	Asp
			325					330					335	Ile
Pro	Leu	Lys	Thr	Arg	Lys	Thr	Ser	Glu	Asp	Gln	Ala	Ala	Ile	Leu
	340						345					350		Pro
Gly	Lys	Leu	Glu	Ile	Cys	Ser	Asp	Asp	Gln	Gly	Asn	Leu	Ser	Pro
	355						360				365			Ser
Arg	Glu	Thr	Ser	Val	Asp	Asp	Gly	Leu	Gly	Ser	Gln	Tyr	Pro	Leu
	370				375						380			Lys
Lys	Asp	Ser	Ser	Gly	Asp	Gln	Phe	Leu	Ser	Val	Pro	Ser	Pro	Phe
385				390					395					400
Trp	Ser	Lys	Pro	Lys	Pro	Gly	His	Thr	Pro	Ile	Phe	Arg	Thr	Ser
			405					410					415	Ser
Leu	Pro	Pro	Leu	Asp	Trp	Pro	Leu	Pro	Thr	His	Phe	Gly	Gln	Cys
		420					425					430		Glu
Leu	Lys	Ile	Glu	Val	Gln	Pro	Lys	Thr	His	His	Arg	Ala	His	Tyr
	435						440				445			Glu
Thr	Glu	Gly	Ser	Arg	Gly	Ala	Val	Lys	Ala	Ser	Thr	Gly	Gly	His
	450				455				460					Pro
Val	Val	Lys	Leu	Leu	Gly	Tyr	Ser	Glu	Lys	Pro	Ile	Asn	Leu	Gln
465				470				475						480
Phe	Ile	Gly	Thr	Ala	Asp	Asp	Arg	Tyr	Leu	Arg	Pro	His	Ala	Phe
			485				490					495		Tyr
Gln	Val	His	Arg	Ile	Thr	Gly	Lys	Thr	Val	Ala	Thr	Ala	Ser	Gln
	500						505				510			Glu
Ile	Ile	Ile	Ala	Ser	Thr	Lys	Val	Leu	Glu	Ile	Pro	Leu	Leu	Pro
	515					520					525			Glu

Asn	Asn	Met	Ser	Ala	Ser	Ile	Asp	Cys	Ala	Gly	Ile	Leu	Lys	Leu	Arg
530						535					540				
Asn	Ser	Asp	Ile	Glu	Leu	Arg	Lys	Gly	Glu	Thr	Asp	Ile	Gly	Arg	Lys
545					550					555					560
Asn	Thr	Arg	Val	Arg	Leu	Val	Phe	Arg	Val	His	Ile	Pro	Gln	Pro	Ser
				565					570					575	
Gly	Lys	Val	Leu	Ser	Leu	Gln	Ile	Ala	Ser	Ile	Pro	Val	Glu	Cys	Ser
			580					585					590		
Gln	Arg	Ser	Ala	Gln	Glu	Leu	Pro	His	Ile	Glu	Lys	Tyr	Ser	Ile	Asn
		595					600					605			
Ser	Cys	Ser	Val	Asn	Gly	Gly	His	Glu	Met	Ile	Val	Thr	Gly	Ser	Asn
610					615						620				
Phe	Leu	Pro	Glu	Ser	Lys	Ile	Ile	Phe	Leu	Glu	Lys	Gly	Gln	Asp	Gly
625					630					635					640
Gly	Pro	His	Trp	Glu	Val	Glu	Gly	Lys	Ile	Ile	Arg	Glu	Lys	Cys	Gln
			645						650					655	
Gly	Ala	His	Ile	Val	Leu	Glu	Val	Pro	Pro	Tyr	His	Asn	Pro	Ala	Val
			660					665					670		
Thr	Ser	Ala	Val	Gln	Val	His	Phe	Tyr	Leu	Cys	Asn	Gly	Lys	Arg	Lys
		675					680					685			
Lys	Ser	Gln	Ser	Gln	Arg	Phe	Thr	Tyr	Thr	Pro	Val	Leu	Met	Lys	Gln
690						695					700				
Glu	Gln	Arg	Glu	Asp	Thr	Asp	Leu	Pro	Ser	Val	Pro	Ser	Leu	Pro	Val
705					710					715					720
Pro	His	Ser	Ala	Gln	Ala	Gln	Arg	Pro	Ser	Ser	Glu	Thr	Gly	His	Pro
			725						730					735	
His	Asp	Arg	Ala	Met	Ser	Ala	Pro	Gly	Gly	Leu	Leu	Cys	Gln	Val	Gln
			740					745					750		
Pro	Ala	Tyr	Thr	Ser	Met	Val	Ala	Ser	Thr	His	Leu	Pro	Gln	Leu	Gln
		755					760					765			
Cys	Arg	Asp	Glu	Gly	Ala	Gly	Lys	Glu	Gln	His	Ile	Ala	Thr	Ser	Ser
770					775						780				
Val	Met	His	Gln	Pro	Phe	Gln	Val	Thr	Pro	Thr	Ser	Pro	Ile	Gly	Ser
785					790					795					800
Ser	Tyr	Gln	Ser	Ile	Gln	Thr	Ser	Met	Tyr	Asn	Gly	Pro	Thr	Cys	Leu
			805						810					815	
Pro	Val	Asn	Pro	Ala	Ser	Ser	Gln	Glu	Phe	Asp	Pro	Val	Leu	Phe	Gln
		820						825					830		
Gln	Asp	Ala	Ala	Leu	Ser	Ser	Leu	Val	Asn	Leu	Gly	Cys	Gln	Pro	Leu
		835					840					845			
Ser	Pro	Ile	Pro	Phe	His	Ser	Ser	Asn	Ser	Asp	Ala	Thr	Gly	His	Leu
850						855					860				
Leu	Ala	His	Ser	Pro	His	Ser	Val	Gln	Thr	Pro	Pro	His	Leu	Gln	Ser
865					870					875					880
Met	Gly	Tyr	His	Cys	Ser	Asn	Ala	Gly	Gln	Thr	Ala	Leu	Ser	Ser	Pro
			885						890					895	
Val	Ala	Asp	Gln	Ile	Thr	Gly	Gln	Pro	Ser	Ser	His	Leu	Gln	Pro	Ile
		900						905					910		
Thr	Tyr	Cys	Pro	Ser	His	Pro	Gly	Ser	Ala	Thr	Ala	Ala	Ser	Pro	Ala
		915					920					925			
Ala	Ser	His	Pro	Leu	Ala	Ser	Ser	Pro	Ile	Ser	Gly	Pro	Ser	Ser	Pro
930						935					940				
Gln	Leu	Gln	Pro	Met	Pro	Tyr	Gln	Ser	Pro	Ser	Ser	Gly	Thr	Ala	Ser
945					950					955					960
Ser	Pro	Ser	Pro	Thr	Thr	Arg	Met	His	Ser	Gly	Gln	His	Ser	Thr	Gln
			965						970					975	
Ala	Gln	Ser	Thr	Gly	Gln	Gly	Gly	Leu	Ser	Val	Pro	Ser	Ser	Leu	Val

	980		985		990
Cys His Ser	Leu Cys Asp Pro Ala Ser Phe Pro Pro Gly Gly Ala Thr				
	995		1000		1005
Val Ser Ile	Lys Pro Glu Pro Glu Asp Gln Glu Pro Asn Phe Ala Thr				
	1010		1015		1020
Ile Gly Leu	Gln Asp Ile Thr Leu Asp Asp Val Asn Glu Ile Ile Gly				
1025		1030		1035	1040
Arg Asp Met	Ser Gln Ile Ser Val Ser Gln Ala Thr Glu Val Met Arg				
	1045		1050		1055
Asp Thr Pro	Leu Pro Gly Pro Ala Ser Pro Asp Leu Met Thr Ser His				
	1060		1065		1070
Ser Ala His					
	1075				

<210> 9
 <211> 1282
 <212> DNA
 <213> Mus musculus

<400> 9
 ggactcgggt gaagatggcg gcagccgagg ccgcgaactg catcatggag aattttgtag 60
 ccaccttggc taatgggatg agcctccagc cgcctcttga agaagtttcc tgtggccaag 120
 cagaaagtag tgagaagccc aacgctgagg acatgacatc caaagactac tactttgact 180
 cctatgccca ctttggcatc cacgaggaga tgctgaagga tgaggtgcgc accctcacat 240
 accgcaactc catgtttcac aatcggcatc tcttcaaaga caaggtggtg ctggatgtgg 300
 gctcaggcac tggcatcctc tgcattgttg ctgccaaggc gggggcccgc aagggttattg 360
 ggattgagtg ttccagtatc tccgattatg ctgtgaagat tgtcaaagcc aacaagttag 420
 accatgtggt gaccatcatc aagggcaagg tggaggaggt ggagctgcc gtggagaagg 480
 tggacatcat catcagcgag tggatgggtt actgcctctt ctacgagtc atgctcaaca 540
 ccgtgctgca cgctcgggac aagtggctgg caccgatgg cctcatcttc ccagaccggg 600
 ccaccttgta tgtgacagcc attgaggacc gacaataaa agactacaag atccactggt 660
 gggagaacgt gtatggcttt gatatgtcct gcattaaaga cgtggccatc aaggagcccc 720
 tgggtggacgt ggtggaccca aagcagctgg tcaccaatgc ctgcctcata aaggaggtgg 780
 acatttacac agtcaagggtg gaggacctga ccttcacctc ccccttctgc ctgcaagtga 840
 agaggaacga ctacgtgcac gcgctggtgg cttacttcaa catcgagttc acccgatgcc 900
 acaagaggac cggtctctcc accagtctg agtccccgta cacacactgg aagcagactg 960
 tgttctacat ggaggactac ctaacagtga agactggcga ggagatcttt ggcaccattg 1020
 gaatgaggcc caatgccaaa aacaatcgtg acttggactt taccatcgac ctggacttca 1080
 agggtcagct gtgtgagctc tcttgttcca ccgactaccg gatgcgctga ggaggtgcc 1140
 ggctggccct cctgcagaag ggggctcggg gggatgggct tgggggatgg gggggtacat 1200
 cgtgactgtg tttttcataa cttatgttt tatatgggtg cgtttatgcc aataaatcct 1260
 cagctgacca tgaaaaaaaa aa 1282

<210> 10
 <211> 371
 <212> PRT
 <213> Mus musculus

<400> 10
 Met Ala Ala Ala Glu Ala Ala Asn Cys Ile Met Glu Asn Phe Val Ala
 1 5 10 15
 Thr Leu Ala Asn Gly Met Ser Leu Gln Pro Pro Leu Glu Glu Val Ser
 20 25 30
 Cys Gly Gln Ala Glu Ser Ser Glu Lys Pro Asn Ala Glu Asp Met Thr
 35 40 45
 Ser Lys Asp Tyr Tyr Phe Asp Ser Tyr Ala His Phe Gly Ile His Glu

50		55		60
Glu Met Leu Lys Asp	Glu Val Arg Thr Leu Thr Tyr Arg Asn Ser Met			
65	70	75	80	
Phe His Asn Arg His	Leu Phe Lys Asp Lys Val Val Leu Asp Val Gly			
	85	90	95	
Ser Gly Thr Gly Ile	Leu Cys Met Phe Ala Ala Lys Ala Gly Ala Arg			
	100	105	110	
Lys Val Ile Gly Ile	Glu Cys Ser Ser Ile Ser Asp Tyr Ala Val Lys			
	115	120	125	
Ile Val Lys Ala Asn	Lys Leu Asp His Val Val Thr Ile Ile Lys Gly			
	130	135	140	
Lys Val Glu Glu Val	Glu Leu Pro Val Glu Lys Val Asp Ile Ile Ile			
	145	150	155	160
Ser Glu Trp Met Gly	Tyr Cys Leu Phe Tyr Glu Ser Met Leu Asn Thr			
	165	170	175	
Val Leu His Ala Arg	Asp Lys Trp Leu Ala Pro Asp Gly Leu Ile Phe			
	180	185	190	
Pro Asp Arg Ala Thr	Leu Tyr Val Thr Ala Ile Glu Asp Arg Gln Tyr			
	195	200	205	
Lys Asp Tyr Lys Ile	His Trp Trp Glu Asn Val Tyr Gly Phe Asp Met			
	210	215	220	
Ser Cys Ile Lys Asp	Val Ala Ile Lys Glu Pro Leu Val Asp Val Val			
	225	230	235	240
Asp Pro Lys Gln Leu	Val Thr Asn Ala Cys Leu Ile Lys Glu Val Asp			
	245	250	255	
Ile Tyr Thr Val Lys	Val Glu Asp Leu Thr Phe Thr Ser Pro Phe Cys			
	260	265	270	
Leu Gln Val Lys Arg	Asn Asp Tyr Val His Ala Leu Val Ala Tyr Phe			
	275	280	285	
Asn Ile Glu Phe Thr	Arg Cys His Lys Arg Thr Gly Phe Ser Thr Ser			
	290	295	300	
Pro Glu Ser Pro Tyr	Thr His Trp Lys Gln Thr Val Phe Tyr Met Glu			
	305	310	315	320
Asp Tyr Leu Thr Val	Lys Thr Gly Glu Glu Ile Phe Gly Thr Ile Gly			
	325	330	335	
Met Arg Pro Asn Ala	Lys Asn Asn Arg Asp Leu Asp Phe Thr Ile Asp			
	340	345	350	
Leu Asp Phe Lys Gly	Gln Leu Cys Glu Leu Ser Cys Ser Thr Asp Tyr			
	355	360	365	
Arg Met Arg				
370				